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The passage of leukocytes across blood vessel walls plays a key role in the immune 
response to infection in inflammatory conditions.  ADAM10 is a ubiquitously expressed 
molecular scissor that proteolytically cleaves key cell surface proteins including vascular 
endothelial (VE)-cadherin and transmembrane chemokines.  Their shedding by ADAM10 
promotes leukocyte transmigration in cell line models, however the precise mechanism 
behind ADAM10’s involvement is unknown.  ADAM10 associates with six different 
membrane organising tetraspanins (Tspan5/10/14/15/17/33) termed the TspanC8s.  
These tetraspanins regulate ADAM10 enzymatic maturation and trafficking to the cell 
surface and emerging evidence indicates that different TspanC8s can promote ADAM10 
cleavage of specific substrates.   
It was hypothesised that ADAM10 promotes leukocyte transmigration by cleaving one of 
its endothelial substrates and one or more of the TspanC8s could facilitate this process.  
The aim of this thesis was to test this hypothesis using in vitro leukocyte adhesion assays 
with primary human leukocytes and human umbilical vein endothelial cells (HUVECs).  
siRNA knockdown or pharmacological inhibition of ADAM10 on HUVECs impaired the 
transmigration of lymphocytes, but not neutrophils or monocytes.  ADAM10 
knockdown/inhibition caused a reduction in VE-cadherin shedding and an increase in VE-
cadherin surface expression.  Partial knockdown of VE-cadherin, in the presence of 
ADAM10 knockdown/inhibition, reduced VE-cadherin levels to normal and restored basal 
lymphocyte transmigration.     
Systematic knockdown of TspanC8s in HUVECs revealed that the presence of either 
Tspan5 or Tspan17 was sufficient to maintain basal lymphocyte transmigration and 
reduced VE-cadherin surface levels.  Tspan5 and Tspan17 are functionally 
uncharacterised, but they are the most highly related TspanC8s by sequence (78% amino 
acid identity) and may share a common role in lymphocyte transmigration by regulation of 
ADAM10 and VE-cadherin.  
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CHAPTER 1   
GENERAL INTRODUCTION 
CHAPTER 1:  GENERAL INTRODUCTION 
2 
1.1 INFLAMMATION AND IMMUNITY 
1.1.1 Inflammation and immunity are protective following injury and 
infection 
Inflammation is a complex response characterised by the host’s reaction to invading 
pathogens, such as viruses, bacteria, fungi, or parasites, but also in response to tissue or 
cell damage.  It serves as a protective mechanism to overcome the initial cause of 
infection or injury with the principle aim in eliminating the harmful stimuli and contributing 
to tissue repair thereby resolving the inflammatory insult (Serhan et al., 2008).  A principle 
component of this response is the ability of circulating blood leukocytes to undergo 
activation and transmigrate to the site of infection or injury in vascularised tissues.  This 
process is regulated by a precisely coordinated sequence of adhesive interactions and 
signalling events that occur between the inflamed vessel wall and leukocytes (Ley et al., 
2007).  In addition, leukocytes have been shown to breach the endothelial barrier rapidly 
with the whole process taking roughly 10 minutes.  Inflammation is characterised by five 
classical symptoms: dolor (pain), calor (heat), rubor (redness), tumor (swelling) and 
function laesa (loss of function) (Majno and Joris, 2008).  A principle component of these 
symptoms is induced by the localised effects of inflammatory mediators on the blood 
vessels surrounding the site of inflammation.  Vasodilatory factors, such as histamine and 
bradykinin, act on the inflamed vasculature to increase blood flow that is characterised by 
redness and heat; an increase in vascular permeability leading to the leakage of plasma 
fluids (exudates) causes increased swelling whilst pain is associated with the localised 
release of chemical stimuli that act upon nerve endings.  If all these systems persist or 
become uncontrollable, this can lead to the eventual loss of organ/tissue function. 
Immunity refers to the host defence, which in higher developed organisms consist of two 
branches, non-specific (innate immunity) or specific (adaptive immunity).  The first line of 
defence, also referred to as the innate immune response, involves a natural resistance 
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defence mechanism that primes the adaptive immune response (Abbas, Abdul K; 
Lichtmann, 2011).  This initial immune response consists of physical and chemical 
components (such as the endothelial cells that line the blood vessel walls), phagocytic 
leukocytes (such as neutrophils, monocytes, and macrophages), and soluble mediators 
(e.g. components of the complement system, chemokines and cytokines).  Tissue 
resident or sentinel cells such as mast cells, macrophages and dendritic cells (DCs) 
mediate the initial stages of leukocyte recruitment during an inflammatory response.  
These cells express surface and intracellular pattern recognition receptors (PRR) such as 
toll-like receptors (TLRs) (Takeuchi and Akira, 2010) through which they are able to 
recognise broad structures of potentially harmful material released by invading 
microorganisms (pathogen-associated molecular patterns; PAMPs) or damaged and/or 
dead cells (damage-associated molecular patterns; DAMPs) in response to tissue and/or 
cellular stress (Medzhitov, 2008).  These cells can then act upon the danger signals by 
releasing a wide range of pro-inflammatory mediators such as cytokines (e.g. tumour 
necrosis factor-α (TNFα) and interleukin-1β (IL-1β)), chemokines (e.g. macrophage 
chemotactic protein-1 (MCP-1/CCL2) and macrophage inflammatory protein-2 (MIP-
2/CXCL12) and other chemoattractants (e.g. leukotriene B4 (LTB4) and prostaglandin-D2 
(PGD2) thereby indicating the site of infection or tissue damage (Bianchi, 2007; McDonald 
et al., 2010; Sadik et al., 2011; Ahmed et al., 2011).  The release of these mediators 
triggers a cascade of events that leads to an increase in blood flow and permeability of 
the microvasculature allowing circulating leukocytes to transmigrate out of the peripheral 
vasculature and into the site of inflammation.  The nature of the inflammatory insult will 
dictate the ability of specific leukocyte subsets to undergo recruitment via the local 
synthesis of chemokines, cytokines, and chemoattractants by both the host and invading 
pathogen.  In addition, vasodilation of the blood vessel wall allows the passage of protein-
rich plasma.  Collectively, these events lead to the resolution of inflammation by clearing 
the infection or further confine the infection to mount a more specific secondary immune 
response. 
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One of the most abundant leukocyte subsets in the circulation is neutrophils.  Neutrophils 
account for around 40-60% or all circulating leukocytes and undergo rapid recruitment 
from the circulation into the extravascular space during an inflammatory response.  Their 
principle function is in pathogen detection and subsequent pathogen destruction by a 
process of phagocytosis.  Much like macrophages, neutrophils express major surface 
receptors to common bacterial components, which upon interaction lead to the 
microorganism or cell debris being engulfed (Finlay and Hancock, 2004).  Upon 
activation, neutrophils release numerous factors, such as granular antimicrobial 
substances and degrading proteases along with oxygen-derived free radicals thereby 
rapidly destroying pathogens.  However, uncontrolled activation of neutrophils can lead to 
the aberrant release of these cytotoxic factors, which can also injure host cells and lead to 
vascular and/or tissue damage (Finlay and Hancock, 2004). 
In addition, neutrophils also assist the secondary recruitment of other leukocytes and their 
subsets by generating and releasing pro-inflammatory cytokines and chemokines, thereby 
further amplifying the inflammatory response.  During an acute inflammatory response, 
the recruitment of neutrophils into the tissue parenchyma is closely followed by the influx 
of monocytes which then differentiate into macrophages that help to clear infections via 
their ability to phagocytose pathogens (Finlay and Hancock, 2004).  Indeed, the innate 
immune response is sometimes not sufficient in resolving the pathogen-associated 
inflammation.  Under these conditions, the priming of the adaptive immune response, 
which initiates a slower but highly specific response, is critical (Abbas, Abdul K; 
Lichtmann, 2011).  In contrast to cells of the innate immune response, cells of the 
adaptive immunity (B- and T-lymphocytes) target highly specific structures of microbial 
molecules (antigens) and can develop a memory to specific pathogens.  The final 
resolving phase of inflammation following pathogen elimination requires the activation of 
tissue repair mechanisms (e.g. promoting fibroblast growth and adherence) (Finlay and 
Hancock, 2004). 
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Inflammation can be acute, lasting for a short period of time (minutes to days), or chronic 
(lasting days to years).  Whereas acute inflammatory responses are transient and 
generally involve neutrophils and plasma exudation, chronic inflammation occurs when 
the inflammatory insult/trigger is persistent (e.g. during autoimmune diseases) and 
involves primarily macrophages/monocytes and lymphocytes.  Collectively, immunity is a 
highly regulated and carefully balanced process.  Disruption of regulatory mechanisms 
can lead to chronic inflammation that is commonly seen in severe pathological conditions, 
such as rheumatoid arthritis, atherosclerosis, and cancer.  Therefore understanding the 
intricacies of the immune system, especially the mechanisms mediating leukocyte 
recruitment, is key to the development of novel anti-inflammatory therapies. 
 
1.1.2 The Leukocyte Adhesion Cascade 
1.1.2.1 Overview 
During inflammation, leukocytes have to breach the vessel wall, which forms a complex 
physical barrier composed of cellular (the endothelium and pericyte sheath) and non-
cellular (vascular basement membrane) components between the circulation and 
extravascular tissue (Nourshargh et al., 2010). The use of advanced imaging modalities 
and intravital microscopy have allowed the visualisation of leukocyte transmigration in 
vivo thereby advancing our knowledge of mechanisms that underpin this process.  In 
particular, leukocyte transmigration occurs in small vessels such as the post-capillary 
venules and involves overcoming the primary barrier of endothelial cells on the luminal 
surface.  Endothelial cells form a cobblestone-like appearance (10-15µm wide and 25-40 
µm long) once confluent, that line the outermost layer of the vascular lumen.  It is now 
well established that leukocyte transendothelial migration requires a cross talk of precisely 
coordinated adhesive interactions and signalling events between adhesion molecules 
expressed on leukocytes and endothelial cells (Ley et al., 2007) (Figure 1.1).  The specific 
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cellular and molecular interactions involved in this process are more commonly known as 
the leukocyte adhesion cascade, which involves multifactorial and distinct steps: capture 
of leukocytes from the circulation, rolling of these cells on the luminal side of the 
endothelium, activation-induced arrest, adhesion strengthening, shape change and 
intraluminal crawling and paracellular or transcellular migration through the endothelium. 
 
1.1.2.2 Leukocyte capture and rolling 
Proinflammatory mediators released by sentinel tissue resident cells act transiently by 
binding to specific high-affinity receptors expressed on their target cells such as 
leukocytes and endothelial cells.  Activation of the endothelium results in the upregulation 
and/or redistribution of adhesion molecules (Nourshargh et al., 2010).  Selectins are a 
class of proteins that are involved in initiating the capture of circulating leukocytes.  
Upregulation of selectin expression (E-selectin and P-selectin) on endothelial cells allows 
leukocytes to undergo capture (also known as tethering) through forming an interaction 
with the respective selectin ligands P-selectin glycoprotein ligand-1 (PSGL-1), E-selectin 
ligand-1 (ESL-1), CD44 and other glycosylated ligands expressed on leukocytes (Zarbock 
et al., 2011; Vestweber and Blanks, 1999).  To date, the selectin family comprises of three 
characterised members: E-selectin, which is expressed on inflamed endothelial cells, L-
selectin, which is expressed on most leukocytes, and P-selectin, which is expressed on 
inflamed endothelial cells and on activated platelets (Ley et al., 2007). Certain leukocyte 
subsets, such as mononuclear cells, have also been shown to roll using α4β7 integrin 
(Johnston, 1996).  Selectin ligands are all fucosylated carbohydrate structures containing 
sulphated-sialyl-Lewisx and are expressed mainly on leukocytes (McEver and Zhu, 2010).  
The sulphated-sialy-LewisX are tetrasaccharide carbohydrates which are recognised by 
the lectin domain of selectins (McEver, 2002). The binding of leukocytes to selectins 
expressed on endothelial cells can also facilitate secondary leukocyte tethering, allowing 
other leukocytes to interact with attached leukocytes through binding of leukocyte L-
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selectin with PSGL-1, thereby further recruiting leukocytes to the sites of inflammation 
(Sperandio et al., 2003; Walcheck et al., 1996). 
Following the capture of leukocytes from the circulation, leukocytes then undergo a period 
of rolling on the endothelial surface.  This process is enabled by high on- and off-rate of 
selectin/selectin receptor bonds that leads to detachment of leukocytes from the 
endothelium and the formation of new adhesive interactions (Alon et al., 1995).  These 
specific interactions between selectins and their respective ligands are also known as 
catch bonds, which strengthen in increased areas of shear stress thereby causing 
leukocyte rolling along the vessel wall (Finger et al., 1996; Lawrence et al., 1997). More 
recently, the formation of long membrane tethers containing PSGL-1, so-called “slings”, 
has been shown to allow efficient leukocyte rolling under conditions of high shear stress 
(Sundd et al., 2012).  The “slings” form at the rear of leukocytes, such as neutrophils, and 
are rapidly mobilised to the front of the cell as it rolls, whereby it re-attaches to the 
underlying endothelium thereby increasing the chances of leukocyte-chemokine 
interactions.  Leukocyte rolling along the luminal side of the vessel wall is pertinent in 
initiating the subsequent steps of the leukocyte adhesion cascade, as exemplified by 
studies using blocking antibodies to the selectins that were found to completely abolish 
leukocyte adhesion and transmigration (Kanwar et al., 1997).  As well as forming 
extracellular interactions with their respective ligands, selectins have functional signalling 
properties.  Upon binding of selectins with their respective ligands, downstream signalling 
events in both endothelial cells and leukocytes induce activation and subsequent integrin-
mediated firm adhesion (Simon et al., 2000; Schmidt et al., 2013).  The majority of the 
known signalling pathways involve changes in kinase activity such as triggering of p38 
mitogen-activated protein kinase (MAPK)-signalling pathways and phosphoinositide 3-
kinase-γ (PI3Kγ) (Simon et al., 2000; Puri et al., 2005; Schmidt et al., 2013).  However, 
the intricacies of these signalling pathways and the precise mechanisms remain unclear. 
 





Figure 1.1  Leukocyte vessel wall interactions during leukocyte adhesion and 
transmigration.  (A) In response to a diverse array of pro-inflammatory mediators, stimulation of 
vascular endothelial cells upregulates leukocyte cellular adhesion molecules that support the 
recruitment and subsequent adhesion of leukocytes to the luminal vessel wall.  Upon activation, 
leukocytes undergo rapid firm adhesion and intravascular crawling that is supported by leukocyte 
selectin and integrin interactions with cellular adhesion molecules.  Integrin-ligand clustering 
increases adhesive interactions between leukocytes and endothelial cells under conditions of 
hydrodynamic shear forces.  Subsequent dissociation of endothelial junctional molecules or 
endothelial cell cytoskeletal rearrangement dictates the mode by which leukocytes breach the 
endothelial barrier and enter the extravascular tissue.  (B) A table detailing some of the key 
adhesion molecules and structures expressed on leukocytes and endothelial cells involved in the 
distinct stages of leukocyte recruitment, activation-induced arrest, and transmigration (Ley et al., 
2007; Nourshargh et al., 2010; Nourshargh and Alon, 2014). 
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1.1.2.3 Leukocyte activation-induced arrest and intraluminal crawling 
A reduction in rolling velocity allows leukocytes to undergo activation and subsequent 
arrest that is triggered by immobilised chemokines (e.g. CXCL1 and CXCL2) that are 
expressed on the apical surface of endothelial cells anchored by glycosaminoglycans 
(GAGs) (Rot, 2010).  This leads to the formation of a chemotactic gradient which guides 
leukocytes through the vasculature to the sites of injury (Phillipson and Kubes, 2011).  
Chemokines and chemoattractants act on leukocytes via G-protein coupled receptors 
(GPCRs).  Upon binding of chemokines or chemoattractants to GPCRs, a complex 
intracellular signalling cascade is triggered that leads to changes in integrin affinity by 
transforming integrins into their high-affinity conformation in a mechanism referred to as 
inside-out signalling (Ley et al., 2007). 
Integrins constitute a family of 30 members that are heterodimeric proteins consisting of 
α- and β-subunits found expressed on the surface of leukocytes and other cells (Herter 
and Zarbock, 2013).  Under quiescent conditions, and with the exception of effector 
lymphocytes and certain monocyte subsets (Carlin et al., 2013; San Lek et al., 2013; 
Shulman et al., 2012), integrins exhibit a non-active conformation that is associated with a 
low binding affinity (Kinashi, 2005).  Chemokine-induced activation of leukocytes rapidly 
changes the affinity of integrins from a low-affinity state to an intermediate affinity and 
finally high-affinity state that promotes their ability to form firm shear-resistant interactions 
with cellular adhesion molecules (CAMs) expressed on endothelial cells (Alon and Dustin, 
2007; Carman and Springer, 2003; Ley et al., 2007).  This is mediated through the 
opening of the ligand binding pocket, increased ligand-binding and decreased ligand 
dissociation of the integrin (Kinashi, 2005).  Moreover, intracellular signals, driven by 
cytoskeletal focal adhesion proteins talin-1 and kindlin-3, further drive integrins into their 
active high-affinity conformations (Lefort et al., 2012; Moser et al., 2009; Ye et al., 2013).  
An important feature of integrin binding stability is the ability of integrins to undergo lateral 
clustering on the leukocyte cell surface that increases the avidity of integrin binding to 
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clustered CAMs expressed on endothelial cells through the formation of multivalent 
interactions.  Upon activation, leukocyte-specific integrins (mainly β1 and β2 integrins) 
readily bind to endothelial cell CAMs (e.g. intercellular adhesion molecule 1 (ICAM-1) and 
vascular cell adhesion molecule 1 (VCAM-1)) (Campbell et al., 1996; Shamri et al., 2005).  
On leukocytes, the major integrins involved in adhesion strengthening and consequently 
leukocyte arrest are lymphocyte function-associated antigen 1 (LFA-1; also known as αLβ2 
integrin) and macrophage antigen-1 (Mac-1; αMβ2), which bind with high affinity to ICAM-
1, and very late antigen 4 (VLA-4; α4β1) which binds to VCAM-1.  This process represents 
the transition between selectin-mediated rolling to integrin-mediated firm adhesion/arrest.  
Upon arrest to the endothelium, leukocytes undergo morphological changes from a 
spherical, rolling phenotype to a flattened and polarised morphology.  These changes are 
dependent on outside-in signalling events that result in the reorganisation of the leukocyte 
cytoskeleton and characteristic presence of lamellipodia and uropod regions at the 
leading and trailing edges, respectively (Nourshargh et al., 2010; Hyun et al., 2012).  This 
allows the adhered leukocytes to undergo cell spreading and intraluminal crawling that is 
mediated by F-actin polymerization at the front of the leukocyte and actin-myosin 
contraction and retraction at the back of the cell.  Leukocytes then crawl to a favoured site 
of transmigration that is transitioned by the presence of a haptotactic gradient of 
chemoattractants (Phillipson et al., 2006; Schenkel et al., 2004).  Leukocytic integrin 
binding to CAMs, in particular, Mac-1 binding to ICAM-1, allows leukocytes to form 
protrusions into endothelial cells and endothelial cell-junctions, which is further associated 
with endothelial cell contraction and the opening of inter-endothelial contacts.  This 
process of directional crawling and sensing of migratory ‘hotspots’ might be important in 
facilitating efficient leukocyte motility to endothelial cell-junctions to facilitate subsequent 
leukocyte transmigration through the endothelial layer (Phillipson et al., 2006; Schenkel et 
al., 2004). 
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1.1.2.4 Leukocyte transmigration through the endothelial barrier 
The migration of leukocytes through the endothelial barrier can occur via both paracellular 
(through endothelial junctions) or transcellular routes (through the body of the endothelial 
cell), although the former is the preferred route of leukocyte transmigration (Ley et al., 
2007).  One important feature of leukocyte transmigration is that it must maintain vessel 
wall integrity by causing minimal disruption to the endothelium.  Recent in vitro studies 
have suggested that endothelial cells are able to support leukocyte transmigration through 
the formation of docking structures or transmigratory cups around the penetrating 
leukocyte that function as endothelial adhesive platforms (Barreiro et al., 2008, 2004; Ley 
and Zhang, 2008; Petri et al., 2011; Carman and Springer, 2004).  It is proposed that 
these transmigratory cups, which are enriched with ICAM-1 and VCAM-1, might form a 
seal around the adherent leukocyte, thereby maintaining endothelial barrier integrity 
(Phillipson et al., 2008).  It is proposed that ligand clustering of ICAM-1 and VCAM-1 is 
induced by tetraspanin or pentaspanin partners CD9, CD151 and CD47 (Barreiro et al., 
2008; Azcutia et al., 2012).  Engagement of leukocytes to these enriched areas of CAMs 
may act as optimal adhesion platforms, which facilitate the opening of endothelial 
junctions and subsequent priming of leukocyte transmigration.  In endothelial cells, this is 
associated with increased intracellular Ca2+ (Huang et al., 1993; Pfau et al., 1995), 
initiation of intracellular signalling pathways such as the MAPK pathway (Hu et al., 2000) 
and generation of reactive oxygen species (ROS) (Deem et al., 2007; Martinelli et al., 
2009).  Altogether, this sequestering of leukocytes might prime the leukocyte for efficient 
transmigration.  Various junctional adhesion molecules, including PECAM-1, ICAM-1, 
JAM-A, JAM-B, JAM-C, ICAM-2, CD99, PVR/CD155, endothelial cell-selective adhesion 
molecule (ESAM) and vascular endothelial cadherin (VE-cadherin), have been implicated 
in facilitating the transendothelial migration of leukocytes (Thompson et al., 2001; Dejana, 
2004; Wegmann et al., 2006; Woodfin et al., 2007; Muller, 2011; Vestweber, 2012b; 
Wessel et al., 2014; Nourshargh and Alon, 2014) (Figure 1.2).  However, the specific 
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adhesion molecules involved in leukocyte diapedesis vary depending on the type of 
leukocyte, the phase of transmigration, the inflammatory stimulus and the vessel wall 
niche (Ley et al., 2007; Muller, 2011; Nourshargh et al., 2010; Vestweber, 2012b; Voisin 




It is now regarded that the most preferred route of leukocyte diapedesis is through 
paracellular means – migration of leukocytes through endothelial cell junctions (Ley et al., 
2007; Muller, 2011; Woodfin et al., 2011; Nourshargh and Alon, 2014).  Endothelial cells 
exhibit highly organised molecular junctional complexes that form between adjacent cells.  
These intercellular junctions are comprised of tight junction (e.g. JAMs and claudins) and 
adherens junction (such as VE-cadherin) proteins.  Junctional proteins usually are 
Figure 1.2  Key adhesion proteins at endothelial cell junctions that are important in 
facilitating paracellular leukocyte transmigration.  Transmigration of leukocytes at endothelial 
cell junctions requires the dissociation of key junction proteins.  Cell-cell contacts between 
adjacent endothelial cells are maintained by members of the junctional adhesion molecule family 
(JAMs), endothelial cell-selective adhesion molecule (ESAM) and CD99.  In addition, endothelial 
cells contain adherence junctional proteins vascular endothelial cadherin (VE-cadherin) and its 
associated tyrosine phosphatase (VE-PTP).  Moreover, platelet-endothelial cellular adhesion 
molecule-1 (PECAM-1) and ICAM-2 are also found at endothelial cell junctions, contributing to 
endothelial-cell adhesion (adapted from (Nourshargh and Alon, 2014)). 
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transmembrane proteins linked to the intracellular cytoskeleton with intracellular signalling 
abilities.  They function as important regulators of vascular permeability controlling the 
passage of circulating cells and plasma proteins into the tissue by providing vascular 
stability (Vestweber, 2012b). 
The use of genetically modified in vivo models of inflammation with highly stabilised 
endothelial junctions has highlighted paracellular transmigration to be the dominant route 
of leukocyte diapedesis (Schulte et al., 2011).  Under physiological conditions of 
leukocyte transmigration, certain junctional proteins (such as VE-cadherin) undergo 
transient dissociation from the endothelial cell junctions and are recycled back to the 
border or undergo proteolytic cleavage (Ley et al., 2007; Muller, 2011; Vestweber, 2012b; 
Voisin and Nourshargh, 2013).  The introduction of a non-internalising stable mutant of 
VE-cadherin in mice led to resistance to vascular permeability upon challenge with 
permeability inducing agents such as histamine and VEGF, that correlated with an 
inhibition in junctional dissociation of VE-cadherin (Schulte et al., 2011).   
Separately, stimulus-specific recruitment of neutrophils in various in vivo inflammatory 
models (IL-1β challenge, formyl-methionyl-leucyl-phenylalanine (fMLP) challenge and 
pathological ischemia-reperfusion (I/R) injury) showed that neutrophils preferentially 
transmigrated at endothelial cell junctions (Woodfin et al., 2011).  Paracellular 
transmigration relies on a well-orchestrated interplay between endothelial cells and 
leukocyte adhesion molecules.  The presence of adhesion molecules at distinct regions of 
endothelial cell junctions may differentially facilitate the leukocyte’s ability to breach the 
endothelial barrier (Muller, 2011).  Particularly, this has been shown to be true for the 
transmigration of neutrophils in a cytokine-dependent manner.  Stimulation of mouse 
cremasteric tissue with IL-1β, but not TNFα or LTB4, caused neutrophils to rapidly 
mobilise on ICAM-2 which guided them to endothelial cell junctions, followed by JAM-A 
which mediated neutrophil transmigration through the endothelial cell junction and finally 
PECAM-1 which supported penetration of neutrophils through the venular basement 
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membrane layer (Woodfin et al., 2007).  Notably, many junctional endothelial cell 
adhesion molecules undergo recycling forming intracellular compartments, such as the 
lateral border recycling compartment, or get integrated into endosomes (Ley et al., 2007; 
Muller, 2011; Vestweber, 2012b). 
The other mode of transmigration, known as transcellular migration, relies on leukocytes 
migrating through the body of the endothelial cell (Feng et al., 1998; Millán et al., 2006; 
Carman et al., 2007; Marmon et al., 2009; Martinelli et al., 2014).  Much less is 
understood about the distinctive mechanisms that mediate this pathway.  This process is 
thought to be mediated by leukocyte protrusions which extend into the endothelial cell 
body searching for permissive sites of migration (Ley et al., 2007).  Binding of leukocyte 
protrusions to endothelial cell ICAM-1 have thought to translocate apical ICAM-1 into 
vesiculo-vacuolar organelles (VVOs), thereby facilitating bound leukocytes to follow a 
migratory pathway through endothelial cells (Millán et al., 2006; Carman et al., 2007).  
However, the physiological relevance of this pathway remains unclear.  Mice lacking 
CD11b (Mac-1) on leukocytes have reduced leukocyte crawling and have a higher 
incidence of transmigration through transcellular means rather than at junctions 
(Phillipson et al., 2006).  More recently, Martinelli et al. showed how lymphocyte 
transmigration could be strongly dictated by the pathway that has the least resistance.  
Using in vitro adhesion assays and transmission electron microscopy the authors 
describe how under conditions of high junctional resistance, lymphocytes make 
‘invadosome’ like protrusions through endothelial cells thereby disrupting actin filaments 
to reduce F-actin density and associated stiffness, thereby allowing lymphocytes to follow 
transcellular migration – a process the authors term ‘tenertaxis’ (Martinelli et al., 2014).  
Indeed, in vascular beds that have high barrier function such as in the central nervous 
system, transcellular migration of leukocytes seems to be the predominant means of 
migration (Engelhardt and Ransohoff, 2012).  These findings suggest that the mode of 
leukocyte transmigration can be dictated by inter-endothelial adhesive strength. 
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1.2 A DISINTEGRIN AND METALLOPROTEASE 10 
(ADAM10) 
 
1.2.1 ADAM proteases: molecular scissors with important roles in 
physiology and pathology 
Chronic inflammatory conditions such as cancer, atherosclerosis, stroke and asthma are 
characterised by the excessive infiltration of leukocytes into the site of inflammation 
(Nourshargh and Alon, 2014; Nourshargh et al., 2010).  Many therapeutic strategies 
against chronic inflammatory conditions have relied on targeting the immune response by 
focusing on the molecular pathways including localised cytokines, growth factors, 
receptors, and adhesion molecules expressed either on leukocytes or on endothelial cells 
that mediate the inappropriate triggering of the immune response.  The identification of 
molecular proteases, that govern the shedding or proteolytic cleavage of many of the 
molecules mentioned, offers a mechanism by which chronic inflammatory conditions 
could be controlled by functionally altering the repertoire of cell surface proteins that are 
expressed on the localised cells at the inflammatory interface.  These metalloproteases, 
which can be sub-classified into matrix metalloproteases (MMPs), MMPs with 
transmembrane-spanning regions (MT-MMPs), snake venom metalloproteases (SVMPs), 
members of the a disintegrin and metalloproteases (ADAMs) and ADAMs with 
thrombospondin motifs (ADAMTS) (Figure 1.3), has highlighted a fundamental role of 
proteolytic shedding in inflammation (Dreymueller et al., 2015).  Although previous studies 
utilising broad-spectrum inhibitors in clinical trials has proven unrewarding (Khokha et al., 
2013; Vandenbroucke et al., 2011), the recent emergence of ADAMs as key regulators of 
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proteolytic shedding offers a potential molecular mechanism which could govern cell 
function during inflammation. 
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1.2.1.1  Overview of ADAMs 
To date, the ADAM family comprises of ~34 members of which 22 have been identified  in 
humans (Edwards et al., 2008).  In terms of their structure, ADAMs are expressed as 
transmembrane proteins consisting of an N-terminal pro-domain followed by a 
Figure 1.3 Schematic representation of the domain structure of metalloproteases.  The 
family members consist of a common propeptide (A) and catalytic metalloprotease domain (B).  In 
addition, matrix metalloproteases (MMPs) and transmembrane MMPs (MT-MMP) contain a 
hemopexin-like domain (C).  A disintegrin and metalloproteases (ADAM) and MT-MMPs contain a 
stalk region (D), a transmembrane region, and a cytoplasmic tail (E).  ADAMs and ADAMs with 
thrombospondin motifs (ADAMTS) contain a disintegrin domain (F), a cysteine region (G), an 
EGF-like domain (H) and ADAMTSs contain addition thrombospondin motifs (I).  Snake-venom 
metalloproteases (SVMP) contain additional C-type lectin domains (J). 
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metalloprotease domain, a disintegrin domain, a cysteine-rich region, an EGF-like domain 
(only present in certain ADAMs),  a transmembrane region and finally a cytoplasmic tail 
(Klein and Bischoff, 2011) (Figure 1.3).  In terms of their function, ADAMs exhibit  
proteolytic or non-proteolytic activity (by interacting with other proteins) or combining both 
functions (Reiss and Saftig, 2009).  The proteolytic activity of ADAMs seems to be the 
dominant characterised function of ADAM.  In this regard, ADAMs can be thought of as 
“molecular scissors,” which proteolytically cleave or “shed” the extracellular regions of 
other transmembrane proteins. 
As the name suggests, the metalloprotease domain facilitates ADAM proteolytic activity.  
A classical component that dictates ADAMs proteolytic activity is the presence of a Zn2+ 
ion in the active metalloprotease domain.  This has shown to be governed by a zinc-
binding motif containing three histidine residues (HEXGHXXGXXHD) and a highly 
conserved methionine-turn in the active site helix (Bode et al., 1993; Orth et al., 2004).  
Based on the presence of this component and through the use of predicted structures of 
the zinc-binding site, ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, 33 and DEC1 have 
been shown to have proteolytic activity in humans and mice (Andreini et al., 2005) (Figure 
1.4).  Crystal structures of the ADAM metalloprotease-disintegrin-cysteine rich domains 
have shown that this region of the ADAM protease forms an arm-like structure, with the 
active metalloprotease domain and cysteine-rich domain interacting with the substrate of 
interest (Igarashi et al., 2007; Takeda et al., 2006) (Figure 1.5).  In addition, the 
cytoplasmic tails of ADAMs have been shown to be important regulators of proteolytic 
activity, signalling, and membrane localisation.  In particular, recent studies have been 
shown that deletion of the cytoplasmic domain from ADAM10 results in reduced 
constitutive shedding activity, possibly because the tail has an endoplasmic retention 
motif that is important for ADAM10 trafficking (Maretzky et al., 2015).  Moreover, inducible 
shedding through treatment of ADAM10-deficient mouse embryonic fibroblasts with 
ionomycin that causes enhanced influx of extracellular Ca2+ did not alter the shedding 
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abilities of the ADAM10 substrate betacellulin in the cytoplasmic tail-mutated ADAM10-
overexpressing cells.  This suggests that the cytoplasmic tail is indispensable for 
ADAM10 inducible activity (Maretzky et al., 2015).  Similar observations have been 
concluded in studies looking at ADAM17 inducible activity, highlighting a dispensable role 
of the cytoplasmic domain for ADAM17 in regulating its activation (Hall and Blobel, 2012).  
In addition, the majority of ADAMs contain potential sites of phosphorylation and proline-
rich regions, which can bind to SH2/3 domain-containing proteins potentially regulating 
ADAM activity (Edwards et al., 2008; Ebsen et al., 2014).  Separate studies have also 
highlighted a role of ADAMs in forming homodimers at the plasma membrane (Xu et al., 
2012; Deng et al., 2014), although the physiological implications of this structural 
modification to ADAMs is less well understood.   
 
 





Figure 1.4  Phylogenetic tree of ADAM proteases.  ADAM proteases expressed in humans 
were analysed for sequence similarity using Clustal OMEGA protein sequence alignment software 
based on the sequence of their metalloproteinase domains.  Proteolytically active ADAMs are 
shown in red (adapted from Edwards et al., 2008). 




As mentioned above, certain ADAMs also exhibit non-proteolytic activity such as in 
regulating adhesion.  In particular the disintegrin domain has been shown to mediate 
interactions with integrins or with extracellular matrix components (Bridges and Bowditch, 
2005).  For example, the disintegrin domain of ADAM15 contains an RGD motif (Arg-Gly-
Asp) that facilitates non-proteolytic interactions with the integrins αvβ3 and α5β1 on 
hematopoietic cell lines (Nath et al., 1999, 2000).  The physiological implications of ADAM 
association on integrin function require further investigations. 
In terms of their synthesis, ADAMs are produced as inactive proenzymes with the 
prodomain functioning as an intramolecular chaperone.  The prodomain is particularly 
important in maintaining the structural integrity of the ADAM through its correct folding 
whilst keeping the protease as an inactive zymogen.  Following ADAM biosynthesis in the 
endoplasmic reticulum, ADAMs are transported to the Golgi, where they undergo 
maturation.  During this maturation process, furin or proprotein convertase 7 cleave the 
prodomain of the ADAM protease (Gonzales et al., 2004; Anders et al., 2001), freeing the 
interaction with the zinc ion in the catalytic site, resulting in the active mature glycosylated 
Figure 1.5  Predicted ADAM10 structure based on its characterised domains.  Predicted  
ADAM10 structure based on the known ADAM10 crystal structure of the disintegrin and cysteine-
rich domains which forms an arm-like structure (Janes et al., 2005). 
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form that is trafficked to the cell surface following packaging and compartmentalisation 
into endosomes in the Golgi (Schlöndorff et al., 2000).  More recently, the shedding of the 
prodomain of ADAM9, 10 and 17 in a newly identified site within the prodomain sequence, 
by a yet unidentified protease, was shown to be prerequisite to the canonical shedding of 
the complete prodomain that promotes maturation of the ADAM sheddases (Wong et al., 
2015).  Mutation of the newly identified prodomain shedding site resulted in reduced 
catalytic activity of the sheddases, suggesting that this site is required for optimal 
maturation of the fully catalytic ADAMs in addition to the previously known separate furin 
cleavage site (Wong et al., 2015). 
Characterised substrates for ADAM proteolysis are generally other cell surface 
transmembrane proteins (Table 1.1).  ADAMs cleave substrates in close proximity to the 
cell surface.  In doing so, proteolytic shedding results in the release of a soluble 
ectodomain fragment of the substrate into the extracellular space which can exhibit 
agonist (e.g. Tumour necrosis factor (TNF)) or antagonist (TNFR) properties.  As such, 
the consequences of proteolytic shedding include the removal of chemokines or cytokines 
from the cell surface, the removal of growth factors, the weakening of cell-cell adhesion or 
the initiation of intracellular signalling pathways.  Subsequently, a cell membrane-bound 
fragment consisting of the transmembrane region and cytoplasmic tail remains at the 
plasma membrane.  It is considered that proteolytic release of the ectodomain results in 
exposure of the generated membrane bound fragment, which is further processed by 
intramembrane proteolysis by the γ-secretase (a process more commonly known as 
regulated intramembrane proteolysis (RIP)), thereby releasing the intracellular tail which 
can then regulate downstream signalling or undergo degradation (Tousseyn et al., 2009) 
(Figure 1.7).  In contrast to other proteolytic enzymes that recognise particular signature 
sequences for their proteolytic activity, ADAMs cleave their substrates with no clearly 
defined amino acid recognition motif that is common to different substrates.  Indeed, 
some ADAM substrate cleavage sites have been mapped.  For example, ADAM10 
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cleaves amyloid precursor protein (APP) in between Lys687 and Leu688 (Lammich et al., 
1999).  However, ADAMs require other structural determinants that are somewhat distinct 
from the cleavage site which facilitate substrate recognition (Stawikowska et al., 2013).  
ADAMs generate their substrate recognition partially through substrate-binding pockets in 
the active metalloprotease domain (Caescu et al., 2009).   In addition the juxtamembrane 
domains, namely the disintegrin and cysteine-rich regions along with the transmembrane 
stalk are required for substrate recognition (Düsterhöft et al., 2014; Janes et al., 2005), at 
least for a select group of substrates which have had their ADAM proteolytic cleavage site 
mapped.  Proteolytic shedding by ADAMs has been implicated as a critical mediator in 
embryonic development but also in physiological and pathological processes in the adult.  
As a result, the role of ADAMs in inflammation and cancer in particular is of increasing 
interest for potential drug targeting (Pruessmeyer and Ludwig, 2009; Rose-John, 2013; 
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Protein Name Alternative Names Known Substrates 
ADAM8 Cell surface antigen 
MS2,  CD156a 
cKit ligand,  L-selectin,  
TGFα,  CX3CL1,  SCF,  
CD16,  TNFα,  TNFR1,  
VCAM-1 
ADAM9 KIAA0021,  MCMP,  
MDC9,  Metrin γ 
ADAM10,  cKit Ligand,  
Delta-like 1,  HB-EGF,  
VCAM-1,  VE-cadherin, prion 
protein 
ADAM10 Kuzbanian,  MADM,  
CD156c 
CD44,  CX3CL1,  CXCL16,  
HB-EGF,  IL-6R,  Notch,  VE-
cadherin,  VEGFRII,  
Betacellulin,  Corin,  
TRANCE,  TNF,   Ephrin,  
APP, MHC class I,  human 
thyrotropin receptor, GPVI  
ADAM12 Meltrin α Betacellulin,  Delta-like 1,  
HB-EGF,  IGFBP 3/5,  
FGFR2iib,  ADAM10,  sonic 
hedgehog,  Kilt1,  VE-
cadherin,  Flk-1,  Tie-2,  
VECAM-1 




IV collagen,  gelatine,  MCIB,  
E-cadherin,  FGFR-2 
ADAM17 CSVP,  TACE,  
CD156b 
CD40,  CD44,  cKit ligand,  
CX3CL1,  Delta-like 1,  
CD163,  EMMPRIN,  EPCR,  
Ephrin B4,  FLT3L,  HB-EGF,  
ICAM-1,  IGFR-1,  IL-1RII,  
IL-6R,  Jagged 1,  JAM-A,  
L1-CAM,  L-selectin,  Notch,  
PECAM,  Semaphorin 4D,  
Syndecan 1 and 4,  TNFα,  
TNF receptor p55 (TNFRI),  
TNF receptor p75 (TNFRII),  
TGFα,  VCAM-1,  VEGFR2,  
TRANCE,  CD74,  Mac-1,  
FCγRIIIA,  EGF,  vasorin, 
GPVI 
ADAM19 Meltrin β, MADDAM cKit ligand,  HB-EGF,  α2 
macroglobulin,  Neuregulins,  
TNFα,  TRANCE 
ADAM28 ADAM23,  MDCL IGFBP3 




Table 1.1  Catalytically active ADAM proteases and their known substrates in vascular 
pathology and physiology (adapted from (Dreymueller et al., 2012b)). 
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The majority of the known shedding on human cells is mediated by two of the most 
closely related ADAM family members, ADAM10 and ADAM17.  The importance of these 
two sheddases is highlighted through whole-body knockout mice.  These  show 
embryonic lethality for ADAM10, with mice dying at embryonic day 9.5 with severe defects 
in heart and somite development, and death shortly after birth for mice lacking ADAM17 
(Hartmann et al., 2002; Peschon et al., 1998).  The abnormalities observed in the global 
ADAM10 knockout mouse phenocopy defects in Notch1 knockout mice (Conlon et al., 
1995).   It is thought that the defects observed in the ADAM17 knockout mice, such as the 
increased heart valve development and the open eye phenotype, are a result of perturbed 
growth factor shedding that is required for epidermal growth factor receptor (EGFR) 
transactivation (Jackson, 2003).  In addition, ADAM10 and ADAM17 are ubiquitously 
expressed both during development and in adult tissue.  As a result, both proteases have 
been implicated in various acute inflammatory diseases, neurodegenerative diseases and 
cancer development (Dreymueller et al., 2015). In contrast, much less is known about the 
other proteolytically active ADAMs (ADAM8, 9, 12, 15, 19, 20, 21, 28, 30, and 33).  This is 
most likely due to relatively weak phenotypes that are observed in the particular knockout 
mice (Dreymueller et al., 2015).   
 
1.2.1.2 ADAM10 in inflammation 
There is now an increasing understanding of the involvement of ADAM10 in inflammation, 
particularly in inflammation associated with the lung (Dreymueller et al., 2015).  ADAM10 
has at least 40 reported targets and is responsible for a substantial proportion of shedding 
on human cells (Saftig and Reiss, 2011).  ADAM10 is known for its shedding of Notch and 
APP (Hartmann et al., 2002) (Figure 1.6). The former shedding event is triggered when 
Notch ligands (for example, Delta like ligands or Jagged) bind to the Notch receptor, 
allowing ADAM10 to then cleave within the membrane proximal region of Notch, releasing 
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the ectodomain fragment.  Activated ADAM17 has also been shown to regulate the 
shedding of Notch, although this appears to be independent of engagement of Notch 
ligands (Bozkulak and Weinmaster, 2009).  Regulated ADAM10-dependent shedding of 
Notch seems to explain the developmental defects that are observed in the ADAM10 
knockout mice (Hartmann et al., 2002). Notch shedding by ADAM10 is crucial for many 
processes in the adult, including tissue regeneration (Weber et al., 2011) and myeloid 
development (Weber et al., 2011; Yoda et al., 2011).  In addition to Notch shedding, 
ADAM10 is also known for its processing of APP.  APP is processed by extracellular α- 
and β-sheddases along with γ-secretase (Prox et al., 2012a). As a result, a variety of 
different ectodomains are generated upon engagement of the various sheddases.  
ADAM10 is regarded as an α-sheddase and cleaves APP between the β- and γ-shedding 
sites, thereby preventing the production of the amyloidβ peptide that is associated with 
promoting Alzheimer’s disease (Saftig and Lichtenthaler, 2015). Overexpression of 
ADAM10 in mouse brains has been shown to protect against Alzheimer’s disease 
(Postina et al., 2004) and as a result, ADAM10 activity in Alzheimer’s is of key therapeutic 
interest (Saftig and Lichtenthaler, 2015). 
 




In inflammation, ADAM10 seems to cleave an array of substrates that are expressed in 
various vascular beds (Figure 1.7).  In particular, ADAM10 has been shown to shed the 
low affinity IgE receptor CD23 which is implicated in initiating the allergic immune 
response (Weskamp et al., 2006), VE- and E-cadherin that mediate cell adhesion and 
vascular permeability (Schulz et al., 2008; Maretzky et al., 2005), EGF that regulates 
transactivation of its receptor(s) thereby controlling cell proliferation and differentiation 
(Yan et al., 2002), the two transmembrane chemokines, CX3CL1 and CXCL16 that 
mediate leukocyte adhesion (Abel et al., 2004; Hundhausen et al., 2003), and the 
receptor for advanced glycation endproducts (Raucci et al., 2008) (Figure 1.7).  Many of 
these substrates have been identified through the use of in vitro shedding assays and a 
limited amount of in vivo data exists through the use of ADAM10 cell-specific knockout-
mice. 
Figure 1.6  ADAM10 is the principle sheddase for Notch and amyloid precursor protein 
(APP).  Engagement of Notch ligands to Notch leads to conformational changes in Notch that 
allow ADAM10 to cleave the extracellular fragment.  This then allows the γ-secretase complex to 
further process the membrane bound stump of Notch, which leads to the production of a 
transcriptionally active intracellular domain, which can be trafficked to the nucleus and control cell 
fate decisions (left).  ADAM10-dependent shedding of APP prevents the production of the 
amyloidβ peptide (inside red oval) that is responsible for Alzheimer’s disease by cleaving APP 
between its BACE1 shedding site and γ-secretase shedding site (right). 




In addition to ADAM10, ADAM17 has been shown to have a dominant role in 
inflammation, by acting on its endothelial and leukocytic substrates, such as ICAM-1 and 
L-selectin.  Rapid shedding of L-selectin from the surface of leukocytes, such as 
neutrophils, has been shown to cause reduced leukocyte rolling and a subsequent 
decrease in leukocyte-endothelial adhesive interactions under in vitro flow conditions 
(Smalley and Ley, 2005).  In addition, generation of mice expressing a mutant shedding 
resistant form of L-selectin in the T-cell lineage revealed that L-selectin shedding is 
required for optimal re-entry of antigen-activated T-cells into the peripheral lymph nodes 
(Galkina et al., 2003).  In vivo models of acute inflammation using ADAM17 deficient 
neutrophils have revealed through models of thioglycollate or Escherichia coli-induced 
peritonitis that L-selectin mediates the early recruitment of neutrophils into the peritoneum 
(Long et al., 2010; Tang et al., 2011).  In addition to shedding of L-selectin, ADAM17 has 
also been implicated in in vitro studies as the primary sheddase that cleaves endothelial 
CAMs, ICAM-1 and VCAM-1 under protein kinase C-induced conditions (Singh et al., 
2005; Tsakadze et al., 2006).   The shedding of these two CAMs may prime leukocytes to 
Figure 1.7  Key endothelial ADAM10 substrates implicated in inflammation.  Engagement of 
ADAM10 regulates the shedding of various endothelial cell substrates, such as Notch, CD44, 
CX3CL1, CXCL16, EGF, and VE-cadherin.  
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locomote along the apical surface of endothelial cells in search for exit points for 
transmigration as well as regulating leukocyte transmigration by inducing intracellular 
signalling pathways within the endothelial cells. 
 
1.2.1.2.1 ADAM10-dependent shedding of endothelial substrates 
Endothelial cells play a critical role in inflammation by facilitating efficient leukocyte 
recruitment and subsequent transmigration of leukocytes as well as regulating vascular 
permeability (Vestweber, 2015).  Indeed, endothelial ADAM10 has been implicated in 
regulating inflammation by promoting neovascularisation and facilitating the inflammatory 
responses of endothelial cells, in addition to ADAM10’s established role in the early 
development of vascular structures (van der Vorst et al., 2012). 
The generation of the ADAM10 endothelial-specific knockout mice (driven by Tie2-Cre) 
highlighted an important role of ADAM10 in vascular development (Glomski et al., 2011).  
These conditional endothelial ADAM10 knockout mice are largely viable displaying mild 
abnormalities in the retinal vasculature with enhanced vessel branching (Glomski et al., 
2011) and shorter femurs, tibiae and humeri attributed to defects in osteoclastogenesis at 
the chondro-osseus junction (Zhao et al., 2014).  These defects in endothelial cells seem 
to be driven by Notch-dependent cell fate decisions that require Notch shedding by 
ADAM10.  Indeed, downstream Notch signalling target genes such as Snail and Brmp2 
have impaired expression in ADAM10 deficient endothelial cells, suggesting a critical role 
of ADAM10 in Notch signalling and cardiac development (Zhang et al., 2010). 
To date, characterised ADAM10 endothelial substrates involved in inflammation have 
largely been discovered through the use of in vitro models.  One of the initial endothelial 
ADAM10 substrates discovered to play a role in guiding leukocytes during inflammation, 
were the two transmembrane chemokines, CX3CL1 and CXCL16 (Hundhausen et al., 
2007). These chemokines have been shown to be important in mediating leukocyte 
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adhesion by binding to their respective ligands expressed on leukocytes, namely CX3CR1 
and CXCR6 (Ludwig and Weber, 2007).  Through the utilisation of cell lines made to 
overexpress either of the two transmembrane chemokines, Hundhausen et al. showed 
that ADAM10 was required to provide a chemokine-shedding event that then allowed the 
bound leukocytes to locomote along the endothelium and undergo subsequent 
transmigration, a term the authors called ‘de-adhesion’ (Hundhausen et al., 2007).  The 
subsequently cleaved ectodomain of the chemokines also act as chemotactic gradients 
that are required for promoting adhesion of circulating leukocytes (Hundhausen et al., 
2007).  In addition to ADAM10, ADAM17 has also been shown to cleave CX3CL1 under 
PMA-induced conditions (Garton et al., 2001).  Indeed, ADAM10 is largely regarded as a 
constitutive sheddase and regulates the homeostatic shedding of CX3CL1, whilst under 
certain stimulatory conditions, such as PMA treatment, ADAM17 could dominate the 
proteolytic shedding event (Garton et al., 2001; Hundhausen et al., 2003).  More recently, 
the membrane dynamics surrounding CX3CL1 shedding by ADAM10 have been explored 
using single-particle tracking methodologies.  In this study, Wong et al. showed that 
CX3CL1 is confined at the plasma membrane via its intracellular tail that forms an 
interaction with the cortical actin cytoskeleton.  Disruption of the cortical actin cytoskeleton 
resulted in increased CX3CL1-ADAM10 interactions and subsequent enhanced shedding 
of the transmembrane chemokine (Wong et al., 2014).  
ADAM10 has also been shown to regulate vascular permeability (Ponnuchamy and Khalil, 
2008).  VE-cadherin, a junctional adhesion molecule that acts as a gateway for the 
passage of leukocytes or macromolecules (Vestweber, 2015), has been shown to be 
proteolytically cleaved by ADAM10 (Schulz et al., 2008).  In this study, Schulz et al. 
demonstrated that inhibition of ADAM10 on endothelial cells using siRNA or 
pharmacological inhibitors resulted in reduced VE-cadherin shedding.  This shedding 
capability of ADAM10 was enhanced following stimulation of endothelial cells with the 
calcium ionophore, ionomycin, and was associated with increased endothelial barrier 
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permeability as assessed using a FITC-dextran permeability dye (Schulz et al., 2008).  
The authors also went on to show that thrombin induced vascular permeability was 
reduced following endothelial ADAM10 inhibition (Schulz et al., 2008).  In addition, the 
transmigration of THP-1 immortalised monocytic cells across ADAM10 inhibited or 
knocked down endothelial cells was compromised (Schulz et al., 2008).  However, the 
authors did not definitively show if the reduction in THP-1 cell migration was due to 
increased VE-cadherin at the endothelial cell junctions.  In addition to VE-cadherin, 
endothelial ADAM10 also regulates the shedding of the Ephrin guidance molecule, 
Ephrin-A (Janes et al., 2005). Ephrin-A mediates cell-cell adhesion by binding to its 
respective receptor EphA.  ADAM10 mediated shedding of Ephrin-A disrupts this complex 
leading to cell detachment (Coulthard et al., 2012).  Moreover, soluble Ephrin-A has been 
shown to induce vascular permeability, a process that is mediated through direct 
interaction with its receptor EphA and is dependent on downstream intracellular NFκB 
mediated responses (Coulthard et al., 2012).   
 
1.2.1.2.2 ADAM10-dependent shedding of leukocytic substrates 
The most characterised role of ADAM10 in leukocyte adhesion and transmigration has 
been shown with the use of leukocytic cell lines and more recently through the use of in 
vivo conditional ADAM10 knockout mice with deletions of ADAM10 in the myeloid and 
hematopoietic lineages.  Initial in vitro studies highlighted that ADAM10 was important in 
the chemotactic migration of neutrophils and monocytes across immortalised endothelial 
cell monolayers (ECV-304 cells) (Pruessmeyer et al., 2014).  Pharmacological inhibition 
of ADAM10 expressed on human neutrophils or on the monocytic derived cell line THP-1 
cells resulted in reduced migration of these cells towards the chemokines IL-8 and CCL2, 
respectively (Pruessmeyer et al., 2014).  Furthermore, genetic ablation of ADAM10 on 
human neutrophils or THP-1 cells revealed a similar phenotype to that observed following 
pharmacological inhibition of ADAM10 (Pruessmeyer et al., 2014).  The reduced migration 
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of neutrophils and THP-1 cells was attributed to various intracellular signalling and 
adhesive events that are required for leukocyte transmigration.  Pharmacological 
inhibition or genetic silencing of ADAM10 on neutrophils or THP-1 cells caused a 
reduction in p38 phosphorylation, reduced Rho GTPase activation, diminished F-actin 
polymerisation and reduced adhesion to fibronectin attributed to the improper activation of 
α5-integrin (Pruessmeyer et al., 2014). Furthermore, Pruessmeyer et al. confirmed the 
relevance of these findings by using in vivo conditional ADAM10 knockout mice, lacking 
ADAM10 in the myeloid lineage and hematopoietic lineage.  Deletion of ADAM10 on 
myeloid cells, as driven by a LysM-Cre promoter, resulted in reduced recruitment of 
neutrophils and monocytes into the lung and reduced inflammation-induced oedema 
formation (Pruessmeyer et al., 2014).  In addition, ADAM10 deletion in the hematopoietic 
lineage (as driven by a Vav-Cre promoter) impaired the recruitment of neutrophils and 
monocytes into the lung alveoli following intranasal administration of LPS (Pruessmeyer 
et al., 2014).  However, the precise mechanisms surrounding ADAM10’s role in leukocyte 
transmigration remain unknown.    
Due to the importance of these and other substrates in a variety of processes, ADAM10 is 
of major research interest in developmental biology, the cardiovascular system, 
immunology, cancer, and Alzheimer’s disease.  However, the regulation of this 
ubiquitously expressed metalloprotease, in terms of activation and localisation to 
substrates during inflammation, is poorly understood. 
 
1.3 TETRASPANINS 
1.3.1 Introduction to tetraspanins 
Tetraspanin superfamily proteins are composed of four transmembrane regions, two 
extracellular loops of unequal size, one intracellular loop and short intracellular N- and C-
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terminal tails (Figure 1.8) (Hemler, 2014).  The tetraspanins are further characterised by a 
conserved gene structure and conserved cysteine residues that are important for the 
structure of the main extracellular loop.  Tetraspanins function by interacting with other 
transmembrane ‘partner proteins’, which include integrins, immunoglobulin superfamily 
(IgSF) member proteins and others such as ADAM10 (Charrin et al., 2014; Hemler, 
2014).  Tetraspanins regulate various aspects of partner protein function, namely 
biosynthesis, intracellular trafficking, and lateral mobility and clustering at the cell surface 
(Charrin et al., 2014; Hemler, 2014).  There are 33 tetraspanins in mammals and the 
superfamily extends to other animals, plants, and multicellular fungi (Huang et al., 2005).  
Human cells typically express approximately 20 different tetraspanins, and tetraspanin 




Figure 1.8  The conserved structure of tetraspanin proteins.  (adapted from (Hemler, 2014)).   
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1.3.2 Structure of tetraspanins 
The use of cryo-electron microscopy has helped to reveal the low resolution structure of 
uroplakin tetraspanins UPla and UPlb, detailing a compact, rod-like structure, composed 
of four transmembrane helices along with two extracellular regions (namely, EC1 and 
EC2) in which the extracellular regions protrudes 3.5-5 nm above the plasma membrane 
(Min et al., 2006) (Figure 1.9). 
 
 
Figure 1.9  Ribbon schematics of the low resolution cryo-EM and predicted 3D structure of 
CD81.  (adapted from (Seigneuret, 2006; Min et al., 2006). 
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The use of crystallography (Kitadokoro et al., 2001) and nuclear magnetic resonance 
(NMR) (Rajesh et al., 2012) resolved the structure of the EC2 domain of CD81, revealing 
a hydrophobic patch that was shown not to mediate tetraspanin-tetraspanin interactions.  
Combining this with computational methods resulted in the complete modelling of the 
predicted structure of the tetraspanin CD81 (Figure 1.9) (Seigneuret et al., 2001; 
Seigneuret, 2006). 
Tetraspanins also undergo post-translational modifications that include palmitoylation at 
cysteine residues within the cytoplasmic tails at membrane proximal regions, N-linked 
glycosylation within the large extracellular loop and ubiquitination of the cytoplasmic tails 
(Charrin et al., 2009a).  Palmitoylation of membrane proximal cysteines facilitates the 
association of tetraspanins with other tetraspanins and has shown to promote clustering 
of tetraspanin-tetraspanin interactions at the plasma membrane (Israels and McMillan-
Ward, 2010; Delandre et al., 2009; Zhu et al., 2012).  This palmitoylation process occurs 
during trafficking of the tetraspanin through the Golgi and is mediated by 
palmitoyltranferases (for example, DHHC2 which palmitoylates tetraspanins CD9 and 
CD151) (Sharma et al., 2008) and disruption of this process results in loss of tetraspanin 
function and an increase in protein degradation (Sharma et al., 2008).  In addition to 
cysteine palmitoylation, N-linked glycosylation within the large extracellular loop of certain 
tetraspanins has been shown to be important in tetraspanin functioning.  For example, N-
linked glycosylation of CD151 is important in mediating the adhesive strengthening of the 
α3 integrin subunit that it associates with (Baldwin et al., 2008).  Tetraspanins also share 
varying levels of protein sequence homology amongst other members of the superfamily 
with certain tetraspanins (e.g. Tspan5 and Tspan17) sharing high levels (~78%) sequence 
homology in humans and others sharing less protein sequence homology (e.g. 26% 
sequence homology for the distantly related Tspan15 and Tspan10).  Nevertheless, 
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tetraspanins seem to have arisen from a common ancestor since several intron/exon sites 
are conserved within tetraspanin genes (Garcia-España et al., 2008).   
 
1.3.2 Tetraspanins as membrane organisers 
Tetraspanins form dynamic interactions with specific partner proteins and with other 
tetraspanins (Charrin et al., 2014; Hemler, 2014).  By doing this, tetraspanins are able to 
promote the trafficking, clustering and lateral mobility of their respective partner proteins 
(Charrin et al., 2014; Hemler, 2014).  Some of the best characterised tetraspanin-partner 
protein interactions include integrins (e.g. α3β1, α6β1, α6β4 which all associate with CD151, 
IgSF members (EWI-F, EWI-2, CD19, ICAM-1, VCAM-1 which associate with CD81, CD9, 
CD81, CD9 and CD151, respectively), proteases (ADAM10 and MT-MMP1 which 
associate with the TspanC8 subgroup of tetraspanins and CD151, respectively) and 
intracellular signalling proteins (protein kinase C enzymes associate with CD151) (Charrin 
et al., 2014). Previous studies highlighted that tetraspanins were able to recruit specific 
partner proteins and other tetraspanins into larger membrane microdomains (typically 
consisting of three or more different tetraspanins) which acted as optimal platforms for 
adhesion and cell signalling (Barreiro et al., 2008; Espenel et al., 2008).  However, recent 
studies of tetraspanins using advanced microscopy, such as super resolution microscopy 
and single particle tracking analysis, have highlighted that tetraspanins are more dynamic 
at the plasma membrane, shuttling from regions of high tetraspanin density and the rest of 
the membrane and forming tetraspanin-tetraspanin interactions in both of these distinct 
areas (Espenel et al., 2008) 
. 
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1.3.2.1 Tetraspanins regulate membrane protein compartmentalisation   
The tetraspanin association with their respective partner proteins has largely been 
deduced through the use of different detergents and subsequent co-immunoprecipitation 
experiments.  Many of these biochemical experiments have relied on the use of 
detergents with varying stringency and the levels of interaction with other tetraspanins 
and specific partner proteins, especially weak interactions, can be misinterpreted as 
artefacts of the lysis conditions.  Therefore caution has to be taken when solely 
considering biochemical assays to decipher tetraspanin-protein interactions.  Primary 
tetraspanin interactions are thought to be strong interactions between tetraspanins and 
specific partner proteins that are maintained under stringent lysis conditions, such as 
Triton X-100 or Digitonin (Serru et al., 1999; Yauch et al., 1998).  Examples of primary 
tetraspanin-partner protein interactions include CD151 with the laminin binding integrin 
α3β1,, and CD9 with the IgSF member EWI-F (Charrin et al., 2001; Serru et al., 1999).  
Secondary tetraspanin interactions are maintained under less stringent conditions (e.g. 
Brij97).  These tetraspanin-partner interactions are not direct, but are maintained by 
tetraspanin-tetraspanin interactions in Brij97 that would be disrupted in more stringent 
detergents (Berditchevski et al., 1996).  In addition, these tetraspanin-tetraspanin 
interactions are regulated by cholesterol and gangliosides (Charrin et al., 2003; Odintsova 
et al., 2006) along with intracellular palmitoylation of cysteine residues (Charrin et al., 
2002), which regulate tetraspanin membrane dynamics and subsequent clustering 
(Espenel et al., 2008; Termini et al., 2014). 
The use of chimeric protein constructs to map tetraspanin-partner protein interactions 
have proven invaluable.  Chimeric tetraspanin proteins are made by swapping various 
regions of the tetraspanin with regions of a tetraspanin that does not interact with the 
partner protein.  By utilising this approach, many tetraspanin partner protein interactions 
have been deciphered.  For example, CD81 interacts with the fourth IgSF domain of EWI-
2 along with a glycine-zipper motif located in the transmembrane region (Montpellier et 
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al., 2011).  On CD81, the larger extracellular loop and transmembrane regions 3 and 4 
are required for its interaction with EWI-2 (Montpellier et al., 2011).  CD9 also interacts via 
its fourth transmembrane region to the transmembrane region with the second EWI 
member, EWI-F (Charrin et al., 2009b).  More recently, the Tomlinson group have 
mapped the interacting regions of six tetraspanins (Tspan5, 10, 14, 15, 17 and 33; 
collectively referred to at the TspanC8 subgroup of tetraspanins) and their partner protein 
ADAM10, using a similar approach to that explained previously (Noy et al., 2016) (see 
Section 1.3.3).  However, these biochemical assays are limited by the fact that the 
dynamics of specific tetraspanin-partner protein interactions cannot be investigated. 
Tetraspanins are now thought of as proteins that dynamically patrol the plasma 
membrane forming interactions with specific partner proteins.  Single particle tracking 
analysis of fluorescent tagged CD9 molecules revealed that CD9 molecules preferentially 
followed a Brownian motion, moving to and from small clusters of CD9 (Espenel et al., 
2008).  More recently, the use of dual colour stimulated emission depletion (STED) 
microscopy has highlighted the nanoscale organisation of these tetraspanin enriched 
domains (Zuidscherwoude et al., 2015).  This study showed that endogenous tetraspanin 
nanoclusters on B cells are smaller than 120 nm in size and revealed that these clusters 
contain less than 10 CD53 molecules, which prefer to form homodimeric interactions with 
one another (Zuidscherwoude et al., 2015).  These nanoclusters seem to be specific to a 
single tetraspanin and respective tetraspanin partner proteins seem to form separate 
clusters that are in close proximity to their tetraspanin partners (Zuidscherwoude et al., 
2015).  An individual tetraspanin enriched cluster contained, on average, 3.5 molecules of 
CD53 and where multiple tetraspanins could interact with a single partner protein (e.g. 
MHC class II and tetraspanins CD53 and CD37) the tetraspanin clusters overlapped with 
the partner protein in which the tetraspanins were adjacently positioned at the plasma 
membrane (Zuidscherwoude et al., 2015). Similar observations were made in a study 
looking at CD82 distribution in KG1a cells, which revealed a nanocluster size of 90 nm 
CHAPTER 1:  GENERAL INTRODUCTION 
38 
using stochastic optical reconstruction microscopy (STORM) (Termini et al., 2014).  
These data suggest that tetraspanin clusters are organised into smaller nanoclusters that 
form distinct distribution patterns at the plasma membrane with their respective partner 
proteins (Zuidscherwoude et al., 2015). 
 
1.3.2.2 Tetraspanins mediate partner protein function via their 
trafficking, lateral mobility and clustering 
One function of tetraspanins is their ability to regulate the biosynthesis and maturation of 
their specific partner proteins.  A well-characterised example of this is the association of 
the tetraspanin CD81 and its partner protein CD19.  CD19 is an IgSF member that is 
expressed on B cells and forms a complex with CD81 and CD21 (Bradbury et al., 1992; 
Matsumoto et al., 1993).  Mice deficient in CD81 displayed a 50% reduction in cell surface 
CD19 compared to wild-type mice.  This phenotype was due to impaired trafficking of 
CD19 from the endoplasmic reticulum to the Golgi (Shoham et al., 2003).  Furthermore, 
CD19 expression in a CD81 deficient human patient showed abrogated CD19 expression 
at the surface of B cells due to impaired trafficking of CD19 by CD81 (Van Zelm et al., 
2010).  Both the mouse study and the human patient study showed impaired B cell 
antibody responses upon challenge (Levy and Shoham, 2005; Van Zelm et al., 2010). 
Another function of tetraspanins is their ability to promote clustering of their partner 
proteins at the plasma membrane, which then promotes partner protein function such as 
signalling and adhesion.  Tetraspanins have been shown to enhance the adhesive 
capacity of their partner proteins by promoting clustering during the process of leukocyte 
extravasation.  This has been demonstrated on endothelial cells under pro-inflammatory 
cytokine conditions.  Endothelial tetraspanins CD9, CD63 and CD151 have been shown 
to form essential interactions with their partner proteins, ICAM-1, P-selectin and VCAM-1, 
respectively (Barreiro et al., 2008; Doyle et al., 2011) (also see Section 1.1.3) (Figure 
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1.10).  Doyle et al. (2011) were able to show that CD63 knockdown using siRNA and the 
knockout of CD63 in mice resulted in a reduction in P-selectin expression and subsequent 
loss of P-selectin specific recruitment of monocytes, thereby mimicking phenotypes 
observed in P-selectin knockout mice.  Image analysis using scanning electron 
microscopy showed that CD63 co-localises with P-selectin on endothelial cells to form 
part of larger tetraspanin adhesion microdomains by mediating CD63 dependent 
clustering of P-selectin.  Moreover, CD63 and P-selectin localised to intracellular 
organelles such as lysosomes and Weibel-Palade bodies and upon activation of the 
endothelium were rapidly trafficked to the cell surface to support leukocyte capture (Doyle 
et al., 2011).  In addition to this study, another two endothelial tetraspanins, CD9 and 
CD151, have been shown to interact with the CAMs ICAM-1 and VCAM-1, respectively 
(Barreiro et al., 2008, 2005).  Initial experiments showed how ICAM-1 and VCAM-1 were 
recruited into docking structures upon co-incubation of endothelial cells with leukocytes 
(Barreiro et al., 2005).  The same authors also published that ICAM-1 and VCAM-1 
associated with tetraspanins CD9 and CD151 in tetraspanin-enriched microdomains.  
Upon adhesion of leukocytes to cytokine-stimulated endothelial cells, CD9 and CD151 
clustered ICAM-1 and VCAM-1 forming endothelial adhesive platforms and subsequently 
increasing the formation of microvilli that encapsulate the leukocyte and prime it for 
transmigration (Barreiro et al., 2008).  In addition to this, leukocyte tetraspanins CD81 and 
CD9 are important in inducing adhesion strengthening by clustering leukocyte integrins 
VLA-4 and LFA-1, respectively (Feigelson et al., 2003; Reyes et al., 2015).  The 
tetraspanin CD151 interacts with and regulates the avidity of laminin binding integrins 
α3β1, α6β1, and α6β4 (Sterk et al., 2002).  CD151 associates with the α-subunit of these 
integrins (Hemler, 2014) and its implicated roles include decreased diffusion of the α6 
subunit, thereby making the integrin stable for adhesive functioning (Yang et al., 2012) 
along with affecting distribution and recycling of α3 and α6 subunits during cell migration 
(Winterwood et al., 2006; Yang et al., 2008).  The role of CD151 in regulating integrin 
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function has resulted in interest in the role of this tetraspanin in pathological angiogenesis 




In addition to trafficking and clustering of partner proteins, tetraspanins also regulate 
efficient partner protein signalling.  One of the most characterised examples of tetraspanin 
dependent partner protein signalling is the regulation of Frizzled 4 signalling in response 
to its ligand Norrin by the tetraspanin Tspan12 (Junge et al., 2009).  Frizzled 4 belongs to 
the Wnt receptor family and it associates with its co-receptors Lrp5 and Lrp6.  Binding of 
Norrin to Frizzled 4 stabilises β-catenin that exhibits transcriptional activity in the nucleus.  
Knockout of Tspan12 in mice phenocopied mice deficient in Frizzled 4, Lrp5 or Norrin 
exhibiting vascular abnormalities in the retina (Junge et al., 2009).  In in vitro studies, 
overexpression of Tspan12 promoted Norrin-induced Frizzled 4 signalling and this 
Figure 1.10  Tetraspanin-associated partner proteins on endothelial cells and leukocytes 
involved in leukocyte adhesion and transmigration.  Endothelial tetraspanins CD151, CD9, 
and CD63 associate with the CAMs VCAM-1, ICAM-1 and P-selectin, respectively.  In addition, 
leukocyte tetraspanins CD81 and CD9 associate with leukocyte integrins VLA-4 and LFA-1, 
respectively (Barreiro et al., 2008; Doyle et al., 2011; Feigelson et al., 2003; Reyes et al., 2015). 
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pathway was compromised when Tspan12 was knocked down.  This interaction was 
specific to Tspan12 and Norrin/Frizzled 4 since when different tetraspanins were 
investigated or the introduction of Wnt (another Frizzled 4 ligand) was used, the signalling 
downstream of Frizzled 4 was unaffected, suggesting the Tspan12 interaction with 
Frizzled 4/Norrin is specific.  Co-immunoprecipitation assays revealed that Tspan12 
associated with Frizzled 4 and was required for clustering of Frizzled 4 (Junge et al., 
2009).  Furthermore, mutations of Tspan12 causes familial exudative vitreoretinopathy, an 
inherited blinding disorder characterised by abnormal retinal vascular system 
development (Nikopoulos et al., 2010; Poulter et al., 2010). 
 
1.3.3 ADAM10 associates with the TspanC8 subgroup of tetraspanins 
In addition to the functions highlighted above, tetraspanins have been also shown to 
associate with ADAM proteases.  ADAM10 was initially described to be tetraspanin-
associated under mild detergent lysis conditions with several tetraspanins including CD9, 
CD81 and CD82 (Arduise et al., 2008).  This study showed incubation of Raji cells with 
mAb antibodies to the respective tetraspanins enhanced the shedding of ADAM10 
substrates EGF and TNFα by altering ADAM10 localisation at the plasma membrane 
(Arduise et al., 2008).  In addition to this study, ADAM10 was also shown to interact with 
Tspan12 which promoted ADAM10 maturation and subsequent shedding of APP (Xu et 
al., 2009).  However, this was later confirmed not to be a direct tetraspanin-partner protein 
interaction through the use of more stringent lysis detergents (Dornier et al., 2012; 
Haining et al., 2012).  ADAM10 was subsequently shown by the Tomlinson group and two 
other independent research groups to associate with six, largely understudied but related 
tetraspanins (Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012b).  These 
tetraspanins included Tspan5, 10, 14, 15, 17 and 33 which all belong to the TspanC8 
subgroup of tetraspanins, as characterised by the presence of eight cysteine residues 
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within their large extracellular loop (Dornier et al., 2012; Haining et al., 2012; Prox et al., 
2012b).  The TspanC8s were shown to promote ADAM10 exit from the endoplasmic 
reticulum, enzymatic maturation (during which the inhibitory prodomain is removed), and 
trafficking to the cell surface (Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012b) 
(Figure 1.11).  Indeed, this mechanism of trafficking has been shown to hold true in 
human endothelial cells (Haining et al., 2012), mice (Haining et al., 2012) and Drosophila 
(Dornier et al., 2012) indicating that TspanC8s are fundamental to ADAM10 function.  
This interaction was characterised through the use of co-immunoprecipitation assays 
which revealed that the TspanC8s specifically immunoprecipitated with ADAM10 under 
stringent lysis conditions (Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012b).  
Overexpression of the TspanC8s in various cell line-models promoted the maturation and 
trafficking of ADAM10 to the cell surface and the large extracellular loop of the TspanC8s 
was required for ADAM10 maturation (Dornier et al., 2012; Haining et al., 2012; Noy et al., 
2016).  In addition, knockdown of TspanC8s affected ADAM10 surface expression.  
Haining et al. showed that HUVECs express at least five of the TspanC8s at the mRNA 
level, and siRNA-mediated knockdown of the most highly expressed HUVEC TspanC8, 
Tspan14, lead to a 50% reduction in the surface expression of ADAM10 and decreased 
the shedding of the endothelial ADAM10 substrate VE-cadherin (Haining et al., 2012).  In 
addition Tspan33 knockout erythrocytes showed reduced cell surface expression of 
ADAM10 (~90% compared to wild type erythrocytes) (Haining et al., 2012).  Dornier et al. 
showed ADAM10 trafficking becomes compromised following deletion of TspanC8s in the 
HeLa cell line.  Deletion of Drosophila orthologs of Tspan5, 10 and 14 resulted in an 
increase in the number of sensory organ precursor cells and a dramatic bristle loss 
phenotype as a result of impaired ADAM10 and Notch activity (Dornier et al., 2012). 




It could be regarded that ADAM10 exists as six distinct proteases depending on which 
TspanC8 tetraspanin it forms an interaction with and these individual TspanC8/ADAM10 
complexes could differentially traffic ADAM10 to distinct substrates.  Such evidence exists 
in cell line models whereby the shedding of key ADAM10 substrates has been assessed 
by co-transfecting the various TspanC8s with a particular ADAM10 substrate.  These 
experiments showed that Tspan5 and  Tspan14, but not Tspan15, promoted Notch 
cleavage (Dornier et al., 2012).  In U20S-N1 cells (U20S stably expressing Notch 1) 
stably expressing Tspan15, a 60% decrease in OP9-DLL1 (OP9 cells stably expressing 
Delta-like ligand 1)-induced Notch activity was observed when compared to control cells.  
Figure 1.11  Tetraspanin regulation of ADAM10 trafficking to the cell surface.  Schematic 
shows a proposed mechanism by which TspanC8s promote ADAM10s trafficking to the cell 
surface where ADAM10 can then interact with its various endothelial-specific substrates such as 
CX3CL1, CXCL16, VE-cadherin and Notch.  The consequences of ADAM10-dependent shedding 
are shown in red boxes. 
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Silencing of Tspan15 in U2OS-N1/Tspan15 cells restored Notch activity (Jouannet et al., 
2016).  Furthermore, Tspan15 suppressed ADAM10-mediated APP shedding in U2OS-N1 
and PC3 cells (Jouannet et al., 2016) but promoted shedding of APP in HEK and N2A 
cells (Dornier et al., 2012).  Moreover, the Tomlinson group have recently shown using a 
similar co-transfection model that Tspan15 promotes cleavage of N-cadherin, while 
Tspan14 protects shedding of the platelet collagen receptor GPVI in HEK293T cells (Noy 
et al., 2016).  These distinct TspanC8/ADAM10 complexes have been shown to have 
distinct TspanC8 subcellular localisation patterns in cell lines (Dornier et al., 2012).  For 
example, Tspan10 and Tspan17 were shown to re-localise ADAM10 into intracellular 
compartments that co-localised with the late endosome marker, CD63.  In contrast, 
Tspan5, 14, 15 and 33 all promoted ADAM10 membrane localisation in a HeLa cell line 
model (Dornier et al., 2012).  Tspan5 and Tspan15 were shown to localise ADAM10 
differently, with Tspan5 being predominantly membrane localised and Tspan15 being 
more localised in the late endocytic compartment (Jouannet et al., 2016).  The mapping of 
the binding regions of TspanC8s to ADAM10 has revealed distinct binding abilities of the 
TspanC8s to ADAM10.  By using a chimeric approach, Noy et al. showed that a 
membrane-proximal region of ADAM10, encompassing the stalk, cysteine-rich and 
disintegrin domains, mediated its co-immunoprecipitation with Tspan14 (Noy et al., 
2016).  Truncated ADAM10 constructs revealed differential TspanC8 binding 
requirements: Tspan15 interacted with the ADAM10 stalk alone, all other TspanC8s 
required the stalk plus cysteine-rich region, and Tspan17 interaction was impaired by 
inclusion of the disintegrin domain (Noy et al., 2016).  Since ADAM10 shedding of its 
substrates appears to be not defined by a specific amino acid motif, the data outlined by 
Noy et al. strongly suggests that ADAM10 may adopt distinct conformations in complex 
with different TspanC8s, which could impact on substrate selectivity and ADAM10 activity. 
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1.4 HYPOTHESIS & AIMS 
Hypothesis:   
ADAM10 on primary endothelial cells is essential for primary human leukocyte 
transmigration under flow conditions, due to its cleavage of VE-cadherin and/or the 
transmembrane chemokines CX3CL1 and CXCL16.  Furthermore, one or more TspanC8 
tetraspanins may regulate this function of ADAM10 by specifically affecting the cleavage 
of one of these substrates. 
 
Aims: 
1. To elucidate the effects of endothelial ADAM10 knockdown on the adhesion and 
transmigration of different leukocyte subsets in vitro. 
An in vitro flow-based adhesion assay in combination with static adhesion assays were 
utilized in which endothelial ADAM10 was targeted using siRNA knockdown or inhibited 
using a pharmacological inhibitor prior to assessing the recruitment and transmigration of 
neutrophils, peripheral blood lymphocytes (PBLs) or monocytes. 
 
2. To determine the mechanism by which endothelial ADAM10 exerts its effect by 
identifying the key substrate(s) involved. 
HUVECs were screened for their expression of CX3CL1, CXCL16 and VE-cadherin using 
flow cytometry and Western blotting approaches under pro-inflammatory conditions.  
Manipulation of VE-cadherin surface levels in the presence of ADAM10 knockdown or 
inhibition were assessed to elucidate the function of VE-cadherin in PBL transmigration. 
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3.  To investigate the role of specific endothelial TspanC8 tetraspanins that are 
required for ADAM10’s role in PBL transmigration. 
Lentiviral overexpression and siRNA knockdown of endothelial TspanC8s were used to 
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2.1 LIST OF REAGENTS 
2.1.1 General reagents 
Cell culture reagents 
Reagent Details and source 
Amphotericin B Life Technologies Invitrogen Compounds 
(Paisley, UK) 
Bovine brain extract First Link (UK) Ltd. (Wolverhampton, UK) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Poole, Dorset, UK) 
Dulbecco’s Modified Eagles Medium 
(DMEM) 
1000 mg/L glucose, Sigma-Aldrich (Poole, 
Dorset, UK) 
Epidermal growth factor (EGF) Sigma-Aldrich (Poole, Dorset, UK) 
Ethylene diamine tetraacetic acid 
(EDTA) 
0.02%, Sigma-Aldrich (Poole, Dorset, UK) 
Fetal bovine serum (FBS) Gibco (Paisley, UK) 
Heparin Sigma-Aldrich (Poole, Dorset, UK) 
Hydrocortisone Sigma-Aldrich (Poole, Dorset, UK) 
L-Glutamine 200mM, Gibco (Paisley, UK) 
M119 medium Earls salts, Sigma-Aldrich (Poole, Dorset, 
UK) 
Penicillin/Streptomycin Sigma-Aldrich (Poole, Dorset, UK) 
Phosphate Buffer Saline (PBS) 1X PBS with calcium and magnesium, 
Sigma-Aldrich (Poole, Dorset, UK) 
1X PBS without calcium and magnesium, 
Sigma-Aldrich (Poole, Dorset, UK) 
Trypsin-EDTA solution Diluted from 10X to 2X in PBS, Sigma-
Aldrich (Poole, Dorset, UK) 
 
Human leukocyte isolation reagents 
Reagent Details and source 
Bovine serum albumin (BSA) 7.5% V, Gibco (Paisley, UK) 
Histopaque-1077 Sigma-Aldrich (Poole, Dorset, UK) 
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Histopaque-1119 Sigma-Aldrich (Poole, Dorset, UK) 
 
Cytokines and inhibitors 
Reagent Details and source 
GI254023X Cat No.: SML0789, Sigma-Aldrich (Poole, 
Dorset, UK) 
N-[N-(3,5-difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester (DAPT) 
Cat No.: D5942, Sigma-Aldrich (Poole, 
Dorset, UK) 
Recombinant human Interferon-γ (IFNγ) Cat No.: 300-02, Preprotech (London, UK) 
Recombinant human Interleukin-1-β (IL-
1β) 
Cat No.: SRP3083, Sigma-Aldrich (Poole, 
Dorset, UK) 
Recombinant human Tumour necrosis 
factor-α (TNFα) 
Cat No.: 210-TA, R&D systems (Abingdon, 
Cambridge, UK) 
 
Commonly used buffers 
Antigen Details 
2X SDS non-reducing 
sample buffer 
20 ml 1 M Tris, pH 6.8 
80 ml 10% SDS 
40 ml Glycerol 
60 ml dH2O 
5 mg Bromophenol blue 
Antibody incubation 
buffer 
15 g BSA 
0.6 g NaN3 
500 ml TBST 
Blocking solution 1 g Marvel 
10 ml TBST 
FACS buffer 10 g  BSA 
1ml NaN3 
500 ml PBS 
SDS polyacrylamide 
resolving buffer  
30.3 g Tris 
2 g SDS 
pH 8.8 
500 ml dH2O 
SDS polyacrylamide 
stacking buffer 
30.3 g Tris 
2 g SDS 
pH 6.8 
500 ml dH2O 
SDS-Page running 
buffer 
15 g Tris 
72 g Glycine 
50 mL 10% SDS 
5 L dH2O 
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TBS 20 mM Tris 
137 mM NaCl 
pH 7.6 
2 L dH2O 
TBST 20 mM Tris 
137 mM NaCl 
5 ml Tween 
pH 7.6 
5 L dH2O 
TBST high salt wash 
buffer 
500 mM NaCl 
2 L TBST 
Triton X-100 lysis buffer 250 ml 2% Triton X-100 
1 M Tris, pH 7.5 
5 M NaCl 
0.5 M EDTA, pH 8.0 
0.05 g NaN3 
250 ml dH2O 
Western blot stripping 
buffer 
1 M Tris, pH 7.6 
50 ml 10% SDS  
500 ml dH2O 
Western transfer buffer 15 g Tris 
72 g Glycine 
1 L Methanol 
5 L dH2O  
 
Other reagents 
Reagent Details and source 
Acrylamide 30%, Geneflow (Lichfield, UK) 
Ammonium persulfate (APS) 10%, Sigma-Aldrich (Poole, Dorset, UK) 
Bromophenol Blue Bio-Rad (Hemel Hempstead, Hertfordshire, 
UK) 
Collagenase Type Ia, Stock kept at: 10 mg/ml, Sigma-
Aldrich (Poole, Dorset, UK) 
Ethanol 70%, Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Ethylenediaminetetraacetic acid (EDTA) 0.02%, Sigma-Aldrich (Poole, Dorset, UK) 
Gelatine 0.1% in PBS 
Glycerol  Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Glycine Sigma-Aldrich (Poole, Dorset, UK) 
Lipofectamine RNAiMAX Life Technologies Invitrogen Compounds 
(Paisley, UK) 
Marvel Premiere Foods (St Albans, Hertfordshire, 
UK) 
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Sigma-Aldrich (Poole, Dorset, UK) 
OptiMEM Gibco (Paisley, UK) 
Paraformaldehyde 36.5%, Sigma-Aldrich (Poole, Dorset, UK) 
Polybrene Sigma Aldrich (Poole, Dorset, UK) 
Polyethylenimine Sigma-Aldrich (Poole, Dorset, UK) 
Polyvinylidene fluoride (PVDF) 
membrane 
Immobilon-FL, Merck Millipore (Watford, 
Hertfordshire, UK) 
Protease inhibitor cocktail Sigma-Aldrich (Poole, Dorset, UK) 
Protein marker BLUEyeTM, Geneflow (Lichfield, UK)  
Puromycin Sigma-Aldrich (Poole, Dorset, UK) 
Sodium azide (NaN3) Sigma-Aldrich (Poole, Dorset, UK) 
Sodium chloride (NaCl) 150 mM, Sigma-Aldrich (Poole, Dorset, UK) 
Sodium dodecyl sulphate (SDS) Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Tris Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Triton X-100 lysis buffer 1%, Sigma-Aldrich (Poole, Dorset, UK) 
Whatman filter paper 3MM, GE Healthcare (Amersham, 
Buckinghamshire, UK) 
β-mercaptoethanol Sigma-Aldrich (Poole, Dorset, UK) 
 
2.1.2 List of antibodies 
Primary antibodies 
Antigen Details and source 
ADAM10 Purified monoclonal mouse anti-human ADAM10 FITC, R&D Systems 
(Abingdon, UK), working concentration: 10 µg/ml (flow cytometry) 
CD3 Purified monoclonal mouse anti-human CD3 PerCPCy5.5, clone OKT3, 
eBiosciences (Hatfield, UK), working concentration: 2 µg/ml (flow 
cytometry) 
CD4 Purified monoclonal mouse anti-human CD4 APCCy7, clone OKT3, 
eBiosciences (Hatfield, UK), working concentration: 2 µg/ml (flow 
cytometry) 
CD8 Purified monoclonal mouse anti-human CD8 PB, clone SK1, eBiosciences 
(Hatfield, UK), working concentration: 2 µg/ml (flow cytometry) 
CD14 Purified monoclonal mouse anti-human CD14 APC, clone OKT3, 
eBiosciences (Hatfield, UK), working concentration: 2 µg/ml (flow 
cytometry) 
CD19 Purified monoclonal mouse anti-human CD19 PECy7, clone OKT3, 
eBiosciences (Hatfield, UK), working concentration: 2 µg/ml (flow 
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cytometry) 
CD56 Purified monoclonal mouse anti-human CD56 PE, clone CMSSB, 
eBiosciences (Hatfield, UK), working concentration: 2 µg/ml (flow 
cytometry) 
CX3CL1 Purified monoclonal mouse anti-human CX3CL1/Fractalkine FITC, R&D 
Systems (Abingdon, UK), working concentration: 2 µg/ml (flow cytometry) 
CX3CR1 Purified monoclonal mouse anti-human CX3CR1 FITC, R&D Systems 
(Abingdon, UK), working concentration: 2 µg/ml (flow cytometry) 
CXCL16 Purified monoclonal mouse anti-human CXCL16 APC, R&D Systems 
(Abingdon, UK), working concentration: 2 µg/ml (flow cytometry)  
CXCR6 Purified monoclonal mouse anti-CXCR6 APC, R&D Systems (Abingdon, 
UK), working concentration: 2 µg/ml (flow cytometry) 
FLAG Purified monoclonal anti-human FLAG M2, clone M2, Sigma-Aldrich 
(Poole, Dorset, UK), working concentration: 1 µg/ml (Western blotting) 
Human BD 
Fc BlockTM  
Purified recombinant Fc protein, BD Biosciences (Oxford, UK), working 
concentration: 2.5 µg/ml (flow cytometry) 
Rabbit IgG Purified polyclonal rabbit anti-human Rabbit IgG, Cell Signalling 
Technology (Danvers, USA), working concentration: 1 µg/ml (Western 
blotting) 
VE-cadherin Purified monoclonal mouse anti-human VE-cadherin (F-8), Santa Cruz 
Biotechnology Inc. (Santa Cruz, USA), working concentration: 1 µg/ml 
(Western blotting) 
Purified monoclonal mouse anti-human VE-cadherin APC, clone 16B1, 
eBiosciences (Hatfield, UK), working concentration: 2 µg/ml (flow 
cytometry) 
α-Tubulin Purified monoclonal mouse anti-human α-Tubulin, clone DM1A, Sigma-
Aldrich (Poole, Dorset, UK), working concentration: 1 µg/ml (Western 
blotting) 
 
Isotype control antibodies 
Isotype Details and source 
Mouse IgG1 FITC-conjugated, clone 51637, R&D Systems (Abingdon, UK) 
Mouse IgG2B APC-conjugated, clone 123413, R&D Systems (Abingdon, UK) 
Mouse IgG2B FITC-conjugated, clone 163003, R&D Systems (Abingdon, UK) 
Rat IgG2A APC-conjugated, clone 256213, R&D Systems (Abingdon, UK) 
 
Secondary antibodies 
Antigen Details and source 
Mouse IgG Goat anti-Mouse IRDye 680RD, LI-COR (Cambridge, UK) 
Goat anti-Mouse IRDye 800CW, LI-COR (Cambridge, UK) 
Rabbit IgG Goat anti-Rabbit IRDye 800CW, LI-COR (Cambridge, UK) 
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2.2 CELL CULTURE 
All cells were kept in a humidified incubator at 37°C, 5% CO2. 
 
2.2.1 Cell lines 
2.2.1.1 Culture of HEK292T cells 
The HEK293T human embryonic kidney cell line was obtained from laboratory stocks and 
cultured in DMEM media with added supplements: 10% heat inactivated FBS, 4 mM 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
 
2.2.2 Isolation and culture of primary human umbilical vein 
endothelial cells (HUVECs) 
2.2.2.1 Isolation of HUVECs 
Human umbilical cords were obtained from the Human Biomaterials Resource Centre 
(University of Birmingham) (09/H1010/75) which holds ethical approval and collection of 
fully consented tissue from the Birmingham Women’s Hospital NHS Trust.  HUVECs were 
isolated using the collagenase digestion method (Cooke et al., 1993).  Briefly, umbilical 
cords were placed on a tray and sprayed down with 70% ethanol in a tissue culture hood.  
The vein was identified and cannulated at both ends of the umbilical cord using cable ties.  
Venous blood was removed from the cord by perfusion of PBS.  Residual PBS was then 
removed by passing air through the cord using an empty syringe.  For the digestion of the 
endothelial cells from the venular wall, collagenase type Ia was diluted to a working 
concentration of 1 mg/ml in PBS before being passed through the vein.  Once both 
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cannulae were filled with collagenase, the cannulae were clamped at both ends and cord 
was placed into an incubator for 15 minutes at 37°C and 5% CO2.  The cord was then 
massaged gently for a minute prior to the contents of the vein being flushed out using 
PBS into a 50 ml centrifuge tube (Corning, UK).  Residual PBS in the cord was removed 
by passing air through the cord and collected into the same 50 ml centrifuge tube.  The 50 
mL centrifuge tube was centrifuged at 400g for 5 minutes at room temperature.  Following 
centrifugation, the supernatant was removed and the pellet was resuspended in 1 ml of 
complete HUVEC growth medium or complete HUVEC medium, depending on what the 
cells were going to be used for (see Section 2.2.2.2 for media recipes) post cell count. 
 
2.2.2.2 Culture of isolated cells 
Depending on the nature of use, HUVECs were cultured under two different conditions.  
For subculture, HUVECs were cultured in M199 media with added supplements (referred 
to as complete HUVEC growth medium): 10% heat inactivated FBS, 4 mM glutamine, 
0.3% bovine brain extract (provided by Dr Victoria Heath), 90 µg/ml heparin and 100 U/ml 
penicillin and 100 µg/ml streptomycin.  These HUVECs were used up to passage six and 
grown in 10cm dishes that had previously been treated with 0.1% gelatine.  For adhesion 
assays, passage zero/one HUVECs were used in M199 media with added supplements 
(referred to as complete HUVEC medium): 20% heat inactivated FBS, 4 mM glutamine, 
100U/ml penicillin and 100 µg/ml streptomycin, 10 ng/ml epidermal growth factor, 1 µg/ml 
hydrocortisone and 2.5 µg/ml amphotericin B.  Under both culture conditions, the media 
was changed every two days.  Once confluent, endothelial cells exhibit a cobblestone-like 
morphology (Figure 2.4).  
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2.2.3 Determination of cell number 
Cell number was determined using an automated cell counter.  Briefly, media from cell 
dishes/flasks was removed and 2 ml trypsin/EDTA was added.  For HUVECs, the cell 
monolayer was washed once with pre-warmed PBS prior to adding trypsin/EDTA.  The 
cells were placed into an incubator at 37°C and 5% CO2 for 2 minutes.  The cells were 
then viewed under a microscope until the cells became round in shape.  The dish/flask 
was tapped gently to detach the cells and the trypsin was inactivated by adding 8 ml 
culture medium (dependent on cell type; complete HUVEC medium/complete HUVEC 
growth medium for HUVEC or DMEM for HEK293T cells) to the culture dish/flask and the 
cell suspension was transferred into a 15 ml centrifuge tube (Corning, UK).  The cell 
suspension was centrifuged at 400g for 5 minutes at room temperature.  Following 
centrifugation, the supernatant was aspirated and the pellet was resuspended in 1 ml of 
the respective medium.  To determine cell count, the cell suspension was diluted 1:20 by 
transferring 20 µl of the cell suspension into an Eppendorf containing 380 µl of media.  20 
µl of this solution was then transferred into a Cell-o-meterTM cell counting slide and 
counted using the digital cell counting software (Nexecelom Bioscience, Lawrence, MA, 
USA).  The original cell suspension was then adjusted accordingly based on the cell 
count. 
 
2.2.4 Cell transfection protocols 
2.2.4.1 Transfection of HEK293T using PEI 
HEK293T cells were transiently transfected using polyethylenimine (PEI) (Ehrhardt et al., 
2006 & Haining et al., 2012).  Briefly, HEK293T cells were plated out into 6-well plates at 
a cell density to reach 60% - 80% confluency 24 hours before transfection in complete 
DMEM medium.  100 µl Opti-MEM serum-free media was incubated with 1 µg DNA with 4 
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µl PEI (1 mg/ml stock) for 10 minutes at room temperature to allow DNA/PEI complexes 
to form.  The DNA/PEI mix was then added directly to the HEK293T cells in culture media 
and cells were used 48 hours after transfection for flow cytometry. 
Specific plasmids transiently transfected into HEK293T cells include a pcDNA3.1 mock 
vector (Invitrogen) or a pcDNA3.1 vector containing either human CX3CL1 or CXCL16 
fused with 2Z tags (a kind gift from Andreas Ludwig, Aachen, Germany) which were used 
to assess expression of these chemokines in HEK293T cells. 
 
2.2.4.2 Transfection of HUVECs with siRNA 
HUVECs were transiently transfected using Lipofectamine RNAiMAX (Life Technologies 
Invitrogen Compounds) and at least two individual siRNA duplexes to ADAM10, VE-
cadherin, Tspan5, Tspan10, Tspan14, Tspan15, Tspan17 and Tspan33 (Life 
Technologies Ambion Compounds) to knockdown proteins of interest during various 
endothelial functional assays, as previously described (Haining et al., 2012).  Briefly, 
HUVECs were plated out at a cell density to reach 60% - 80% confluency 24 hours before 
transfection in either complete HUVEC growth medium or in complete HUVEC medium, 
depending on the nature of the functional assay the HUVEC were going to be used for 
(see Section 2.2.2.2).  A duplex mix, containing siRNA duplex(s) and Opti-MEM serum 
free media were prepared.  For the introduction of individual siRNA duplexes, a final 
siRNA concentration of 10 nM was used.  When assessing combinational knockdowns, a 
final siRNA total of 30 nM or 25 nM was used.  Separately, a Lipofectamine mix 
containing just Lipofectamine RNAiMAX and Opti-MEM was prepared.  The two mixes 
were kept at room temperature for 5 minutes before being combined and left at room 
temperature for a further 10 minutes.  The HUVECs were prepared by washing twice with 
PBS, and the respective duplex/Lipofectamine mixes were added to the cells.  In addition, 
further Opti-MEM was added to dilute the duplex/Lipofectamine mix 5-fold.  The HUVECs 
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were incubated for 4 hours at 37°C and 5% CO2 after which the media was changed to 
complete HUVEC media without antibiotics or complete HUVEC growth media without 
antibiotics and the HUVECs were then used for functional assays at the 48-hour time 
point post siRNA transfection.  Typical cell counts and volumes of reagents are listed 












12 well 8.75 x 104 1.25 µl 83.75 µl 1.5 µl 13.5 µl 500 µl 
6 well 1.75 x 105 2.5 µl 167.5 µl 3 µl 27 µl 1 ml 
6 cm 3.6 x 105 3.6 µl 241.4 µl 4.3 µl 38.7 µl 2 ml 
Table 2.1  Reagents and quantities required for siRNA transfection of HUVECs. 
 
2.2.4.3 Lentiviral transduction of HUVECs 
In order to transduce HUVECS to stably express specific proteins of interest, HEK293T 
cells were used as surrogate cells to produce lentivirus that could then be used to infect 
HUVECs.  Briefly, 5x105 HEK293T cells were plated onto six well plates in complete 
DMEM media.  Following 24 hours, a PEI transfection was performed as described in 
Section 2.2.4.1.  In addition, the amount of DNA introduced was reduced since three 
different vectors were being introduced into the cells: 0.54 µg transfer vector (plasmid 
containing gene of interest), 0.33 µg packaging vector (PSPAX2) and 0.13 µg envelope 
vector (PMD2G) per well of the six well plate.  For the gene of interest plasmids, mouse 
TspanC8 tetraspanins with N-terminal FLAG tags were expressed using the pLVX vector, 
which contains an IRES-driven puromycin resistance cassette (Clontech, Mountain View, 
CA, USA) (prepared by Dr Jing Yang).  The HEK293T cells were incubated at 37°C and 
CO2 for 48 hours and the resulting viral media was used to infect HUVECs. 
To transduce HUVECs, the HUVECs were initially plated into 0.1% gelatine coated six 
well plate at a cell density of 1.75x105 cells per well in complete HUVEC growth medium.  
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Following 24 hours, virus containing media was collected from the HEK293T cells and 
centrifuged for 5 minutes at 195 g to remove cell debris.  The viral media was 
supplemented with 8 µg/ml polybrene, 90 µg/ml heparin and 0.3% bovine brain extract 
before being passed through a 0.45 µm pore filter (Corning).  The media on the HUVECs 
was aspirated and replaced with the supplemented virus-containing media and the 
HUVECs were incubated for a further 72 hours at 37°C and 5% CO2.  Following 72 hours, 
the virus containing media on the HUVECs was aspirated and replaced with complete 
HUVEC growth medium with 0.5 µg/ml puromycin.  The HUVECs were cultured for a 
further 48 hours or until the mock transfected HUVECs had all died, as confirmed by 
checking the HUVECs using a microscope.  Stably transduced HUVECs were then 
cultured in complete HUVEC growth media and used in various endothelial function 
assays. 
 
2.2.5 Measuring trans-endothelial electrical resistance of HUVEC 
monolayers 
The electrical resistance across a monolayer of HUVEC either treated with the ADAM10 
inhibitor (GI254023X) or following endothelial ADAM10 knockdown was assessed using 
the Minicell-ERS resistance according to the manufacturer’s instructions (Merck Millipore, 
USA).  HUVECs were plated in complete HUVEC growth medium into 0.1% gelatine-
coated 0.4 µm polyester membrane transwell-clear filters (Corning, Flintshire, Cheshire, 
UK) at a cell density of 4x104 cells/300 µl, a concentration of cells that has previously 
been shown to form a complete monolayer within 24 hours of seeding (McGettrick et al., 
2009).  Following 24 hours, the HUVEC media in the filters was changed and replaced 
with complete HUVEC growth medium either containing 0.02% DMSO or 20 µM 
GI254023X and resistance readings were taken at 0, 4, 12, 24 and 48 hours after inhibitor 
treatment.  For assessing the effects of ADAM10 knockdown on the trans-endothelial 
CHAPTER 2:  MATERIALS AND METHODS 
59 
electrical resistance of HUVECs, HUVECs were cultured as above and transfected 
separately with two siRNA duplexes to ADAM10 as explained in Section 2.2.4.2.  4 hours 
after transfection the HUVECs were cultured in complete HUVEC growth medium without 
antibiotics and resistance readings were taken sequentially at 0, 4, 12, 24 and 48 hours.  
The 0 hour time point corresponded to 4 hours after endothelial ADAM10 knockdown. 
When making the resistance readings, the electrodes were initially calibrated by 
immersing them in fresh complete HUVEC growth media for 15 minutes and manually 
adjusting the basal resistance reading to zero.  The filters were sequentially placed into 
the electrode chamber that contained 700 µl complete HUVEC growth medium and the 
top electrode was placed into the filter so that it was centrally located to ensure maximal 
reproducibility.  The electrical resistance across the HUVEC monolayer was measured 
and recorded.  Between resistance readings, the electrodes were washed in fresh 
HUVEC growth medium.  To calculate the electrical resistance across the complete 
HUVEC monolayer, the resistance of a blank filter was subtracted from the resistance of a 
sample filter.  This value was then multiplied by the area of the filter, to calculate the 
resistance in Ωcm2. 
 
2.2.6 Analysis of cell surface molecules by flow cytometry 
For characterisation of surface expression of adhesion molecules and specific ADAM10 
substrates on HUVECs or isolated PBLs a cytometric assay was used as described 
before (Haining et al., 2012).  Untreated HUVECs or HUVECs stimulated with different 
inflammatory cytokines were analysed.  HUVECs cultured in 24 well plates were initially 
washed once with PBS.  The cells were then treated with accutase to dissociate adherent 
cells.  The action of accutase was counteracted using an equal volume of HUVEC growth 
media followed by centrifugation for 5 minutes at 300g at room temperature.  The cells 
were then incubated with primary conjugated antibodies (ADAM10, VE-cadherin, 
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CX3CL1, CXCL16, and VCAM-1) along with appropriate control antibodies (detailed 
information about antibodies used are listed in Section 2.1.2).  Incubation was performed 
for 30 minutes on ice in the dark.  Subsequently, stained cells were washed twice with 
FACS buffer by centrifugation for 5 minutes at 300g.  As such, the stained cells were 
diluted in 500 µl FACS buffer before being processed by the flow cytometer.  Live cell 
populations were gated on by adding 1 µl propidium iodide (10 µg/ml) to each sample 
prior to running it through the flow cytometer.  Propidium iodide is a membrane 
impermeable dye that is only taken up by dead cells, so can be used to distinguish live 
and dead cell populations (Haining et al., 2012). 
For staining of distinct PBL/PBMC subsets for their parental markers and chemokine 
receptors, 2x106 cells/ml were divided into FACS tubes and centrifuged at 300g for 5 
minutes at room temperature prior to being incubated with 5 µg/ml BD Fc BlockTM in 
FACS buffer (see Section 2.1.2) for 30 minutes on ice to block unspecific binding.  After 
the blocking step, 16 µl of primary antibody cocktail in FACS buffer was added.  The 
cocktail of antibodies contained 2 µl of the following PBMC markers: CD3, CD4, CD8, 
CD56, CD14, CD19 along with either CXCR6 or CX3CR1.  PBL/PBMC were also stained 
for the appropriate control antibodies (detailed information about antibodies used in this 
study including concentrations are listed in Section 2.1.2).  Incubation was performed for 
30 minutes on ice in the dark.  Subsequently, stained cells were washed twice with FACS 
buffer by centrifugation for 5 minutes at 300g and the stained cells were diluted in 500 µl 
FACS buffer before being processed by the flow cytometer. Samples were originally 
gated on size and granularity before being gated to show the individual PBL populations.  
Manual compensation was carried out in every experiment to ensure that there was no 
bleeding of the fluorophores (Figure 2.1). 




Samples were acquired on a Beckman CyAnTN ADP flow cytometer (Beckman Coulter 
(UK) Ltd., High Wycombe, UK) using Summit acquisition software (Beckman Coulter) and 
analysed using FlowJo software (Tree Star Inc. Ashland, OR, USA).  Flow cytometry data 
were presented as the percentage surface expression calculated by subtracting isotype 
control mean fluorescence intensity (MFI) values from the positively stained MFI values.  
Control cells (DMSO control treated or No siRNA treated) MFI values were normalised to 
100% and respective treated cells were expressed relative to this value as a percentage. 
 
Figure 2.1  Gating strategy for PBL subsets using flow cytometry.  A total of 1x106 cells were 
originally gated on size and granularity prior to being gated for specific lymphocyte populations. 
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2.3 IN VITRO ADHESION ASSAYS 
Two well characterised in vitro models of leukocyte adhesion were utilised in this study; 
flow-based adhesion assays and static adhesion assays (Munir et al., 2015; Butler et al., 
2009)  
 
2.3.1 Cell seeding 
For flow-based adhesion assays, HUVECs were seeded in Ibidi µ-slides VI0.4 (Ibidi, 
Maastricht, Germany).  Briefly, HUVECs were trypsinised from a confluent 10 cm dish 
(~3x106 cells) as explained in Section 2.2.3.  The HUVECs were resuspended in 760 µl 
complete HUVEC media (1x10 cm dish seeded four 6-channel Ibidi microslides 
(~1.25x105 cells/channel)).  30 µl of the cell suspension was added to each of the 
channels (this volume of media had previously been shown to adequately cover the 
growth area of the channel through capillary action (Munir et al., 2015)). The Ibidi 
microslide was incubated at 37°C and 5% CO2 for an hour.  After this, 140 µl of fresh pre-
warmed complete HUVEC media was added to each of the channels and subsequently 
aspirated.  This was repeated for an additional two times to remove any non-adherent 
HUVECs.  Finally, 140 µl of complete HUVEC medium was added to each of the channels 
and the Ibidi microslide was cultured for a further 24 hours at 37°C and 5% CO2.  Any 
remaining cell suspension was resuspended in 10 ml fresh pre-warmed complete HUVEC 
growth medium and sub-cultured in a 0.1% gelatine coated 10 cm dish at 37°C and 5% 
CO2. 
For static adhesion assays, HUVECs from a confluent 10cm dish were trypsinised as 
explained in Section 2.2.3.  The HUVECs were resuspended in 1 ml complete HUVEC 
medium and adjusted to a working concentration of 1.75x105 cells/ml.  1 ml of the cell 
suspension was added to each well of a 0.1% gelatine coated 12-well plate.  In addition, 1 
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ml of complete HUVEC medium was added to each well and the HUVECs were cultured 
for 24 hours at 37°C and 5% CO2.   
 
2.3.2 Cytokine stimulation of endothelial cells 
To asses leukocyte recruitment and transmigration to primary HUVECs in vitro, a range of 
different cytokines were used that have previously been shown to support the recruitment 
and subsequent transmigration of specific leukocyte subsets by upregulating various 
cellular adhesion molecules (CAMs) and chemokines (Munir et al., 2015; Ahmed et al., 
2011; Rainger et al., 2001).  For stimulation of HUVECs with tumour necrosis factor-α 
(TNFα), a stock vial of previously frozen TNFα (1x105 U/ml) was thawed and diluted 
1:1000 in complete HUVEC medium to a final concentration of 100 U/ml (equivalent to 
~10 ng/ml).  The resuspended TNFα was added to the Ibidi microslide channels or 12-
well plates and treated cells were incubated at 37°C and 5% CO2 for 4 hours prior to the 
flow adhesion assay.  TNFα was also used in combination with interferon-γ (IFNγ).  For 
stimulation of HUVECs with TNFα/IFNγ, a stock vial of previously frozen IFNγ (10 µg/ml) 
was thawed and diluted 1:1000 in complete HUVEC medium to a final concentration of 10 
ng/ml.  This was added to complete HUVEC medium containing previously diluted TNFα 
at 100 U/ml, as explained above.  The TNFα/IFNγ media was then added to HUVECs 
grown in Ibidi microslide channels or to HUVECs grown in 12-well plates and treated cells 
were incubated at 37°C and 5% CO2 for 24 hours prior to the adhesion assay.  A final 
cytokine that was used was interleukin-1β (IL-1β).  This was prepared by thawing a 500 
ng/ml stock IL-1β and diluting 1:100 in complete HUVEC media to a final concentration of 
5 ng/ml (~2.5 nM).  The HUVECs in the Ibidi microslide channels were treated with IL-1β 
at 37°C and 5% CO2 for 4 hours prior to the adhesion assay.   
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2.3.3 Isolation of leukocyte subsets 
Primary human neutrophils, PBLs or monocytes were isolated from venous blood using a 
two-step density gradient method (Rainger et al., 2001) (Figure 2.2).  Blood samples were 
obtained from healthy donors with written informed consent that had previously been 
approved from the University of Birmingham Local Ethical Review Committee (ERN_07-
058).  Venous blood was drawn from donors and aliquoted directly into EDTA tubes 
(Sarstedt, Nümbrecht, Germany), and gently inverted.  2.5 ml of Histopaque 1077 was 
layered onto 2.5 ml Histopaque 1119 followed by layering of 5 ml whole blood in a 10 ml 
round bottomed tube (Appleton Woods Ltd., Birmingham, UK).  The tube was centrifuged 
at 800g for 30 minutes to isolate peripheral blood mononuclear cells (PBMCs) or for 40 
minutes to isolate neutrophils at room temperature.  PBMCs were harvested by taking the 
upper band at the interface of human plasma and Histopaque 1077.  Neutrophils were 
harvested by taking the lower band at the interface of Histopaque 1077 and Histopaque 
1119 (above the erythrocyte layer) (Figure 2.2).  Harvested cells were transferred into 15 
ml centrifuge tubes and made up to 10 ml with PBSA.  PBSA was prepared by diluting a 
7.5% BSA solution 1:50 in 50 ml PBS to a final concentration of 0.15% (w/v; PBSA).  The 
tubes were centrifuged at 400g for 5 minutes at room temperature.  The supernatant was 
aspirated and the pellet was resuspended in 10 ml PBSA and further centrifuged at 400g 
for 5 minutes.  The pellet was resuspended and cell number was counted as explained in 
Section 2.2.3.  For isolating a PBL purified population, PBMCs were panned on culture 
plastic for 30 minutes at 37°C to remove monocytes.  The PBL were washed again using 
PBSA and centrifuged at 400g for 5 minutes.  Following centrifugation, the pellet was 
resuspended and the cell number was counted as explained in Section 2.2.3.  The 
isolated leukocytes were adjusted to a final concentration of 1x106 cells/ml in PBSA for 
flow adhesion assays or in M199+BSA for static adhesion assays (M199+BSA was made 
similarly to how PBSA by swapping PBS with M199).  The cells were maintained at room 
temperature prior to the adhesion assays. 





Monocyte isolation for static adhesion assays was carried out slightly differently compared 
to the isolation of neutrophils or PBLs.  Briefly, monocytes were isolated by taking the 
PBMC layer following centrifugation of whole blood, as explained above.  The PBMC 
fraction was centrifuged twice in room temperature MACS buffer (28.2 ml calcium-free 
PBS, 8.8 ml 0.2% EDTA and 3.3 ml 7.5% BSA) at 800g for 5 minutes.  The PBMCs were 
then counted, as explained in Section 2.2.3, before undergoing positive selection through 
the use of MACS columns (Miltenyi Biotec Ltd, Woking, Surrey, UK).  The MS column 
was prepared by initially rinsing the column with ice-cold MACS buffer.  The eluate was 
discarded.  Next 500 µl of the washed PBMC fraction was put through the column.  The 
column was then washed three times with 500 µl ice-cold MACS buffer to remove any 
non-adherent peripheral blood leukocytes.  The column was then flushed using 1 ml ice-
cold MACS buffer and the plunger and the cells were collected.  The monocytes were 
centrifuged at 800g for 5 minutes at 4°C and subsequently counted, as explained in 
Section 2.2.3.  The final concentration was then adjusted to 1x105 monocytes per ml of 
M199+BSA and used in the static adhesion assays, similarly to PBLs. 
Figure 2.2  Two-step density centrifugation of whole blood to isolate peripheral blood 
lymphocytes (PBLs), monocytes or neutrophils.  Blood (5ml) was layered onto 2.5 ml 
Histopaque 1077 and 2.5 ml Histopaque 1119.  The tube was centrifuged for either 30 minutes to 
isolate PBLs or monocytes or for 40 minutes to isolate neutrophils at 800g at room temperature.  
After centrifugation, the specific leukocyte layers were collected and purified (Rainger et al., 
2001). 
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2.3.4 Flow adhesion assays 
Flow adhesion assays were set up as shown in Figure 2.3.  Prior to the adhesion assay, 
the heater was turned on and set to 37°C.  A 20 ml syringe without its plunger and a 5 ml 
syringe were attached to a 3-way tap and secured in place within the perspex chamber 
using micropore tape.  Silicon tubing (~2-4 mm thickness) (referred to as thick tubing) was 
cut to the right distance between the electronic value and the 3 way tap.  Roughly 8-
10mm silicon tubing (~1-3 mm thickness) (referred to as thin tubing) was cut and inserted 
to one end of the thick tubing.  The thick tubing was attached to the side of the 3 way tap 
and the other side of the thick tubing (containing the short piece of thin tubing) was 
connected to the electronic 3-way microvalve corresponding to the ‘wash buffer 
reserviour’ connection.  A 6-8 mm piece of thick and thin tubing was cut.  The thin tubing 
was inserted into one end of the thick tubing before the thick tubing was inserted onto the 
end of a 2 ml syringe containing no plunger.  The 2 ml syringe was then connected onto a 
port on the electronic microvalve corresponding to the ‘perfused cell reserviour’.  Further 
thin tubing was cut to measure the distance between the electronic valve and the middle 
of the stage of the microscope. In addtion, a short piece (~8-10 mm) of thick tubing was 
cut and attached to one end of the thin tubing. An L-shaped connector was placed on the 
end of the thick tubing and used to connect to the Ibidi microslide channel.  The tubing 
was primed by inititally filling up the wash buffer reserviour with PBSA and flowing through 
this buffer to remove any air bubbles.  On the other end of the flow adhesion assay setup, 
Manometer tubing (~29 mm) was attached to a 50 ml glass syringe.  The glass syringe 
was primed using PBSA.  To the end of the Manometer tubing (Smiths Medical, Ashford, 
Kent, UK) that was not connected to the glass syringe, a small piece of thick tubing (~10-
12 mm) was attached to securely connect an L-shapped connector.  The glass syringe 
was placed into a syringe pump for infusion/withdrawal (Harvard system).  The refill flow 
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rate required to generate the desired wall shear stress of 0.05Pa was calculated (0.4 
ml/min) and programmed into the Harvard system. 
The Ibidi microslide was placed onto the stage of an inverted phase contrast microscope.  
The L-shaped connectors were connected to opposing ends of the channel (one in the 
inlet port and the other in the outlet port).  PBSA was initially run through the channel.  
The syringe pump on the Harvard System was set to refill and ‘run’ was pressed.  The 
focus of the microscope was adjusted to visualise the HUVEC monolayer. 
Two minutes prior to starting the adhesion assay, 2 ml of purified leukocytes (either 
neutrophils or PBLs) were added to the ‘perfused cell reserviour’ and allowed to 
aclimatise to the temperatute.  The HUVEC monolayer was washed by perfusing PBSA 
for 2 minutes.  Upon completion of this, the electronic valve was turned ON to perfuse the 
leukocytes across the HUVEC monolayer.  Following perfusion of leukocytes for 4 
minutes, the electronic valve was switched OFF and PBSA from the ‘wash buffer 
reserviour’ was perfused for the remainder of the experiment.  
The recruitment and transmigration of leukocytes under flow conditions was done post-
perfusion of leukocytes.  All digital recordings were made of at least 5-10 fields of view in 
the centre plane of the flow channel.  The centre was identified by moving the microscope 
objective to the edge of the channel at the inlet port and identifying the middle of the port.  
Initial recordings of leukocyte behaviour post-leukocyte perfusion were made 2 minutes 
after perfusion of the leukocyte bolus.  For these videos, 10 second recordings (taking 
images every second) were made of 5-10 randomised fields of view down the centre of 
the flow channel.  Following these videos, a field of view that contained at least 10 
transmigrated leukocytes was selected and a single recording was made for 5 minutes, 
taking images every 30 seconds.  This video was used to calculate the velocity of 
migrated cells either above or below the HUVEC monolayer.  Finally, another series of 10 
second videos of 5-10 fields of view (typically 9 minutes post-perfusion of leukocytes) 
were made to assess prolonged transmigration.  Upon completion of this, the syringe 
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pump connected to the Harvard System was stopped and the tubing connected to the 
Ibidi microsclide was removed.  The perfused cells reservoir was rinsed with PBSA and 




































Figure 2.3  In vitro flow-based adhesion assay setup.  (A) HUVECs were seeded in µ-Ibidi slides and grown until confluence before being cytokine-
stimulated and incorporated into the flow adhesion assay.  Endothelial ADAM10 was targeted by either using siRNA to ADAM10 or by using the ADAM10 
preferential inhibitor, GI254023X.  (B) The µ-Ibidi slide was mounted on the stage of a phase contrast microscope within a 37°C Perspex enclosure.  
Freshly isolated leukocytes were placed in the perfused cell reservoir which was electronically controlled.  Wash buffer was placed in the wash buffer 
reservoir.  All of the various components were connected using silicon piping to a Harvard System to mimic physiological shear stresses.  Images were 
taken via a phase contrast microscope and analysed digitally. 
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2.3.5 Static adhesion assays 
Static adhesion assays were utilised to assess PBL or monocyte transmigration, since it is 
a more high-throughput method compared to flow adhesion assays (Butler et al., 2009).  
HUVECs were plated into 12-well plates and treated with pro-inflammatory cytokines as 
described in Sections 2.3.1 and 2.3.2.  Prior to the adhesion assay, the heater on the 
microsope was turned on and set to 37°C.  For these adhesion assays, M199+BSA buffer 
was used as a wash buffer.  Initally, the HUVEC monolayer was rinsed twice with 1 ml 
M199+BSA to remove any residual cytokines/inhibitors.  1 ml of freshly isolated PBLs 
(see Section 2.3.3) were added to the HUVEC monolayers and the 12-well plate was 
placed into the incubator for seven minutes at 37°C and 5% CO2.  This period of time has 
been shown to be sufficient to visualise adequate numbers of transmigrated PBLs or 
monocytes (Chimen et al., 2015).  Following incubation, the cellular suspension was 
aspirated and the HUVEC monolayers were subsequently rinsed with two washes of 1 ml 
M199+BSA.  The HUVEC monolayers were then fixed using 2% paraformaldehyde for 5 
minutes at room temperature.  Excess paraformaldehyde was removed and the wells 
were washed for a further two times using PBS.  A final volume of 1 ml PBS was left in 
the wells and the HUVEC monolayers were imaged using a phase-contrast microscope. 
 
2.3.6 Quantification of leukocyte behaviours 
For flow adhesion assays, leukocyte recruitment and behaviour was analysed using the 
videos captured during the assays using ImagePro analysis software.  Initially the 10-
second recordings 2 minutes post-perfusion of leukocytes were analysed for leukocyte 
behaviour.  The number of leukocytes were counted that were present throughout the 10 
second recording.  From this value the mean number of adherent neutrophils per field 
was calculated.  In order to calculate the total adhesion, the area of a single field was 
calculated by measuring the length and width of a single frame.  This was multiplied by 
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the mean number of leukocytes that were counted and further multiplied by the amount of 
leukocytes perfused (e.g. 1x106 cells/ml * refill flow rate (Q) [0.4 ml/min] * 4 minutes) to 
get a value corresponding to the total adhesion (adherent cells/mm2/106 cells perfused). 
Leukocytes were classified based on three distinct behaviours: leukocytes were either 
rolling, firmly adherent or transmigrated (Figure 2.4).  A rolling leukocyte was classified as 
a phase bright cell moving very slowly along the HUVEC monolayer (1-10 µm/s).  A firmly 
adherent leukocyte was a phase bright cell bound to the surface of the HUVEC monolayer 
either not moving during the duration of the video or showing evidence of having 
undergone shape-change and exhibiting migratory properties on the HUVEC monolayer.  
A transmigrated leukocyte was classified as a cell that appeared phase-dark with altered 
cell morphology and had migrated underneath the HUVEC monolayer.  The percentage of 
leukocytes exhibiting the various behaviours was calculated.  For leukocyte velocity 
calculations, the rolling velocity of leukocytes was calculated by measuring the distance 
travelled by a tracked leukocyte over a period of 10 seconds.  The distance (measured in 
microns (µm)) was converted into µm/sec by dividing by the duration of the video (e.g. 10 
seconds).  The velocity of surface adherent (phase bright) and transmigrated (phase dark) 
leukocytes was calculated using the 5 minute velocity recording.  To do this, an outline 
was drawn around the migrated leukocytes at the beginning of the sequence and their 
movement was tracked throughout the duration of the video recording.  X and Y 
coordinates of the centroid were noted at each 30-second interval for each tracked 
leukocyte.  Pythagoras’ theorem was applied to the X and Y values to calculate the 
distance travelled in µm/min.  A minimum of 10 migrated leukocytes were tracked and 
used to calculate a mean velocity of either firmly adherent leukocytes or transmigrated 
leukocytes. 




For analysis of static adhesion assays, leukocytes were classified as either firmly 
adherent (phase bright; on top of the HUVEC monolayer) or transmigrated (phase dark; 
beneath the HUVEC monolayer).  Digital images of the HUVEC monolayers were made 
immediately after the final wash stage.  Images of five randomised fields of view were 
taken to count adherent cells.  Since the HUVEC monolayers were fixed using 2% 
paraformaldehyde, velocity data could not be calculated from static adhesion assays.  
Total cell counts were made and results were expressed as percentages of the respective 
leukocyte behaviour (either firmly adherent or transmigrated).  A total adhesion value was 
also calculated similarly to how the total adhesion was calculated under flow adhesion 
assay conditions.  
 
2.4 BIOCHEMICAL ASSAYS 
 
Figure 2.4  Phase contrast images highlighting leukocyte behaviours.  HUVECs were grown 
to confluence and either left unstimulated (left image) or stimulated for 4 hours with 100 U/ml 
TNFα (right image).  Neutrophils were then perfused over the monolayer and representative 
images are shown.  Leukocytes were classified as either rolling (phase bright cell moving very 
slowly along the HUVEC monolayer (1-10 µm/s)), firmly adherent (leukocyte was a phase bright 
cell bound to the surface of the HUVEC monolayer either not moving during the duration of the 
video or showing evidence of having undergone shape-change and exhibiting migratory properties 
on the HUVEC monolayer), or transmigrated (cell that appeared phase-dark with altered cell 
morphology and had migrated underneath the HUVEC monolayer).  R – rolling, FA – firmly 
adherent, T – transmigrated leukocyte.  Scale bar: 80 µm.  
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2.4.1 Analysis of protein expression by Western blotting 
2.4.1.1 Whole cell protein extraction 
Whole cell extracts were made from 1x106 HUVEC plated in 6 cm dishes.  Initially media 
from the cells was aspirated and the cell monolayers were washed twice using PBS at 
room temperature.  A volume of 1 ml PBS was added to each well and subsequently the 
cell monolayer was scraped and transferred into a 1.5 ml Eppendorf tube (Eppendorf, 
Stevenage, UK) placed on ice and centrifuged at 80g for 3 minutes to pellet the cellular 
contents.  The supernatant was aspirated and the pellet was resuspended in 60 µl 1% 
Triton X-100 lysis buffer (see Section 2.1.1) containing a protease inhibitor cocktail.  
Subsequently, the cells were vortexed before being incubated on ice for 30 minutes.  The 
cell suspension was then centrifuged at 2100g for 10 minutes at 4°C to pellet any nuclear 
debris.  The supernatant or cell extract was transferred into a new 1.5 ml Eppendorf tube 
and incubated at 100°C in a heat block for 5 minutes in an equal volume of 2x SDS non-
reducing sample buffer (see Section 2.1.1) prior to being subjected to separation by gel 
electrophoresis (see Section 2.4.1.2) or stored at -20°C for later use. 
 
2.4.1.2 Separation of proteins by gel electrophoresis 
SDS polyacrylamide gels were prepared in gel cassettes (Novex, Life Technologies, 
Paisley, UK) and a SDS polyacrylamide resolving gel was prepared (see Section 2.1.1) 
and poured into the plate.  After the resolving gel had set, a SDS polyacrylamide stacking 
gel was prepared and poured onto the set resolving layer.  In addition, a 12-well comb 
was placed into the stacking layer. 
Once the gel had set, the comb was removed along with the tape running at the bottom of 
the cassette and placed into the separation tank as described in the manufacturer’s 
instructions (XCell SureLockTM Mini-Cell Electrophoresis system, Life Technologies, 
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Paisley, UK).  Protein samples prepared in Section 2.4.1.1 were loaded onto the gel along 
with a protein ladder (BLUEyeTM) diluted 1:10 in 2x SDS non-reducing sample buffer.  The 
gel separation tank was filled with SDS Page non-gradient gel buffer (see Section 2.1.1).  
The SDS polyacrylamide gel was then run at 125V (constant voltage) for 90 minutes or 
until the gel front had reached the bottom of the gel, as detected by the presence of 
bromophenol blue in the loading dye. 
  
2.4.1.3 Transfer of proteins from SDS-polyacrylamide gel onto 
polyvinylidene difluoride (PVDF) Immobilon-FL membrane 
After running the gel, it was removed from its cassette and the stacking gel was discarded 
before being soaked in Western transfer buffer (see Section 2.1.1) for 20 minutes prior to 
assembling the transfer chamber.  A PVDF Immobilon-FL membrane (Merck Millipore 
IPVH00010) was pre-activated in methanol for a second or two, and then soaked in 
Western transfer buffer for a further 30 minutes.  The gel transfer apparatus (XCell IITM 
Blot Module, Life technologies) along with 3MM whatman filter paper (Amersham, 
Buckinghamshire, UK) were soaked in Western transfer buffer.  To set up the transfer, 
three blotting pads were initially placed onto the anode side of the transfer casing.  Onto 
this a piece or previously soaked 3MM whatman paper was placed on top of which the 
PVDF Immobilon-FL membrane was placed followed by a further piece of 3MM whatman 
paper.  At this point, a plastic tube was rolled over the stacked gel and membrane to 
remove any air bubbles.  A further three blotting pads were added and the cathode side of 
the transfer casing was placed on top before transferring and securing the whole stack 
into the gel transfer apparatus.  The gel tank was then filled with Western transfer buffer 
and set to run at 30V for 1 hours and 30 minutes. 
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2.4.1.4 Immune-detection of proteins 
Following transfer, membrane was then blocked in a 1x TBST solution containing 5% 
(w/v) milk (Marvel) on a rotating platform at room temperature for a minimum of 1 hour. 
Excess milk was tipped off and discarded and the membrane was washed once with 1x 
TBST.  The membrane was then incubated with antibody buffer (see Section 2.1.1) with 
the required primary antibody (see Section 2.1.2) for 24 hours at 4°C on a rotating 
platform.  Following primary antibody incubation, the membrane was washed 5 times for 5 
minutes in 1x TBST high salt wash buffer (see Section 2.1.1), before a 2 hour incubation 
at room temperature in antibody buffer with the required secondary antibody (see Section 
2.1.2) on a rotating platform.  The membrane was then washed for a further 5 times as 
explained previously. 
After the membrane had been probed with the relevant antibodies, the membrane was 
washed with two swirls of TBS to remove excess tween.  The membrane was then 
imaged using the Odyssey Infrared Imaging System (LI-COR, Cambridge, UK) using the 
manufacturer’s guidance. 
For certain experiments, such as detecting loading controls, the membrane was stripped 
using stripping buffer (see Section 2.1.1).  Briefly, the membrane was placed in pre-
warmed stripping buffer in a 60°C water bath for 30 minutes.  The stripping buffer was 
then tipped off and the membrane was washed five times for five minutes in 1x TBST high 
salt wash buffer before being re-probed with the appropriate antibodies and subsequently 
developed as explained above. 
 
2.4.1.5 Quantitative analysis of Western blots 
Following scanning of the membrane, the densities of the bands were analysed using the 
Odyssey software (LI-COR).  Briefly, the background method was selected by using the 
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drawing panel to select an area of the blot that well represented the background (i.e. 
contained no bands of interest).  Rectangle boxes were then drawn around the bands of 
interest and relative band intensities were noted.  Proteins of interest were compared to 
loading controls.   
 
2.4.2 Cell-based cleavage assay 
To assess the effects of ADAM10-dependent shedding of VE-cadherin, a cleavage-based 
assay was adopted (Schulz et al., 2008; Haining et al., 2012).  In this assay, HUVECs 
were cultured in complete HUVEC growth medium on 0.1% gelatine coated 6 cm dishes.  
ADAM10 activity was targeted either through the use of the ADAM10 preferential inhibitor 
(GI254023X) or through gene silencing of ADAM10 using siRNA.  For ADAM10 inhibitor 
cleavage assays, HUVECs were grown till confluence before being treated with either 
0.02% DMSO or 20 µM GI254023X along with 10 µM of the γ-secretase inhibitor, DAPT 
for 24 hours at 37°C and 5% CO2.  For ADAM10 siRNA knockdown experiments, 
HUVECs were transfected with one of two siRNA duplexes as explained in Section 
2.2.4.2 and grown for 48 hours.  24 hours before harvesting the ADAM10 knockdown 
HUVECS, 10 µM DAPT was added to prevent further processing of the C-terminal 
fragments of VE-cadherin.  HUVECs were then harvested and subsequently underwent 
Western blotting as explained in Section 2.4.1.  The results were imaged and quantified 
on the Odyssey Infrared Imaging System.  For quantification of protein bands during 
shedding assays, bands were drawn around known full-length and cleaved fragments of 
the protein.  The percentage cleaved protein was calculated by adding the cleaved 
band(s) intensity along with the full-length band(s) intensity to get a total protein band 
intensity value.  The cleaved band(s) intensity was then divided by the total protein band 
intensity value and multiplied by 100 to get the percentage cleaved value. 
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2.4.3 Analysis of protein knockdown by real time quantitative PCR 
(qPCR) 
2.4.3.1 Extraction of mRNA from HUVECs 
Total RNA was extracted from 1x106 HUVECs.  Briefly, HUVECs were harvested by 
dissociation using Trypsin/EDTA solution and centrifuged as explained in Section 2.2.3.  
Following centrifugation, the pellet was washed twice using PBS to remove excess media.  
RNA was isolated directly from the cell pellet using the RNeasy mini kit (Qiagen, 
Manchester, UK), according to the manufacturer’s instructions.  Initially, the cells were 
passed through a QIAshredder (Qiagen) to homogenise the cells prior to RNA isolation. 
 
2.4.3.2 Conversion of mRNA to cDNA 
The total yield of RNA isolated was detected using a NanoDrop (NanoDrop 1000, 
Wilmington, DE, USA) and adjusted to 1 µg/µl.  This was then reverse-transcribed to a 
single strand of cDNA using a High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Paisley, UK).  10X reverse transcription buffer along with 25X dNTP mix (100 
nM), 10X reverse transcriptase random primers and MultiScribeTM reverse transcriptase 
were combined with the RNA in a final volume of 20 µl.  The reactions were incubated in a 
thermocycler at the following conditions: 25°C for 10 minutes, 37°C for 120 minutes 
followed by an 85°C step for 5 minutes. 
 
2.4.3.3 qPCR 
Real time PCR was performed using the Taqman® Gene Expression Assay (Applied 
Biosystems) using the ABI Prism 7000 system (Applied Biosystems).  Taqman FAM-
TAMRA primers for GAPDH, Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and 
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Tspan33 were used.  A 20 µl reaction mixture, containing 10 µl 2x Taqman® Master Mix, 
1 µl desired gene Taqman® FAM-TAMRA hydrolysis probes along with 50 ng cDNA was 
amplified using the following thermal cycle parameters: a single cycle at 50°C for 2 
minutes followed by a single cycle at 95°C for 10 minutes (denaturation) prior to 44 cycles 
of 95°C for 15 seconds denaturation and 44 cycles of 60°C for annealing and extension.  
The data was analysed using the ABI PRISM 7000 SDS Software (Applied Biosystems).  
A form of the ΔΔCt method was used to calculate the total mRNA levels in the PCR 
reactions used to assess knockdown efficiency (Pfaffl, 2001).  Ct marks the point at which 
the threshold line meets the amplification curve in the exponential phase of the reaction.  
A baseline was initially set to remove any background non-specific noise at the initial 
stages of the reaction.  The threshold was manually adjusted so that it crossed the 
exponential phase of all the PCR reactions in each experiment.  From this, Ct values were 
noted.  The Ct values of TspanC8s were compared to CT values of the housekeeping 
gene GAPDH.  From this ΔΔCt values (2-ΔΔCt) were recorded and represented as the 
relative mRNA expression. 
 
2.5 STATISTICAL ANALYSIS 
All data analysis was performed using GraphPad Prism® 5 software.  Data were 
presented as means ± standard error of the mean.  Differences between two groups (e.g. 
untreated versus treated) were analysed using Students t test.  To analyse differences 
between multiple groups (e.g. varying concentrations) one-way or two-way analysis of 
variance (ANOVA) followed by Dunnett’s post hoc or Bonferroni multiple comparisons 
post hoc tests were used.  Percentage data underwent arcsine transformation to normally 
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3.1 INTRODUCTION 
The recruitment of leukocytes via a process of margination from blood flow, through the 
vessel wall to sites of inflammation, is a crucial event in host defence during injury and 
infection.  The principle barrier that circulating leukocytes have to overcome first in order 
to extravasate into the tissue, is the endothelial cell barrier (Nourshargh et al., 2010).  
This is facilitated by the action of pro-inflammatory stimuli on the endothelial cells that 
lead to vessel wall leakiness and subsequently allows leukocyte transmigration to occur.  
This process requires the interaction of adhesion molecules expressed on immune cells 
as well as the endothelium (Vestweber, 2007).  In chronic inflammatory diseases, the 
process of leukocyte recruitment and transmigration becomes accelerated.  An emerging 
molecular mechanism that can regulate leukocyte recruitment and transmigration is the 
proteolytic cleavage or ‘ectodomain shedding’ of key CAMs.  Several leukocyte receptors 
have been documented to undergo ADAM-mediated ectodomain shedding during 
leukocyte recruitment and transmigration (Dreymueller et al., 2012b, 2015).  Some of the 
major receptors that undergo ectodomain shedding include the endothelial expressed 
cellular adhesion molecules ICAM-1 and VCAM-1, the two transmembrane chemokines 
CX3CL1 and CXCL16, the junctional proteins VE-cadherin and JAM-A, and the leukocyte 
homing receptor L-selectin (Tsakadze et al., 2006; Singh et al., 2005; Hundhausen et al., 
2003; Abel et al., 2004; Schulz et al., 2008; Koenen et al., 2009; Hafezi-Moghadam et al., 
2001).  Many of the molecules involved in leukocyte adhesion and transmigration are 
shed by ADAM10 (e.g. VE-cadherin), others by ADAM17 (e.g. L-selectin) and some by 
both proteases (e.g. CX3CL1) (Schulz et al., 2008; Peschon et al., 1998; Garton et al., 
2001; Hundhausen et al., 2003).  
A role of ADAM10 in leukocyte adhesion and transmigration has previously been shown 
by regulating the shedding of endothelial transmembrane chemokines, CX3CL1 and 
CXCL16, and the adherens junction molecule VE-cadherin (Hundhausen et al., 2003, 
2007; Schulz et al., 2008).  However, most of these studies deciphered a role of ADAM10 
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using cell lines or transfected cells and the mechanism by which ADAM10 regulates 
leukocyte transmigration in primary cells and under physiological flow conditions is not 
clear.  Therefore, the principle aim of this study was to determine whether endothelial 
ADAM10 could differentially regulate the efficient recruitment and transmigration of 
human leukocytes by shedding key cell surface receptors involved in the distinct stages of 
leukocyte capture, activation induced arrest and transmigration.  To investigate this, 
endothelial ADAM10 expressed on HUVECs was targeted using gene knockdown 
techniques or through the use of a preferential ADAM10 pharmacological inhibitor 
(GI254023X).  This pharmacological inhibitor has been shown to have 100-fold more 
binding specificity for ADAM10 over its most closely related family member, ADAM17 
(Ludwig et al., 2005).  Separately, leukocyte-expressed ADAM10 was also targeted using 
the ADAM10 inhibitor.  The cells were then incorporated into either an in vitro flow-based 
adhesion assay or a static adhesion assay and characteristic leukocyte behaviours during 
an inflammatory response were analysed by phase-contrast video microscopy.  This 
forms the basis of investigations undertaken in this chapter. 
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3.2 RESULTS 
3.2.1 Effects of ADAM10 knockdown/inhibition on lymphocyte cell 
recruitment and transmigration 
3.2.1.1   Endothelial ADAM10 regulates the transmigration of lymphocytes 
In order to assess the role of endothelial ADAM10 in regulating the recruitment and 
transmigration of peripheral blood lymphocytes (PBLs) under physiological flow 
conditions, ADAM10-targetted siRNAs were used to reduce endothelial ADAM10 levels.  
Low passage (P0 – P1) HUVECs were used because these cells have been extensively 
characterised for use in leukocyte adhesion assays.  In addition, HUVECs upregulate the 
various selectins/CAMs that support leukocyte adhesion and transmigration similar to the 
endothelial cells found in the post-capillary venules (Sheikh et al., 2003).  For these 
experiments, HUVECs in wells of a 6-well plate were transfected with either a non-
silencing control or with one of two siRNA duplexes to ADAM10.  4 hours post 
transfection the HUVECs were dissociated and re-plated into a 6-well Ibidi microslide.  24 
hours post transfection HUVECs were stimulated for a further 24 hours with 100 U/ml 
TNFα and 10 ng/ml IFNγ, a cocktail of potent cytokines that when used in combination 
have been shown to support the adhesion and transmigration of PBLs by upregulating the 
interferon-inducible chemokines CXCL9-12 (Ahmed et al., 2011).  Freshly isolated PBLs 
were extracted from venous blood following density centrifugation on Histopaque as 
described in Section 2.3.3 and adjusted to a working concentration of 1x106/ml.  The Ibidi 
microslide was incorporated into a flow adhesion assay to assess PBL recruitment and 
transmigration by mounting onto the stage of a phase contrast microscope within a 37°C 
Perspex chamber (as described in Section 2.3.4).  Respective videos were recorded for 
leukocyte behaviours and were subsequently analysed and total adhesion calculated as 
explained in Section 2.3.6.  
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As shown in Figure 3.1, knockdown of endothelial ADAM10 reduced the ability of PBLs to 
transmigrate by 50% (Figure 3.1 A & B).  This reduction was accompanied by a 
subsequent increase in the percentage of adherent PBLs on the surface of the HUVEC 
monolayer (Figure 3.1 A & B).  Interestingly, knockdown of ADAM10 resulted in reduced 
PBL transmigration that was still apparent at 9 minutes post-perfusion of PBLs when 
compared to the negative control siRNA control (Figure 3.1 A & B).  No differences were 
observed in PBL rolling behaviour (Figure 3.1 A & B).  In addition, no differences in total 
adhesion were observed following endothelial ADAM10 knockdown (Figure 3.1 B).  The 
knockdown efficiency of endothelial ADAM10 was assessed by flow cytometry.  
Expression of ADAM10 was significantly reduced in siRNA treated cells (~90% reduced 
upon quantification) (Figure 3.1 D & E).  
In addition to PBL behaviours, PBLs were also analysed for velocity behaviours.  For 
rolling velocities, PBLs classified as rolling were tracked over a 10 second video and the 
distance was noted in microns.  This was then converted to give a value in microns per 
second.  To assess the velocities of firmly adherent or transmigrated PBLs, the 
locomotion of firmly adherent or transmigrated PBLs was tracked over a period of 5 
minutes.  The distance of 10-tracked cells in each experiment per treatment condition was 
converted from microns into microns per minute.  Similar tracking velocities were noted 
for PBLs on cytokine-stimulated HUVECs as previously published (McGettrick et al., 
2009).  However, knockdown of endothelial ADAM10 had no significant effect on PBL 
velocities (Table 3.1). 
To conclude, knockdown of endothelial ADAM10 reduces the transmigration of PBLs 
under physiological flow conditions. 
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Figure 3.1  Knockdown of endothelial ADAM10 decreases the transmigration of 
lymphocytes under in vitro flow conditions.  HUVECs were transfected with two different 
siRNA duplexes to ADAM10 (red bars) alongside a non-specific siRNA (black bars) at a final 
concentration of 10 nM prior to being seeded into 6-well Ibidi slides.  24 hours after transfection, 
the HUVECs were stimulated with 100 U/ml TNFα along with 10 ng/ml IFNγ for an additional 24 
hours.  Freshly isolated PBLs were then perfused over the pre-activated HUVEC monolayer at 
0.05 Pa in PBSA for 4 minutes.  Video-recordings of five different fields of view of the 
endothelial monolayer were made using time-lapse video microscopy at two-minutes (A) or 
nine-minutes (B) post perfusion of PBLs, respectively.  PBLs were classified as rolling, firmly 
adherent or transmigrated.  The total number of cells classified for each of the behaviours were 
combined to give a total adhesion count (C).  HUVECs transfected with siRNA were analysed 
by flow cytometry to measure surface ADAM10 expression.  The red line represents ADAM10 
staining and the black line isotype control staining (D).  Surface ADAM10 levels from panel D 
were quantitated and normalised to the “No siRNA” treated condition (E).  Error bars represent 
the standard error of the mean from five independent experiments.  Data were normalised by 
arcsine transformation and statistically analysed by a one-way ANOVA and Dunnett’s post-hoc 
comparisons test for total adhesion or knockdown confirmation (***p < 0.001 compared to 
negative control siRNA transfected data) or by a two-way ANOVA and Bonferroni post-hoc 
comparisons test for cell behaviours (**p < 0.01, ***p < 0.001 compared to the negative control 
siRNA transfected data). 
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Table 3.1  Knockdown of endothelial ADAM10 has no effect on PBL velocities.  PBL 
velocities were tracked using ImagePro cell tracking software.  For PBL rolling velocities, PBLs 
classified as rolling were tracked over a 10-second video of a single frame and the total distance 
travelled was converted to µm sec-1.  For firmly adherent or transmigrated PBL velocities, firmly 
adherent or transmigrated PBLs were drawn around and tracked over a 5-minute video of a single 
frame.  The distance travelled was calculated by applying Pythagoras theorem for calculated ‘x’ 
and ‘y’ distances of tracked PBLs and converted to µm min-1.  Values represented are mean ± 
standard error of 20, 30, or 50 tracked cells for rolling, firmly adherent or transmigrated conditions 






















No siRNA 6.17 ± 0.24 5.25 ± 0.56 15.21 ± 1.20 
Negative control 
siRNA 
6.15 ± 0.60 5.67 ± 1.15 13.56 ± 1.11 
ADAM10.1 siRNA 6.39 ± 0.36 4.26 ± 0.78 16.29 ± 0.73 
ADAM10.2 siRNA 6.44 ± 0.54 4.87 ± 0.98 15.92 ± 0.84 
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To establish a more high-throughput assay of transmigration to facilitate future 
mechanistic studies, PBL transmigration was assessed under static conditions.  HUVECs 
were transfected with siRNA duplexes targeting ADAM10 or a negative control non-
specific siRNA duplex before stimulation with 100 U/ml TNFα and 10 ng/ml IFNγ, as 
described previously.  PBL were then isolated, purified and adjusted to a working 
concentration at 1x106/ml.  The PBL were allowed to adhere and undergo transmigration 
by incubating the plate at 37°C for 7 minutes, an optimal time-point to see differences in 
PBL adhesion and transmigration under static conditions (Chimen et al., 2015).  Non-
adherent PBLs were washed off and the HUVEC monolayers were fixed with 2% 
formaldehyde before being imaged using phase-contrast microscopy.  PBL behaviours 
and total adhesion were calculated from the captured images.  Consistent with studies 
under flow (Figure 3.1), knockdown of endothelial ADAM10 reduced PBL transmigration 
by approximately 45% with a consequent increase in the percentage of firmly adherent 
cells that had not transmigrated (Figure 3.2 A).  Similar observations were also seen 
when looking at PBL total adhesion, with knockdown of endothelial ADAM10 having no 
effect on this parameter (Figure 3.2 B).  Knockdown of ADAM10 expression in endothelial 
cells was confirmed as previously described by flow cytometry and found to be at least 
85% reduced (Figure 3.2 C & D). 
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Figure 3.2  Knockdown of endothelial ADAM10 decreases the transmigration of 
lymphocytes under in vitro static conditions.  HUVECs were transfected with two different 
siRNA duplexes to ADAM10 (red bards) alongside a non-specific siRNA (black bars) at a final 
concentration of 10 nM in 12-well plates.  Following 24 hours, HUVECs were stimulated with 
100 U/ml TNFα along with 10 ng/ml IFNγ for an additional 24 hours.  Freshly isolated PBLs 
were then added to the pre-activated HUVEC monolayer in M199+BSA and incubated for 7 
minutes.  Non-adherent PBLs were washed off using M199+BSA and HUVEC monolayers were 
fixed using 2% formaldehyde.  Images of five different fields of view of the endothelial 
monolayer were made using phase-contrast microscopy.  PBLs were classified as firmly 
adherent or transmigrated (A).  The total number of cells classified for each of the behaviours 
were combined to give a total adhesion count (B).  Knockdown of ADAM10 was assessed as 
described in the legend for Figure 3.1 (C) and (D).  Error bars represent the standard error of 
the mean from five independent experiments.  Data were normalised by arcsine transformation 
and statistically analysed by a one-way ANOVA and Dunnett’s post-hoc comparisons test for 
total adhesion data and confirmation of knockdown (***p < 0.001 compared to the negative 
control siRNA transfected data) or by a two-way ANOVA and Bonferroni post-hoc comparisons 
test for PBL cell behaviour (**p < 0.01 compared to the negative control siRNA transfected 
data). 
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To determine whether an ADAM10 inhibitor (GI254023X) yields similar data to the 
knockdown, initial experiments were carried out to establish an appropriate concentration 
of inhibitor to use.  For these experiments, HUVECs were plated into 12-well plates and 
grown until confluent.  Previously published data using this pharmacological inhibitor 
showed a dose of 10µM was sufficient in reducing the transmigration of PHA-blast T-cells 
or a pre-B cell line L1.2 cells across ECV304 monolayers (Hundhausen et al., 2007; 
Schulz et al., 2008; Schwarz et al., 2010; Powers et al., 2012).  Therefore, HUVEC 
monolayers were subjected to either 0.02% DMSO control or 2.5 µM, 5 µM, 10 µM, 20 µM 
or 40 µM GI254023X treatment alongside cytokine treatment as previously described for 
static adhesion assays.  Phase-contrast images following 24-hour incubation with the 
ADAM10 inhibitor at the various doses revealed that the inhibitor did not affect HUVEC 
monolayer integrity (Figure 3.3 A).  Inhibition of HUVEC-expressed ADAM10 mimicked 
the phenotype observed when HUVEC-expressed ADAM10 was knocked down under 
static conditions, resulting in a decrease in the ability of PBLs to transmigrate, with a 
concentration of 10 µM or 20 µM being significant to visualise this phenotype (Figure 3.3 
B).  This was supported by a dose-dependent concomitant increase in firmly adherent 
PBLs (Figure 3.4 B).  Moreover, inhibition of endothelial ADAM10 did not alter the total 
adhesion of PBLs (Figure 3.3 C).  These data lead to the adoption of 20 µM of the 
inhibitor for future experiments. 
  
CHAPTER 3:  THE ROLE OF ENDOTHELIAL ADAM10 IN REGULATING LEUKOCYTE 





Figure 3.3  Inhibition of endothelial ADAM10 decreases lymphocyte transmigration under 
in vitro static conditions.  HUVECs were plated into 12-well plates.  Once confluent, the 
HUVECs were stimulated as previously described in the legend for Figure 3.2 along with either 
0.02% DMSO (black bar) or increasing concentrations of the ADAM10 inhibitor (2.5, 5, 10, 20 or 
40 µM GI254023X) (red bar) for 24 hours before being incorporated into a static adhesion assay 
to assess PBL adhesion and transmigration.  Representative phase contrast images of PBL 
adhesion at 7 minutes post-incubation were made to assess HUVEC monolayer integrity (A) 
and analysed for PBL behaviours (B) along with total adhesion (A), as previously described in 
the legend for Figure 3.2.  Error bars represent the standard error of the mean from four 
independent experiments.  Data were normalised by arcsine transformation and statistically 
analysed by a one-way ANOVA and Dunnett’s post-hoc comparisons test for total adhesion 
(***p < 0.001 compared to DMSO control data) or by a two-way ANOVA and Bonferroni post-
hoc comparisons test for cell behaviours (*p < 0.05, ***p < 0.01 compared to DMSO control 
data).  Examples of FA – firmly adherent (phase bright) or T – transmigrated (phase dark) cells 
are highlighted (A). Scale bar: 50µm. 
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To further the ADAM10 inhibitor data findings in Figure 3.3, the effects of ADAM10 
inhibition on PBL transmigration under flow conditions was investigated.  Confluent 
HUVEC monolayers were seeded into Ibidi microslides and stimulated with 100 U/ml 
TNFα and 10 ng/ml IFNγ for 24 hours in the presence of 0.02% DMSO or 20 µM 
GI254023X – a concentration that was shown to reduce PBL transmigration to similar 
levels to that observed following ADAM10 siRNA (Figure 3.3).  PBL behaviours were 
analysed, as explained previously.  Inhibition of HUVEC-expressed ADAM10 mimicked 
the phenotype observed when HUVEC-expressed ADAM10 was knocked down.  
Inhibition of HUVEC-expressed ADAM10 resulted in a decrease in the ability of PBLs to 
transmigrate (Figure 3.4 A & B).  This was supported by a concomitant increase in the 
percentage of firmly adherent PBLs (Figure 3.4 A & B).  No differences were observed 
between the ADAM10 inhibitor treated cells and for DMSO control cells when looking at 
PBL rolling behaviour (Figure 3.4 A & B) or PBL velocity behaviours (Table 3.2).  In 
addition, no differences in total adhesion were observed following endothelial ADAM10 
inhibition (Figure 3.4 C). 
In summary, these data demonstrate that endothelial ADAM10 is able to regulate the 
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Figure 3.4  Inhibition of endothelial ADAM10 decreases the transmigration of 
lymphocytes under in vitro flow conditions.  HUVECs were plated into 6-well Ibidi slides.  
Once confluent, the HUVECs were stimulated as previously described in the legend for Figure 
3.1 along with either 0.02% DMSO (black bar) or 20 µM GI254023X (red bar) for 24 hours 
before being incorporated into the flow adhesion assay to assess PBL adhesion and 
transmigration.  Video recordings of PBL adhesion at specific time-points were made and 
analysed for PBL behaviours (A) and (B) along with total adhesion (C), as previously described 
in the legend for Figure 3.1.  Error bars represent the standard error of the mean from five 
independent experiments.  Data were normalised by arcsine transformation and statistically 
analysed by a one-way ANOVA and Dunnett’s post-hoc comparisons test for total adhesion 
(***p < 0.001 compared to DMSO control data) or by a two-way ANOVA and Bonferroni post-
hoc comparisons test for cell behaviours (*p < 0.05, **p < 0.01, ***p < 0.001 compared to DMSO 
control data).  
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- 5.92 ± 0.28 3.51 ± 0.25 13.76 ± 1.37 
DMSO 
control 
6.07 ± 0.17 4.23 ± 0.88 14.83 ± 1.32 
GI254023X 5.54 ± 0.26 3.41 ± 0.47 16.21 ± 0.62 
PBL treatment DMSO 
control 
6.61 ± 0.33 4.27 ± 0.39 15.29 ± 0.71 
GI254023X 5.56 ± 0.38 3.86 ± 0.34 14.03 ±1.51 
Table 3.2  Inhibition of endothelial or PBL-expressed ADAM10 has no effect on PBL 
velocities.  PBL velocities were tracked using ImagePro cell tracking software and as explained in 
the legend to Table 3.1.  Values represented are mean ± standard error of 40, 20, or 50 tracked 
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3.2.1.2  Inhibition of lymphocyte-expressed ADAM10 regulates does not 
regulate lymphocyte transmigration 
To further characterise the role of ADAM10 in regulating the recruitment and 
transmigration of PBLs, the role of ADAM10 on PBLs was next targeted using the 
ADAM10 inhibitor.  Similar approaches were used to those described earlier to decipher a 
role of PBL-expressed ADAM10 during PBL recruitment and transmigration.  Initial 
experiments focused on the role of ADAM10 inhibited PBLs under flow adhesion 
conditions.  For these experiments, isolated PBLs were treated with either 0.02% DMSO 
or with 20 µM GI254023X for 30 minutes at room temperature before being incorporated 
into the flow assay.  In addition, 20 µM GI254023X was also added to the wash buffer to 
prevent dilution of the inhibitor treated PBLs during perfusion.  Interestingly, inhibition of 
PBL-expressed ADAM10 did not alter the ability of PBLs to transmigrate under flow 
conditions.  No differences in PBL behaviour were observed when PBL-expressed 
ADAM10 was inhibited (Figure 3.5 A & B).  In addition, no difference in total adhesion was 
observed when PBL-expressed ADAM10 was inhibited (Figure 3.5 A).  Moreover, no 
differences in PBL velocity behaviour were observed following PBL ADAM10 inhibition 
(Table 3.2).  Similar observations were also made when PBL-expressed ADAM10 was 
inhibited and incorporated into a static adhesion assay (Figure 3.6). 
Altogether, these findings suggest a role for endothelial ADAM10, but not PBL-expressed 
ADAM10 in regulating the transmigration of PBLs in models of chronic inflammation under 
both physiological flow conditions and static adhesion conditions.  
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Figure 3.5  Inhibition of lymphocyte-expressed ADAM10 does not alter lymphocyte 
transmigration under in vitro flow conditions.  HUVECs were plated into 6-well Ibidi slides.  
Once confluent, the HUVECs were stimulated as previously described in the legend for Figure 
3.1 before being incorporated into the flow adhesion assay to assess PBL adhesion and 
transmigration.  For ADAM10 inhibitor or DMSO conditions, PBLs were pre-incubated with either 
20 µM GI254023X (red bar) or 0.02% DMSO (black bar) for 30 minutes prior to being 
incorporated into the flow adhesion assay.  In addition, 20 µM GI254023X was added to the 
wash buffer when perfusing ADAM10 inhibited PBLs to prevent dilution of the inhibitor.  Video 
recordings of PBL adhesion at specific time-points were made and analysed for PBL behaviours 
(A) and (B) along with total adhesion (C), as previously described in the legend for Figure 3.1.  
Error bars represent the standard error of the mean from three independent experiments.  Data 
were normalised by arcsine transformation and statistically analysed by a one-way ANOVA and 
Dunnett’s post-hoc comparisons test for total adhesion (***p < 0.001 compared to DMSO control 
data) or by a two-way ANOVA and Bonferroni post-hoc comparisons test for cell behaviours. 
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Figure 3.6  Inhibition of lymphocyte-expressed ADAM10 does not alter lymphocyte 
transmigration under in vitro static conditions.  HUVECs were plated into 12-well plates.  
Once confluent, the HUVECs were stimulated as previously described in the legend for Figure 
3.2 before being incorporated into a static adhesion assay to assess PBL adhesion and 
transmigration.  For ADAM10 inhibitor or DMSO conditions, PBLs were pre-incubated with either 
20 µM GI254023X (red bar) or 0.02% DMSO (black bar) for 30 minutes prior to being 
incorporated into the static adhesion assay.  Phase contrast images of PBL adhesion at 7 
minutes post-incubation were made and analysed for PBL behaviours (A) along with total 
adhesion (B), as previously described in the legend for Figure 3.2.  Error bars represent the 
standard error of the mean from five independent experiments.  Data were normalised by 
arcsine transformation and statistically analysed by a one-way ANOVA and Dunnett’s post-hoc 
comparisons test for total adhesion (***p < 0.001 compared to DMSO control data) or by a two-
way ANOVA and Bonferroni post-hoc comparisons test for cell behaviours. 
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3.2.2 Effects of ADAM10 knockdown/inhibition on myeloid cell recruitment 
and transmigration 
3.2.2.1  Neutrophil recruitment and transmigration is independent of ADAM10 
Neutrophils are the most abundant leukocyte subset found in the peripheral vasculature 
and play a fundamental role in immune surveillance and inflammation.  To elucidate 
whether neutrophil adhesion and transmigration is regulated by ADAM10, HUVEC-
expressed ADAM10 or its activity was reduced either by using siRNA or by using the 
pharmacological inhibitor.  Initial experiments were performed to establish the optimal 
doses of recombinant human TNFα to be administered to maximise the chances of 
visualising changes in neutrophil behaviour under flow conditions.  From preliminary data, 
treatment of HUVECs for 4 hours with a dose of 100 U/ml was deemed sufficient in 
seeing significant changes in neutrophil behaviour under flow conditions (data not shown) 
and correlated with previous cytokine stimulation data published by our group (Munir et 
al., 2015). 
Initial experiments targeted endothelial ADAM10 using a gene knockdown approach.  The 
flow adhesion assay was performed as previously described (Section 3.2.1.1), except 
isolated human neutrophils were used instead of PBLs.  Respective neutrophil behaviours 
were counted and total adhesion values were calculated, as explained earlier.  
Knockdown of endothelial ADAM10 had no effect on neutrophil rolling, arrest and 
transmigration (Figure 3.7 A & B).  In addition, neutrophil adhesion was unaffected by 
endothelial ADAM10 knockdown (Figure 3.7 C).  ADAM10 knockdown efficiency was 
assessed by flow cytometry, as previously described and was ~90% reduced upon 
quantitation (Figure 3.7 D & E).  In addition, neutrophil velocity behaviour was analysed, 
and found to be similar to that observed with PBLs, showing knockdown of endothelial 
ADAM10 did not alter neutrophil rolling, firmly adherent or transmigrated velocities (Table 
3.3).  
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Figure 3.7  Knockdown of endothelial ADAM10 does not alter the ability of neutrophils to 
transmigrate under in vitro flow conditions.  HUVECs were transfected with two different 
siRNA duplexes to ADAM10 (red bars) alongside a non-specific siRNA (black bars) as explained 
in the legend to Figure 3.1.  After 24 hours, the HUVECs were stimulated with 100 U/ml TNFα 
along for 4 hours.  Freshly isolated neutrophils were then perfused over the pre-activated HUVEC 
monolayer at 0.05Pa in PBSA for 4 minutes.  Video recordings of five different fields of view of the 
endothelial monolayer were made using time-lapse video microscopy at two-minutes (A) or nine-
minutes (B) post perfusion of neutrophils, respectively.  Neutrophils were classified as rolling, 
firmly adherent or transmigrated.  The total number of cells classified for each of the behaviours 
were combined to give a total adhesion count (C).  HUVECs transfected with siRNA were 
analysed by flow cytometry to measure surface ADAM10 expression.  The red line represents 
ADAM10 staining and the black line isotype control staining (D).  Surface ADAM10 levels from 
panel E were quantitated and normalised to the ‘No siRNA’ treated condition (E).  Error bars 
represent the standard error of the mean from seven independent experiments.  Data were 
normalised by arcsine transformation and statistically analysed by a one-way ANOVA and 
Dunnett’s post-hoc comparisons test for total adhesion and knockdown confirmation (***p < 0.001 
compared to Negative control siRNA data) or by a two-way ANOVA and Bonferroni post-hoc 
comparisons test for cell behaviours. 
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Table 3.3  Knockdown of endothelial ADAM10 has no effect on neutrophil velocities.  
Neutrophil velocities were tracked using ImagePro cell tracking software as described in the legend 
to Table 3.1.  Values represented are mean ± standard error of 20, 30, or 70 tracked cells for 

























No siRNA 6.17 ± 0.24 5.25 ± 0.56 15.21 ± 1.20 
Negative control 
siRNA 
6.15 ± 0.60 5.67 ± 1.15 13.56 ± 1.11 
ADAM10.1 siRNA 6.39 ± 0.36 4.26 ± 0.78 16.29 ± 0.73 
ADAM10.2 siRNA 6.49 ± 0.33 4.67 ± 0.92 15.22 ± 1.09 
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The endothelial ADAM10 knockdown data findings were further confirmed by repeating 
the assays but this time HUVECs were treated with either 0.02% DMSO or 20 µM 
GI254023X for 24 hours.  Neutrophils were isolated as previously described and the flow 
assay was carried out.  Neutrophil behaviours were analysed, as explained previously.  
Inhibition of HUVEC-expressed ADAM10 mimicked the phenotype observed when 
HUVEC-expressed ADAM10 was knocked down.  Inhibition of HUVEC-expressed 
ADAM10 did not alter the ability of neutrophils to transmigrate (Figure 3.8 A & B).  
Similarly, inhibition of HUVEC-expressed ADAM10 had no effect on neutrophil total 
adhesion (Figure 3.8 C) or neutrophil velocity behaviours (Table 3.4). 
Neutrophil recruitment is regulated by multiple cytokines.  To investigate if the responses 
observed following endothelial ADAM10 inhibition were cytokine dependent, the 
recruitment and transmigration of neutrophils to IL-1β stimulated HUVECs was 
investigated.  For these assays, HUVECs were grown to confluence in Ibidi microslides as 
previously described.  Instead of treating the cells with TNFα, the cells were treated with 5 
ng/ml IL-1β  for 4 hours in addition to treatment of the endothelium with either the 
ADAM10 inhibitor or DMSO control, as previously described.  The Ibidi microslide was 
incorporated into a flow assay and respective neutrophil behaviours were recorded.  
Neutrophils underwent normal recruitment and transmigration on IL-1β stimulated 
HUVECs and no differences were observed when endothelial ADAM10 was inhibited 
(Figure 3.8 D & E).  Moreover, no difference in neutrophil total adhesion was observed 
when endothelial ADAM10 was inhibited (Figure 3.8 F). 
These data confirm, by using two different modes of targeting endothelial ADAM10 
(pharmacological or siRNA knockdown), that neutrophil recruitment and transmigration in 
in vitro models of TNFα-induced or IL-1β-induced inflammation is independent of 
endothelial ADAM10.  
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Figure 3.8  Inhibition of endothelial ADAM10 does not alter the ability of neutrophils to 
transmigrate under in vitro flow conditions.  HUVECs were plated into 6-well Ibidi slides.  
Once confluent, the HUVECs were treated with either 0.02% DMSO (black bar) or 20 µM 
GI254023X (red bar) for 24 hours in addition to being stimulated for the final 4 hours with TNFα as 
previously described in the legend for Figure 3.7 (A – C) or with 5 ng/ml IL-1β (D – F) before being 
incorporated into the flow adhesion assay to assess neutrophil adhesion and transmigration.  
Video recordings of neutrophil adhesion at specific time-points were made and analysed for 
neutrophil behaviours (A & B) and (D & E) along with total adhesion (C) and (F), as previously 
described in the legend for Figure 3.7.  Error bars represent the standard error of the mean from 
five independent experiments.  Data were normalised by arcsine transformation and statistically 
analysed by a one-way ANOVA and Dunnett’s post-hoc comparisons test for total adhesion (***p 
< 0.001 compared to DMSO control data) or by a two-way ANOVA and Bonferroni post-hoc 
comparisons test for cell behaviours. 
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Table 3.4  Inhibition of endothelial or neutrophil-expressed ADAM10 has no effect on 
neutrophil velocities under TNFα stimulated conditions.  Neutrophil velocities were tracked 
using ImagePro cell tracking software and as explained in the legend to Table 3.1.  Values 
represented are mean ± standard error of 45, 30, or 50 tracked cells for rolling, firmly adherent or 
transmigrated conditions over three to five different experiments, respectively. 
 












- 7.09 ± 1.22 5.04 ± 1.06 14.63 ± 0.85 
DMSO 
control 
6.62 ± 0.90 5.63 ± 1.04 14.98 ± 0.87 





6.81 ± 0.54 3.73 ± 0.71 14.45 ± 1.01 
GI254023X 7.34 ± 1.83 4.45 ± 2.20 14.47 ± 2.49 
Table 3.5  Inhibition of endothelial or neutrophil-expressed ADAM10 has no effect on 
neutrophil velocities under IL-1β stimulated conditions.  Netrophil velocities were tracked 
using ImagePro cell tracking software and as explained in the legend to Table 3.1.  Values 
represented are mean ± standard error of 15, 20, or 40 tracked cells for rolling, firmly adherent or 
transmigrated conditions over three to four different experiments, respectively. 
  












- 5.43 ± 0.56 3.44 ± 0.44 12.75 ± 2.93 
DMSO 
control 
4.54 ± 0.56 4.23 ± 0.84 13.94 ± 2.04 





4.67 ± 0.23 4.12 ± 0.45 16.73 ± 0.19 
GI254023X 5.34 ± 0.94 3.20 ± 0.38 14.30 ± 1.29 
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To determine whether ADAM10 expressed on neutrophils has a role in regulating the 
recruitment and transmigration of neutrophils, neutrophil ADAM10 activity was targeted 
using the ADAM10 inhibitor.  For these experiments, isolated neutrophils were treated 
with either 0.02% DMSO or with 20 µM GI254023X for 30 minutes at room temperature 
before being incorporated into the flow assay.  In addition, 20 µM GI254023X was also 
added to the wash buffer to prevent dilution of the inhibitor treated neutrophils during 
perfusion.  Inhibition of neutrophil-expressed ADAM10 did not alter the ability of 
neutrophils to transmigrate under flow conditions.  No differences in neutrophil behaviour 
were observed when neutrophil-expressed ADAM10 was inhibited (Figure 3.9 A & B).  In 
addition, there was no difference in total adhesion when neutrophil-expressed ADAM10 
was inhibited (Figure 3.9 C).  Moreover, no changes in neutrophil velocity behaviour were 
observed following inhibition of neutrophil-expressed ADAM10 (Table 3.4). 
In addition, the recruitment and transmigration of ADAM10 inhibited neutrophils to IL-1β 
stimulated HUVECs was unaltered (Figure 3.9 D & E).  Similarly, no differences in 
neutrophil total adhesion were observed (Figure 3.9 F).  When looking at neutrophil 
velocities on IL-1β stimulated HUVECs, no differences were observed in neutrophil rolling, 
firmly adherent or transmigrated velocities following neutrophil ADAM10 inhibition or 
endothelial ADAM10 inhibition (Table 3.5). 
Taken together, these results show that neutrophil recruitment and transmigration is 
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Figure 3.9  Inhibition of neutrophil-expressed ADAM10 does not alter neutrophil 
transmigration under in vitro flow conditions.  HUVECs were plated into 6-well Ibidi slides.  
Once confluent, the HUVECs were stimulated as previously described in the legend for Figure 3.7 
(A – C) or with 5 ng/ml IL-1β (D – F) before being incorporated into the flow adhesion assay to 
assess neutrophil adhesion and transmigration.  For ADAM10 inhibitor or DMSO conditions, 
neutrophils were pre-incubated with either 20 µM GI254023X (red bar) or 0.02% DMSO (black 
bar) for 30 minutes prior to being incorporated into the flow adhesion assay.  In addition, 20 µM 
GI254023X was added to the wash buffer when perfusing ADAM10 inhibited neutrophils to 
prevent dilution of the inhibitor.  Video recordings of neutrophil adhesion at specific time-points 
were made and analysed for neutrophil behaviours (A & B) and (D & E) along with total adhesion 
(C) and (F), as previously described in the legend for Figure 3.7.  Error bars represent the 
standard error of the mean from four independent experiments.  Data were normalised by arcsine 
transformation and statistically analysed by a one-way ANOVA and Dunnett’s post-hoc 
comparisons test for total adhesion (***p < 0.001 compared to DMSO control data) or by a two-
way ANOVA and Bonferroni post-hoc comparisons test for cell behaviours. 
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The data presented in this chapter has so far shown that endothelial ADAM10 regulates 
the efficient transmigration of PBLs but not neutrophils.  Indeed, neutrophils are known to 
release proteolytic enzymes upon their activation (for example, neutrophil elastase), 
which can act locally to degrade junctional proteins, thereby facilitating their 
transmigration (Pham, 2008).  In order to elucidate the differences observed between 
neutrophil transmigration and PBL transmigration following endothelial ADAM10 inhibition, 
the effects of inhibiting neutrophil elastase was investigated.  For these assays, HUVECs 
were treated with the ADAM10 inhibitor and stimulated as previously described.  Either 
untreated neutrophils or neutrophils that had previously been treated with 100 µg/ml α1-
antitrypsin (an inhibitor to neutrophil elastase release) for 30 minutes at room 
temperature, were perfused over the pre-activated HUVECs and respective neutrophil 
behaviours were recorded and analysed.  Treatment of neutrophils with α1-antitrypsin 
significantly reduced the ability of neutrophils to transmigrate over TNFα stimulated 
HUVECs.  This was accompanied by a subsequent increase in the number of firmly 
adherent neutrophils on the surface of HUVECs (Figure 3.10 A & B).  Similar to the 
findings in Figure 3.9, inhibition of endothelial ADAM10 did not affect the ability of 
neutrophils to transmigrate (Figure 3.10 A & B).  α1-antitrypsin treatment reduced the 
migration of neutrophils over ADAM10 inhibited HUVECs or DMSO treated HUVECs 
equally (Figure 3.10 A & B).  No differences in neutrophil total adhesion following α1-
antitrypsin treatment of neutrophils were observed (Figure 3.10 C).  In addition, neutrophil 
velocities were unaltered following treatment of neutrophils with α1-antitrypsin (Table 3.6).   
These data suggest that the lack of an effect of endothelial ADAM10 inhibition on 
neutrophil transmigration is not because neutrophils use serine proteases such as 
neutrophil elastase to overcome this. 
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Figure 3.10  Inhibition of serine protease activity suppresses neutrophil transmigration 
independently of endothelial ADAM10 inhibition under in vitro flow conditions.  HUVECs 
were plated into 6-well Ibidi microslides.  Once confluent, the HUVECs were treated either with 20 
µM GI254023X or 0.02% DMSO for 24 hours.  For the remaining 4 hours, HUVECs were treated 
with 100U/ml TNFα before being incorporated into the flow assay.  Neutrophils were isolated and 
purified as explained in the legend to Figure 3.7.  Separately, neutrophils were incubated with 100 
µg/ml α1-antitrypsin for 30 minutes before being perfused in the flow assay.  In addition, α1-
antitrypsin treated neutrophils were perfused in wash buffer containing 100 µg/ml α1-antitrypsin to 
prevent dilution of the inhibitor.  Video recordings of neutrophil adhesion at specific time-points 
were made and analysed for neutrophil behaviours (A) and (B) along with total adhesion (C), as 
previously described in the legend for Figure 3.7.  Error bars represent the standard error of the 
mean from four independent experiments.  Data were normalised by arcsine transformation and 
statistically analysed by a one-way ANOVA and Dunnett’s post-hoc comparisons test for total 
adhesion (***p < 0.001 compared to DMSO control data) or by a two-way ANOVA and Bonferroni 
post-hoc comparisons test for cell behaviours (**p < 0.01, ***p < 0.001 compared to DMSO control 
data).  When comparing differences between ADAM10 treated and DMSO treated endothelial 
cells following neutrophil α1-antitrypsin treatments, a Students t-test was used. 
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Table 3.6  Inhibition of endothelial or neutrophil-expressed ADAM10 in the presence of α1-
anti-trypsin treatment has no effect on neutrophil velocities.  Neutrophil velocities were 
tracked using ImagePro cell tracking software and as explained in the legend to Table 3.1.  Values 
represented are mean ± standard error of 15, 20, or 40 tracked cells for rolling, firmly adherent or 






























No treatment DMSO 
control 
5.29 ± 0.77 2.13 ± 0.30 15.61 ± 1.03 





6.35 ± 1.01 2.14 ± 0.11 12.23 ± 1.06 
GI254023X 5.52 ± 2.05 1.92 ± 0.23 12.05 ± 1.81 
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3.2.2.2  Monocyte recruitment and transmigration is independent of ADAM10 
Monocytes are myeloid cells which have been implicated in driving many chronic 
inflammatory diseases such as atherosclerosis.  To investigate the role of endothelial 
ADAM10 in regulating the transmigration of monocytes, an in vitro static adhesion assay 
was utilised.  This assay has previously been well characterised to measure key 
monocyte-endothelial interactions that are important in deciphering optimal monocyte 
adhesion and transmigration (Woodfin et al., 2011).  A HUVEC monolayer was treated 
with either 20µM GI254023X or 0.02% DMSO for 24 hours and stimulated with 100 U/ml 
TNFα for the final four hours.  Monocytes were isolated from peripheral blood 
mononuclear cells (PBMCs) by passing through CD14+ MACS columns to select for 
CD14+ monocytes.  Isolated monocytes were washed and used at 1x105/ml.  Monocytes 
were co-incubated with HUVECs for 7 minutes at 37°C.  Non-adherent monocytes were 
washed off and HUVEC monolayers were fixed using 2% formaldehyde.  Respective 
monocyte behaviours were counted and total adhesion values calculated, as explained for 
previous static adhesion assays.   
Inhibition of endothelial ADAM10 had no effect on monocyte transmigration (Figure 3.11 
A).  In addition, monocyte adhesion was unaffected by endothelial ADAM10 inhibition 
(Figure 3.11 B).  Inhibition of monocyte-expressed ADAM10 did not alter the ability of 
monocytes to transmigrate (Figure 3.12 A).  Similarly, no differences in monocyte total 
adhesion were observed following monocyte-ADAM10 inhibition (Figure 3.12 B). 
These data suggest that monocyte adhesion and transmigration is independent of 
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Figure 3.11  Inhibition of endothelial ADAM10 does not alter the ability of monocytes to 
transmigrate under in vitro static conditions.  Confluent HUVECs were stimulated with 
100U/ml TNFα along with either 0.02% DMSO (black bar) or 20µM GI254023X (red bar) for 24 
hours.  Freshly isolated monocytes were then added to the pre-activated HUVEC monolayer in 
M199+BSA and incubated at 37oC for 7 minutes.  Video-recordings of five different fields of view 
of the endothelial monolayer were made using phase-contrast video microscopy.  Monocytes 
were classified as firmly adherent or transmigrated (A).  The total number of cells classified for 
each of the behaviours were combined to give a total adhesion count (B).  Error bars represent 
the standard error of the mean from three independent experiments.  Data were normalised by 
arcsine transformation and statistically analysed by a one-way ANOVA and Dunnett’s post-hoc 
comparisons test for total adhesion (***p < 0.001 compared to DMSO control data) or by a two-
way ANOVA and Bonferroni post-hoc comparisons test for cell behaviours.   
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Figure 3.13  Inhibition of monocyte-expressed ADAM10 does not alter the ability of 
monocytes to transmigration under in vitro static conditions.  Confluent HUVECs were 
stimulated with 100U/ml TNFα along for 24 hours.  Freshly isolated monocytes were then added 
to the pre-activated HUVEC monolayer in M199+BSA and incubated at 37oC for 7 minutes.  
Separately, monocytes were incubated with either 0.02% DMSO (black bar) or 20µM GI254023X 
(red bar) for 30 minutes prior to being added to the pre-activated HUVEC monolayer.  Video-
recordings of five different fields of view of the endothelial monolayer were made using phase-
contrast video microscopy.  Monocytes were classified as firmly adherent or transmigrated (A).  
The total number of cells classified for each of the behaviours were combined to give a total 
adhesion count (B).  Error bars represent the standard error of the mean from three independent 
experiments.  Data were normalised by arcsine transformation and statistically analysed by a one-
way ANOVA and Dunnett’s post-hoc comparisons test for total adhesion (***p < 0.001 compared 
to DMSO control data) or by a two-way ANOVA and Bonferroni post-hoc comparisons test for cell 
behaviours. 
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3.3 DISCUSSION 
Migration of leukocytes through vessel walls to sites of inflammation is an important 
component of the hosts’ immune response against pathogens and tissue injury.  The role 
of proteolytic shedding of key CAMs and transmembrane inserted chemokines by 
metalloproteases belonging to the ADAM family has been shown to potentially regulate 
transendothelial migration of leukocytes.  However, many studies have utilised cell line 
models and transfected cells to overexpress specific transmembrane proteins under non-
physiological static conditions to decipher the role of proteolytic shedding in leukocyte 
adhesion and transmigration (Hundhausen et al., 2007; Schwarz et al., 2010; Schulz et 
al., 2008).  As such, the role of proteolytic shedding in primary cells under physiological 
flow conditions is still largely unknown.  In this chapter, the role of one ADAM member, 
termed ADAM10, in supporting and facilitating leukocyte transmigration during 
inflammation was investigated in vitro.   
The data presented in this chapter highlights a role of endothelial ADAM10 in regulating 
the efficient transmigration of lymphocytes under physiological flow conditions and static 
adhesion conditions.  These findings are in line with previously published data that 
showed a role of endothelial ADAM10 in regulating the transmigration of cultured human 
T cells pre-activated with the mitogen phytohaemagglutinin (PHA).  In these assays, the 
authors co-incubated PHA blast T cells with unstimulated HUVECs treated with the 
ADAM10 inhibitor (GI254023X) and monitored T cell migration in a static transwell assay 
(Schulz et al., 2008).  Inhibition of endothelial ADAM10 was shown to reduce the 
transmigration of PHA blast T cells (Schulz et al., 2008).  Furthermore, the authors also 
targeted endothelial ADAM10 using siRNA and showed a similar reduction in the ability of 
PHA blast T cells to transmigrate (Schulz et al., 2008).  In addition to this study, a 
separate study by Schwarz et al. showed that knockdown of endothelial ADAM10 
regulated the adhesion of the L1.2 pre-B cell line, stably transfected with CX3CR1, on 
TNFα/IFNγ stimulated HUVECs (Schwarz et al., 2010).  In line with these observations, 
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data presented in this chapter further confirms a role of endothelial ADAM10 in 
lymphocyte transmigration under static conditions, in addition to under physiological flow 
conditions, in a well-characterised model of TNFα/IFNγ-induced inflammation.   
Targeting of ADAM10 on PHA blast T cells has also been shown to reduce the ability of 
lymphocytes to transmigrate under static conditions (Schulz et al., 2008).  To see if similar 
observations could be seen under physiological flow conditions, ADAM10 expressed on 
primary PBLs was targeted using the ADAM10 inhibitor.  Inhibition of ADAM10 on PBLs 
did not alter the ability of PBLs to transmigrate under flow or static conditions in a model 
of TNFα/IFNγ-induced inflammation.  It is possible to speculate that the difference 
observed between the data presented in this chapter and the published data by Schulz et 
al. could be down to nature of the adhesion assay along with the use of primary human 
lymphocytes versus cultured lymphocytes.  Indeed, Schulz et al. showed that 
transmigration of the PHA blast T cells was reduced following co-incubation for 24 hours 
whilst the adhesion assays used in this chapter only lasted for 13 minutes.  In addition, 
the culture condition of PHA blast T cells requires stimulation of these cells with 
interleukin-2, which changes the repertoire of proteins at the cell surface, compared to 
PBLs.  For example, PHA blast T cells have been shown to upregulate the expression of 
the αLβ2 integrin that supports adhesion on endothelial ICAM-1 (McGettrick et al., 2009) 
whilst PBLs utilise α4β1 for their optimal adhesion (Ahmed et al., 2011). 
In the present study, a detailed analysis of ADAM10’s role in neutrophil recruitment and 
transmigration was carried out.  Knockdown or inhibition of endothelial ADAM10 did not 
affect neutrophil recruitment on TNFα or IL-1β stimulated HUVECs under flow conditions.  
However, previously published data by Dreymueller et al. showed that knockdown of 
ADAM10 expression in human lung microvascular endothelial cells decreased the 
transmigration of human neutrophils towards the chemokine interleukin-8, in a static 
transwell chemotaxis model (Dreymueller et al., 2012a).  TNFα stimulation of primary 
HUVECs has been shown to promote the release of interleukin-8 from HUVECs, which 
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supports neutrophil adhesion (Luu et al., 2000).  However, under physiological conditions, 
neutrophils also require engagement of specific CAMs, which facilitate their efficient 
attachment and motility, and therefore differences between chemotactic assays (e.g. IL-8 
stimulation) and adhesion assays (e.g. TNFα stimulation) may overcome any differences 
in neutrophil transmigration that are observed following endothelial ADAM10 knockdown 
or inhibition.  For example, chemotaxis assays largely rely on the directional movement of 
leukocytes towards a specific stimulus and this process takes a substantially longer time 
compared to neutrophil adhesion, which is a rapid response occurring within a few 
minutes of initiation (Nourshargh et al., 2010). 
Following on from the findings that endothelial ADAM10 does not regulate the 
transmigration of neutrophils, the role of neutrophil-expressed ADAM10 in facilitating 
neutrophil transmigration was investigated.  Inhibition of ADAM10 (using GI254023X) on 
human neutrophils reduced the transmigration of neutrophils on ECV304 cells towards 
intrerleukin-8.  This phenotype was associated with a decrease in neutrophil adhesion to 
fibronectin but not ICAM-1, and a decrease in chemokine-induced upregulation of α5-
integrin (Pruessmeyer et al., 2014).  It is worth noting that ECV304 cells are not 
endothelial cells since they lack the expression of key endothelial markers such as VE-
cadherin (Kiessling et al., 1999) and therefore are regarded as poor tools for assessing 
leukocyte adhesion and transmigration.  Furthermore, deletion of ADAM10 in the 
haematopoietic lineage using a vav promoter caused a decrease in neutrophil 
transmigration in the lungs following LPS challenge in vivo.  This suppression in 
transmigration was associated with a reduction in Rho GTPase activation and a reduction 
in actin polymerisation, thereby hindering neutrophil transmigration in ADAM10-deficient 
cells (Dreymueller et al., 2014).  The differences observed following ADAM10 inhibition in 
the present study and previously published data on the deletion of ADAM10 under in vitro 
and in vivo conditions might be best explained through the use of different inflammatory 
models.  Indeed, previously published studies of ADAM10s role in neutrophil 
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transmigration have focused on acute inflammatory models in response to bacterial 
challenge using LPS and the data presented in this chapter has focused on the use of 
cytokine-induced inflammation.  Many differences between in vivo and in vitro models of 
inflammation have been reported concerning neutrophil transmigration.  In line with the 
inflammatory model used in the present study, in vitro studies have largely focussed on 
neutrophil interactions with cultured endothelial cell monolayers without considering the 
tissue stroma and other vessel wall components, which are increasingly becoming more 
important in modulating endothelial cell function during neutrophil transmigration (Proebstl 
et al., 2012).  In addition, visualising neutrophil transmigration in the cremasteric tissue in 
response to pro-inflammatory cytokines in vivo has revealed that the process of neutrophil 
transmigration takes longer (~15-45 minutes) compared to in vitro models using the same 
pro-inflammatory cytokines (~2 minutes) (Woodfin et al., 2009).  The difference between 
in vitro and in vivo models prompts further investigation to elucidate the role of endothelial 
ADAM10 in neutrophil transmigration by using mice with a specific deletion of ADAM10 in 
the endothelial lineage. 
The data presented in the current chapter highlighted a role of endothelial ADAM10 in 
regulating the transmigration of PBLs but not neutrophils.  To investigate the differences 
observed between neutrophil and lymphocyte transmigration following endothelial 
ADAM10 inhibition, the role of neutrophil derived proteases was investigated.  Neutrophils 
are well documented to contain large pools of intracellular proteases that are rapidly 
released upon activation (Pham, 2008), whilst lymphocytes have considerably smaller 
pools of such proteases.  Indeed, the release of neutrophil derived proteases such as 
neutrophil elastase upon neutrophil activation may degrade key junctional proteins, such 
as VE-cadherin, thereby aiding the transmigration of neutrophils (Hermant et al., 2003).  
As such, the aim was to determine if inhibiting neutrophil elastase release caused 
neutrophils to become dependent on endothelial ADAM10 to facilitate their transmigration.  
Pre-treatment of neutrophils with a neutrophil elastase inhibitor (α1-antitrypsin), reduced 
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the transmigration of neutrophils independently of endothelial ADAM10 inhibition.  This 
data suggests that neutrophils are able to utilise other mechanisms such as the release of 
neutrophil elastase to overcome the endothelial barrier during neutrophil transmigration in 
the presence of ADAM10 inhibition.  Moreover, activation of neutrophils has been shown 
to release MMPs such as MMP9, which facilitates the migration of neutrophils through the 
endothelial and venular basement membrane barriers (Stefanidakis et al., 2004).  The 
differences in proteolytic composition between leukocyte subsets might allow certain 
leukocytes, such as neutrophils, to migrate more readily, independently of changes in 
vascular integrity (Hermant et al., 2003; Nourshargh and Marelli-Berg, 2005). 
Under pro-inflammatory conditions, monocytes also undergo recruitment and 
transmigration and therefore could be regulated by ADAM10.  The findings in this chapter 
showed that human primary monocyte transmigration was independent of ADAM10.  
Inhibition of either ADAM10 expressed on monocytes or on HUVECs did not alter the 
transmigration of monocytes on TNFα stimulated HUVECs.  This was not supported by 
data from Tsubota et al. which showed that knockdown of ADAM10 on HUVECs 
suppressed the transmigration of CD14+ monocytes in a transwell static assay (Tsubota et 
al., 2013). Furthermore, data from Tsubota et al. highlighted a role of monocyte-
expressed ADAM17, which regulated the surface expression of the leukocyte-integrin 
complex, Mac-1 that supports monocyte transmigration (Tsubota et al., 2013).  
Knockdown of ADAM17 or ADAM10 on human monocytes was associated with a 
reduction in the release of the Mac-1 integrin complex.  This correlated with prolonged 
migration of ADAM17 knocked down monocytes, but not ADAM10 knocked down 
monocytes, on TNFα-activated HUVECs, suggesting monocyte transmigration is 
independent of ADAM10 (Tsubota et al., 2013). 
It is worth noting that the dosage of ADAM10 inhibitor used in the experiments in the 
present chapter was at 20 µM and previous studies have used the inhibitor at half the 
concentration (10 µM), and as such there is the possibility that the ADAM10 inhibitor 
CHAPTER 3:  THE ROLE OF ENDOTHELIAL ADAM10 IN REGULATING LEUKOCYTE 
RECRUITMENT AND TRANSMIGRATION 
119 
could be having off target effects at such a high dose.  Nevertheless, the inhibitor data are 
consistent with the data from knockdown studies using two different siRNA duplexes.  
In summary, this chapter describes a role for endothelial ADAM10 in regulating the 
transmigration of lymphocytes, but not neutrophils or monocytes, using in vitro 
physiological flow and static adhesion assays with primary HUVECs and leukocytes.  To 
try to elucidate the mechanism by which ADAM10 regulates the transmigration of PBLs, 
the next chapter focused on the role of ADAM10 endothelial substrates that potentially 
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The mechanism by which endothelial ADAM10 promotes leukocyte transmigration, and in 
particular the substrate(s) involved, is not clear.  Of the many substrates identified on 
endothelial cells that undergo proteolytic cleavage, only a handful are proteolytically 
processed by ADAM10.  ADAM10-mediated leukocyte transmigration under inflammatory 
conditions has been shown to be regulated by endothelial cell substrates such as the two 
transmembrane chemokines, CX3CL1 and CXCL16, which regulate THP-1 monocyte 
transmigration (Hundhausen et al., 2007) or the adherens junctional protein, VE-cadherin, 
that regulates vascular permeability (Schulz et al., 2008).  The aim of the present chapter 
was to extend the findings in Chapter 3 by determining the mechanism by which ADAM10 
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4.2.1 ADAM10 surface levels on endothelial cells are not affected by pro-
inflammatory cytokine stimulation 
Before experiments were conducted to determine whether individual substrates could be 
responsible for the role of ADAM10 in PBL transmigration, the expression levels of 
ADAM10 itself were assessed to determine whether cytokine stimulation of HUVECs had 
any effect.  In these experiments, ADAM10 expression was measured by flow cytometry.  
As a control, HUVECs were transfected with either a non-silencing control siRNA or with 
one of two siRNA duplexes to ADAM10 at a final concentration of 10 nM (see Section 
2.2.4.2).  Following 24 hours after transfection, HUVECs were then stimulated with either 
100U/ml TNFα alone or in combination with 10 ng/ml IFNγ or left unstimulated for a 
further 24 hours.  Cytokine stimulation did not alter the relative surface expression of 
ADAM10 (Figure 4.1 A & B).  The efficacy of the cytokine treatment was confirmed by 
upregulation of VCAM-1 expression (Figure 4.1 C & D).  Specificity of the ADAM10 
staining was confirmed by the significant reduction in expression levels following 
knockdown (Figure 4.1 A & B).  This data suggests that ADAM10 surface levels are not 
regulated under conditions of TNFα or TNFα/IFNγ-induced pro-inflammatory conditions. 
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Figure 4.1  ADAM10 surface levels are not affected by cytokine stimulation.  HUVECs were 
transfected with two different siRNA duplexes to ADAM10 alongside a non-specific siRNA at a 
final concentration of 10 nM.  24 hours after transfection, the HUVECs were stimulated with either 
100 U/ml TNFα alone or in combination with 10 ng/ml IFNγ or left unstimulated.  Following 24 
hours of stimulation, HUVECs were dissociated with accutase and stained on ice for ADAM10 
before being analysed by flow cytometry to measure surface ADAM10 expression.  The broken 
red line represents ADAM10 staining of negative control siRNA transfected cells and the red line 
represents ADAM10 staining following ADAM10 knockdown.  The black line represents isotype 
control staining (A).  Surface ADAM10 levels from panel A were quantitated and normalised to the 
“No siRNA” treated condition (B).  The effects of cytokine stimulation were confirmed by flow 
cytometry by staining for VCAM-1.  The green line represents VCAM-1 staining and the black line 
represents isotype control staining (C).  Surface VCAM-1 levels from panel C were quantitated 
(D).  Error bars represent the standard error of the mean from five independent experiments.  
Data were analysed by One-way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc 
test (***p < 0.001).   
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4.2.2 The transmembrane chemokine CX3CL1 is expressed on HUVECs but 
CXCL16 is not  
To begin to elucidate whether CX3CL1 and CXCL16 could be responsible for ADAM10’s 
role in PBL transmigration, their expression on HUVECs was assessed by flow cytometry 
in the presence or absence of ADAM10 siRNA knockdown or following ADAM10 
inhibition.  CX3CL1 was expressed on the surface of HUVECs, but levels were not altered 
by ADAM10 knockdown and/or cytokine treatment (Figure 4.2 A & B).  Consistent with the 
knockdown data findings, inhibition of ADAM10 did not alter the surface expression of 
CX3CL1 on HUVECs (Figure 4.2 C & D).  In contrast to CX3CL1 expression, HUVECs 
seemed not to express CXCL16 (Figure 4.3).  Moreover, the expression of CXCL16 was 
unaltered following ADAM10 knockdown or inhibition under the various cytokine 
stimulatory conditions (Figure 4.3 A & B).  To rule out the possibility of the antibody not 
binding to CXCL16, HEK293T cells were transiently transfected with a human expression 
construct for CXCL16.  A positive population of transfected cells was detected, indicating 
that the antibody detects CXCL16 (Figure 4.3 C). 
Collectively, these results suggest that CX3CL1, but not CXCL16, is expressed on 
HUVECs.  However, CX3CL1 is unlikely to be responsible for the role of ADAM10 in 
regulating PBL transmigration, because its levels are not affected by ADAM10 knockdown 
or inhibition. 
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Figure 4.2  CX3CL1 expression on HUVECs is not altered by ADAM10 knockdown or 
inhibition under cytokine stimulated conditions.  HUVECs were transfected with siRNA 
duplexes to ADAM10 as explained in the legend to Figure 4.2 or underwent treatment with 20 µM 
GI254023X or 0.02% DMSO control.  In addition, HUVECs were stimulated with either 100 U/ml 
TNFα alone or in combination with 10 ng/ml IFNγ or left unstimulated.  Following 24 hours of 
stimulation, HUVECs were stained for CX3CL1.  The green line represents CX3CL1 staining of 
negative control siRNA transfected cells and the red line represents CX3CL1 staining following 
ADAM10 knockdown.  The black line represents isotype control staining (A).  Surface CX3CL1 
levels from panel A were quantitated and normalised to the “No siRNA” treated condition (B).  
HUVECs treated with the ADAM10 inhibitor were analysed by flow cytometry to measure surface 
CX3CL1 expression.  The green line represents CX3CL1 staining of DMSO control treated cells 
and the red line represents CX3CL1 staining following GI254023X treatment.  The black line 
represents isotype control staining (C).  Surface CX3CL1 levels from panel C were quantitated 
and normalised to the “DMSO control” treated condition (D).  Error bars represent the standard 
error of the mean from four independent experiments.  Data were analysed by One-way ANOVA 
followed by a Dunnett’s multiple-comparisons post-hoc test.  Confirmation of ADAM10 knockdown 
under the various cytokine stimulatory conditions was assessed by flow cytometry as explained in 
the legend to Figure 4.1 and shown to be ~90% reduced upon quantitation (data not shown). 
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Figure 4.3  CXCL16 is not expressed on HUVECs.  HUVECs were dissociated and stained for 
CXCL16, as explained in the figure legend to Figure 4.2.  HUVECs transfected with siRNA were 
analysed by flow cytometry to measure surface CXCL16 expression.  The cyan line represents 
CXCL16 staining of negative control siRNA transfected cells and the red line represents CXCL16 
staining following ADAM10 knockdown.  The black line represents isotype control staining (A).  
HUVECs treated with the ADAM10 inhibitor were analysed by flow cytometry to measure surface 
CXCL16 expression.  The cyan line represents CXCL16 staining of DMSO control treated cells 
and the red line represents CXCL16 staining following GI254023X treatment.  The black line 
represents isotype control staining (B).  In addition, as a positive control, HEK293T cells were 
transfected with an expression vector containing CXCL16 cDNA, before being stained for 
CXCL16, as explained in panel A (C).  Error bars represent the standard error of the mean from 
four independent experiments.  Confirmation of ADAM10 knockdown under the various cytokine 
stimulatory conditions was assessed by flow cytometry as explained in the legend to Figure 4.1 
and shown to be ~90% reduced upon quantitation (data not shown).  
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4.2.3 The chemokine receptors, CX3CR1 and CXCR6 are differentially 
expressed on major lymphocyte subsets 
Having shown that HUVECs express CX3CL1 but not CXCL16, experiments now focused 
on looking at their receptors, CX3CR1 and CXCR6, on the various PBL subsets.  For 
these experiments, PBLs were incubated with a cocktail of antibodies to define the 
various lymphocyte subsets (namely, CD3, CD4, CD8, CD19, and CD56) and additional 
antibodies to the chemokine receptors, CX3CR1 and CXCR6, were added.  Lymphocyte 
subsets were characterised by their surface antigen expression by gating on the specific 
populations (as explained in Section 2.2.6) and analysed for expression of the chemokine 
receptors.  Expression of the chemokine receptor CX3CR1 was undetectable on PBL 
subsets (Figure 4.4 A) as compared to CD14+ monocytes that were isolated from a 
peripheral blood mononuclear cell (PBMC) preparation, as a positive control.  CXCR6 
expression was found on B cells, NK T cells and CD56low NK cells, with a lower 
expression of the chemokine receptor found on CD4+ and CD8+ T cells along with CD56hi 
NK cells (Figure 4.4 B).  Taken together, these results suggest that PBL subsets express 
the chemokine receptor CXCR6, but not CX3CR1, which could differentially alter the 
transmigration of the distinct PBL subsets.  In particular, the lack of expression of 
CX3CR1 indicates that its chemokine ligand on HUVECs, CX3CL1, is not responsible for 
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Figure 4.4  Major PBL populations differentially express the chemokine receptors CX3CR1 
and CXCR6.  Purified PBLs (or PBMCs for the case of CD14+ monocyte staining) were stained 
with the panel of lymphocyte subset antibodies (CD3 PerCy3.3, CD56 PE, CD4 Alexa Fluor 700, 
CD8 Pacific Blue and CD19 PECy7).  In addition, the PBLs were stained with 2 µl/FACS tube with 
the chemokine receptors, CX3CR1 (FITC) and CXCR6 (APC).  The relative surface expression of 
CX3CR1 or CXCR6 was determined on the various lymphocyte subsets by flow cytometry and 
quantitated (A) and (B).  In addition, CD14 Monocytes isolated from a PBMC preparation were 
stained for CX3CR1 as a positive control for staining (A).  Data are shown as mean ± standard 
error of the mean and are representative of three independent experiments.  Data were analysed 
using one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
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4.2.4 ADAM10 regulates VE-cadherin shedding 
Previous data has suggested a role of ADAM10 in regulating the shedding of VE-cadherin 
(Schulz et al., 2008).  In the absence of ADAM10 activity, VE-cadherin levels were shown 
to be upregulated due to a decrease in its shedding.  However, it is not clear whether the 
elevated VE-cadherin is truly responsible for regulating the transmigratory phenotype 
observed in Chapter 3.  As a first step to test this, experiments were performed to confirm 
that VE-cadherin shedding is impaired in the absence of ADAM10 in HUVECs.  In these 
experiments, HUVECs were transfected with either two different siRNA duplexes to 
ADAM10 or a negative control non-specific siRNA duplex.  24 hours after transfection, 10 
µM DAPT (a γ-secretase inhibitor) was added to prevent additional cleavage by γ-
secretase following ADAM10 cleavage and the cells were cultured for an additional 24 
hours.  Cells were lysed and Western blotted with an antibody to the C-terminal tail of VE-
cadherin.  For control cells, bands at 100 kDa and 35 kDa were observed.  The 100 kDa 
corresponds to full length VE-cadherin and the 35 kDa band is the cleaved C-terminal 
fragment.  Knockdown of endothelial ADAM10 confirmed that cleavage of VE-cadherin is 
dependent on ADAM10 by causing a ~75% or greater decrease in VE-cadherin 
proteolysis (Figure 4.5 A & B).  This was accompanied by the ~90% reduction in ADAM10 
surface expression as analysed by flow cytometry (Figure 4.5 C & D). 
In addition, the knockdown data findings were further validated using the ADAM10 
inhibitor.  In these assays, HUVECs were incubated either with 0.02% DMSO or 20 µM 
GI254023X in addition to 10 µM DAPT for 24 hours.  The cells were harvested and the 
Western blotted with an antibody to the C-terminal tail of VE-cadherin.  As shown in 
Figure 4.6 A, VE-cadherin C-terminal fragment generation was strongly diminished by 
incubation of HUVECs with the ADAM10 inhibitor compared to DMSO control treated 
cells, with a 90% reduction in the C-terminal fragment (Figure 4.6 A & B). 
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Figure 4.5  Knockdown of endothelial ADAM10 reduces VE-cadherin shedding.  HUVECs 
were transfected with two different siRNA duplexes to ADAM10 (red) alongside a non-specific 
siRNA (black bar) at a final concentration of 10 nM.  24 hours after transfection, 10 µM of the γ-
secretase inhibitor, DAPT was added to the culture media to prevent further proteolytic processing 
of VE-cadherin after ADAM10 cleavage.  Following an additional 24 hours, HUVEC lysates were 
Western blotted with an antibody to the C-terminal tail of VE-cadherin or to tubulin as a loading 
control.  The membrane was imaged and bands quantified on the Odyssey Infrared Imaging 
System (A).  The percentage cleaved was calculated by dividing the cleaved VE-cadherin 
fragment (~35 kDa) by the total VE-cadherin (relative band intensities corresponding to full length 
(~100) and cleaved VE-cadherin added together) expressed as a percentage (B).  Knockdown 
efficiency of ADAM10 was confirmed by flow cytometry.  The broken red line represents ADAM10 
surface expression on negative control siRNA transfected cells and the red solid line represents 
ADAM10 surface expression on ADAM10 siRNA transfected cells (C).  Surface ADAM10 levels 
from panel C were quantitated and normalised to the “No siRNA” treated condition (D).  Error bars 
represent the standard error of the mean from five independent experiments.  Data were 
normalised by arcsine transformation and statistically analysed by a Dunnett’s multiple-
comparisons post-hoc test (***p < 0.001 compared to negative control siRNA treated cells). 
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Figure 4.6  Inhibition of endothelial ADAM10 reduces VE-cadherin shedding.  HUVECs were 
treated with either 0.02% DMSO (black bar) or 20 µM GI254023X (red bar) in combination with 10 
µM DAPT and subsequently Western blotted as explained in the legend to Figure 4.5 (A).  The 
percentage cleaved was calculated as explained in the legend to Figure 4.5 (B).  Error bars 
represent the standard error of the mean from four independent experiments.  Data were 
normalised by arcsine transformation and statistically analysed by Students t-test (***p < 0.001 
compared to DMSO control treated cells). 
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4.2.5 VE-cadherin expression is regulated by endothelial ADAM10 
independently of cytokine stimulation 
Having shown that ADAM10 regulates the shedding of VE-cadherin, the effects of 
ADAM10 on VE-cadherin surface levels were next investigated.  In these experiments, 
HUVECs were transfected with siRNA duplexes to ADAM10 and appropriate controls, as 
explained earlier.  In addition, HUVECs were stimulated with either 100 U/ml TNFα alone 
or in combination with 10 ng/ml IFNγ for 24 hours.  The cells were harvested and stained 
for VE-cadherin and analysed by flow cytometry as previously explained.  Knockdown of 
ADAM10 increased the surface expression of VE-cadherin by approximately 40% (Figure 
4.7 A & B).  ADAM10 inhibition of HUVECs caused VE-cadherin surface levels to 
increase to a similar extent to that observed following endothelial ADAM10 knockdown 
(Figure 4.7 C & D).  Furthermore, cytokine treatment did not affect VE-cadherin surface 
levels (Figure 4.7).  These results indicate that endothelial ADAM10 is able to regulate the 
surface expression levels of VE-cadherin independently of cytokine stimulation. 
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Figure 4.7  Knockdown or inhibition of endothelial ADAM10 increases VE-cadherin surface 
expression.  HUVECs were transfected with siRNA duplexes to ADAM10 or underwent treatment 
with the ADAM10 inhibitor as explained in the legend to Figure 4.2.  In addition, HUVECs were 
stimulated with either 100 U/ml TNFα alone or in combination with 10 ng/ml IFNγ or left 
unstimulated.  Following 24 hours of stimulation, HUVECs were stained for VE-cadherin 
expression and processed by flow cytometry (A & C).  VE-cadherin surface levels were 
quantitated and normalised to either ‘No siRNA’ treated or ‘DMSO’ treated conditions (B & D).  
Error bars represent the standard error of the mean from four independent experiments.  Data 
were analysed by One-way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc test 
(*p < 0.05 and ***p < 0.001).  Confirmation of ADAM10 knockdown under the various cytokine 
stimulatory conditions was assessed by flow cytometry as explained in the legend to Figure 4.2 
and shown to be ~90% reduced upon quantitation (data not shown). 
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4.2.6 Knockdown or inhibition of ADAM10 increases endothelial barrier 
function 
Endothelial cell-cell junctions control the intercellular permeability to plasma solutes, and 
their integrity depends on the structure and function of VE-cadherin (Lampugnani et al., 
1995; Vestweber, 2012a; Schulz et al., 2008; Flemming et al., 2015).  Since VE-cadherin 
levels were found to be increased in the absence of ADAM10 in the previous section, an 
experiment was designed to test whether this was accompanied by increased integrity of 
the HUVEC monolayer.  In these experiments, HUVECs were seeded onto gelatine 
coated 0.4 µm pore filters before being transfected with either one or two different siRNA 
duplexes to ADAM10 or a negative control non-specific siRNA duplex.  These transwell 
filters were placed into a previously calibrated EndOhm chamber and resistance readings 
were taken at 0, 4, 12, 24, and 48-hour time points.  The resistance readings were 
converted to represent the resistance across the whole filter.  Knockdown of endothelial 
ADAM10 results in an increase in electrical resistance when compared to negative control 
siRNA transfected cells (Figure 4.8 A).  This was apparent 24 and 48 hours after seeding 
the cells (Figure 4.8 A), when the monolayers had reached confluence (Figure 4.8 B).  
These were also the time points at which ADAM10 knockdown had reached substantial 
levels (Figure 4.8 C & D). 
To further validate the knockdown data findings, a similar assay was setup in which 
HUVECs were treated with either 0.02% DMSO or 20 µM GI254023X and resistance 
readings were taken at specific time points as described above.  Inhibition of endothelial 
ADAM10 resulted in an increase in electrical resistance (Figure 4.9 A).  Again, the 
increase in resistance was apparent when the cells had reached full confluence (24 and 
48 hours after seeding) (Figure 4.9 B). 
CHAPTER 4:  ADAM10 REGULATES LYMPHOCYTE TRANSMIGRATION BY 
REGULATING CELL SURFACE EXPRESSION LEVELS OF ITS SUBSTRATE VE-
CADHERIN 
142 
Altogether, endothelial ADAM10 seems to regulate endothelial barrier integrity by 
increasing resistance through a mechanism that potentially relied on the increased 
formation of junctional protein complexes. 
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Figure 4.8  Knockdown of endothelial ADAM10 increases transendothelial electrical 
resistance.  HUVECs were transfected with two different siRNA duplexes to ADAM10 (red bars) 
alongside a non-specific siRNA (black bar) at a final concentration of 10 nM on gelatine-coated 
0.4 µM pore filters.  In addition, HUVECs were plated into 12 well plates and transfected with 
siRNA duplexes to assess knockdown efficiency as explained above.  Resistance readings were 
then taken at respective time points post siRNA transfection following calibration of the EndOhm 
chamber (A).  HUVEC monolayers were checked for confluency prior to taking resistance 
readings by taking phase contrast images at the respective time points (B).  ADAM10 knockdown 
confirmation was confirmed by flow cytometry as explained in the legend to Figure 4.1.  The 
broken red line represents ADAM10 expression on negative control siRNA transfected cells whilst 
the solid red line represents ADAM10 expression following ADAM10 knockdown at the specific 
time points (C).  Surface ADAM10 levels from panel C were quantitated and normalised to the “No 
siRNA” treated condition (D).  Error bars represent the standard error of the mean from four 
independent experiments.  Data were analysed by two-way ANOVA followed by a Bonferroni 
multiple-comparisons post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 compared to negative 
control siRNA treated conditions).  Scale bar: 80 µM 
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Figure 4.9  Inhibition of endothelial ADAM10 increases transendothelial electrical 
resistance.  HUVECs were plated on transwell filters as detailed in the legend to Figure 4.8.  
HUVEC were then treated with media containing either 0.02% DMSO or 20 µM GI254023X and 
resistance readings were taken at the respective time points as explained in the legend to Figure 
4.8 (A).  HUVEC monolayers were checked for confluency prior to taking resistance readings by 
taking phase contrast images at the respective time points (B).  Error bars represent the standard 
error of the mean from three independent experiments.  Data were analysed by two-way ANOVA 
followed by a Bonferroni multiple-comparisons post-hoc test (*p < 0.05, **p < 0.01 compared to 
negative control siRNA treated conditions).  Scale bar: 80 µM  
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4.2.7 Partial VE-cadherin knockdown to normal levels rescues the PBL 
transmigration defect 
The increased VE-cadherin expression and monolayer integrity could explain the impaired 
PBL transmigration in the absence of ADAM10.  To test this hypothesis, experiments 
were designed to partially knock down VE-cadherin back to wildtype levels, in the 
absence of ADAM10, and to then test whether PBL transmigration is restored.  As a first 
step, and with the sole aim of establishing VE-cadherin knockdown, static adhesion 
assays were carried out in which VE-cadherin was targeted at varying final siRNA 
concentrations (0.01 nM, 0.1 nM, 1 nM, or 10 nM) or a non-specific control siRNA duplex.  
VE-cadherin knockdown efficiency by flow cytometry revealed a dose-dependent 
decrease in VE-cadherin surface expression with increasing concentrations of siRNA over 
time (Figure 4.10 A & B).  Knockdown of VE-cadherin with 10 nM siRNA resulted in a 
~60% reduction in VE-cadherin surface levels that was maintained 72 hours post-
transfection (Figure 4.10 A & B).  Phase contrast images of HUVEC monolayers 
confirmed that a partial loss of VE-cadherin was sufficient to maintain endothelial 
monolayer integrity (Figure 4.10 C).  Static adhesion assays were setup with the VE-
cadherin transfected HUVECs as previously described whereby HUVEC were stimulated 
with 100 U/ml TNFα and 10 ng/ml IFNγ for 24 hours before co-incubating the cytokine 
stimulated HUVECs with 1x106 PBLs for 7 minutes.  These assays revealed that a partial 
loss of VE-cadherin did not alter the ability of PBLs to transmigrate (Figure 4.10 D).  
Furthermore, no differences in PBL total adhesion were observed following endothelial 
cell VE-cadherin knockdown at the various siRNA concentrations (Figure 4.10 E).  
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Figure 4.10  Partial knockdown of VE-cadherin does not alter lymphocyte adhesion and 
transmigration under in vitro static adhesion conditions.  HUVECs were transfected with two 
different siRNA duplexes to VE-cadherin (blue bars) at varying final concentrations (0.01 nM, 0.1 
nM, 1 nM or 10 nM) alongside a non-specific siRNA (black bar) at a final concentration of 10 nM 
before being analysed by flow cytometry to measure surface VE-cadherin expression.  The 
broken blue line represents VE-cadherin staining of cells transfected with a negative control 
siRNA and the solid blue line represents VE-cadherin staining following VE-cadherin knockdown.  
The black line isotype control staining (A).  Surface VE-cadherin levels from panel A were 
quantitated and normalised to the “No siRNA” treated condition (B).  Effects of VE-cadherin 
knockdown on PBL transmigration were assessed.  24 hours after transfection, the HUVECs were 
stimulated with 100 U/ml TNFα along with 10 ng/ml IFNγ for an additional 24 hours and static 
adhesion assays were carried out as previously described in Section 2.3.5.  Phase contrast 
images of five different fields of view per well were made to assess lymphocyte transmigration and 
monolayer integrity (C).  PBLs were classified as firmly adherent or transmigrated (D).  The total 
number of cell classified for each of the behaviours was combined to give a total adhesion count 
(E).  Error bars represent the standard error of the mean from five independent experiments.  
Data were normalised by arcsine transformation and statistically analysed by one-way ANOVA 
and Dunnett’s post-hoc comparisons test for total adhesion data and confirmation of siRNA 
knockdown (*p < 0.05, **p < 0.01, ***p < 0.001 compared to Negative control siRNA data) or by a 
two-way ANOVA and Bonferroni post-hoc comparisons test for PBL cell behaviour.   
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To determine whether the ADAM10-dependent PBL transmigration defect can be rescued 
by restoring elevated VE-cadherin levels back to normal, the effects of knockdown of 
ADAM10 in combination with a partial VE-cadherin knockdown was investigated.  From 
the VE-cadherin siRNA titration data, a final concentration of 0.5 nM VE-cadherin siRNA 
was chosen due to its expected ~45% reduction in VE-cadherin surface levels (Figure 
4.10).  For these static adhesion assays, HUVECs were transfected with one of two 
siRNA duplexes to VE-cadherin either alone or in combination with one of two siRNA 
duplexes to ADAM10.  Strikingly, reduction of VE-cadherin back to wildtype levels 
restored the transmigration defect in the absence of ADAM10 (Figure 4.11 A).  No 
differences in PBL total adhesion were observed following individual or combined 
knockdowns of VE-cadherin and ADAM10 (Figure 4.11 B).  Flow cytometry confirmed that 
VE-cadherin expression levels had returned to normal levels following the partial 
knockdown of VE-cadherin in combination with ‘complete’ ADAM10 knockdown; 
quantitation revealed that this was significant (Figure 4.11 C & D). 
In addition to studies carried out using ADAM10 knockdown, the ADAM10 inhibitor was 
also used in combination with a partial VE-cadherin knockdown.  For these static 
adhesion assays, HUVECs were transfected with one of two siRNA duplexes to VE-
cadherin (at a final concentration of 0.5 nM) and compared to non-specific control siRNA 
duplex treated cells.  Following 24 hours, HUVECs were stimulated and 20 µM 
GI254023X was added to respective conditions and the PBL static adhesion assay was 
carried out as previously described.  In a strikingly similar manner to the ADAM10 
knockdown data findings in Figure 4.11, partial knockdown of VE-cadherin in the 
presence of the ADAM10 inhibitor restored PBL transmigration (Figure 4.12 A).  No 
differences in PBL total adhesion were observed following knockdown of VE-cadherin in 
the presence of absence of the ADAM10 inhibitor (Figure 4.12 B).  Flow cytometry 
confirmed that VE-cadherin expression levels had returned to normal following the partial 
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knockdown in the presence of the ADAM10 inhibitor and quantitation revealed this was 
significant (Figure 4.12 C & D). 
Taken together, these results strongly suggest that the elevated VE-cadherin surface 
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Figure 4.11  Partial knockdown of VE-cadherin in the presence of ADAM10 knockdown 
restores normal PBL transmigration under in vitro static adhesion conditions.  HUVECs 
were transfected with two different siRNA duplexes to VE-cadherin (blue bars) at a final 
concentration of 0.5 nM either alone or in combination with two different siRNA duplexes to 
ADAM10 (red bars) at a final concentration of 10 nM alongside a non-specific siRNA (black bar) at 
a final concentration of 10 nM in 12 well plates.  24 hours after transfection, the HUVECs were 
stimulated and PBL adhesion and transmigration was assessed as previously described.  PBLs 
were classified as firmly adherent or transmigrated (A).  The total number of cell classified for 
each of the behaviours was combined to give a total adhesion count (B).  HUVECs transfected 
with siRNA were analysed by flow cytometry to measure surface VE-cadherin expression.  The 
broken blue line represents VE-cadherin staining of cells transfected with a negative control 
siRNA and the solid blue line represents VE-cadherin staining following VE-cadherin knockdown 
with the solid red line representing VE-cadherin staining following ADAM10 knockdown.  The 
black line represents isotype control staining (C).  Surface VE-cadherin levels from panel C were 
quantitated and normalised to the “No siRNA” treated condition (D).  Error bars represent the 
standard error of the mean from five independent experiments.  Data were normalised by arcsine 
transformation and statistically analysed by one-way ANOVA and Dunnett’s post-hoc comparisons 
test for total adhesion data and knockdown confirmation (***p < 0.01 compared to Negative 
control siRNA transfected data) or by a two-way ANOVA and Bonferroni post-hoc comparisons 
test for PBL cell behaviour (***p < 0.01 compared to the negative control siRNA transfected data).  
Confirmation of ADAM10 knockdown was assessed by flow cytometry as explained in the legend 
to Figure 4.2 and shown to be ~90% reduced upon quantitation (data not shown). 
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Figure 4.12  Partial knockdown of VE-cadherin in the presence of ADAM10 inhibition 
restores normal PBL transmigration under in vitro static adhesion conditions.  HUVECs 
were transfected with two different siRNA duplexes to VE-cadherin (blue bars) at a final 
concentration of 0.5 nM alongside a non-specific siRNA (black bar) at a final concentration of 10 
nM.  24 hours after transfection, the HUVECs were stimulated as previously explained in the 
legend to Figure 4.11 in addition to treatment with 20 µM GI254023X or 0.02% DMSO control.  
Following 24 hours, PBL adhesion, and transmigration was assessed as previously explained in 
the legend to Figure 4.10.  PBLs were classified as firmly adherent or transmigrated (A).  The total 
number of cell classified for each of the behaviours was combined to give a total adhesion count 
(B).  HUVECs transfected with siRNA were analysed by flow cytometry to measure surface VE-
cadherin expression as explained in the legend to Figure 4.11 (C).  Surface VE-cadherin levels 
from panel C were quantitated and normalised to the “Negative control siRNA” treated condition 
(D).  Error bars represent the standard error of the mean from four independent experiments.  
Data were normalised by arcsine transformation and statistically analysed by one-way ANOVA 
and Dunnett’s post-hoc comparisons test for total adhesion data and knockdown confirmation (*p 
< 0.05, **p < 0.01, ***p < 0.001 compared to DMSO control data) or by a two-way ANOVA and 
Bonferroni post-hoc comparisons test for PBL cell behaviour (***p < 0.01 compared to DMSO 
control data). 
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Paracellular transmigration of leukocytes through the endothelial cell junctions is now 
regarded as the primary mode through which leukocytes breach the endothelial cell 
barrier in the peripheral vasculature (Nourshargh and Alon, 2014; Ley et al., 2007).  This 
requires the transient dissociation and disassembly of key endothelial cell junctional 
proteins, such as VE-cadherin and other homophilic interactions between adjacent 
endothelial cells (Turowski et al., 2008).  Upon binding of leukocytes to the vessel wall, 
outside-in signalling events dictate endothelial cell junction protein fate by facilitating their 
disassembly and transient internalisation and recycling (Nottebaum et al., 2008; Vockel 
and Vestweber, 2013; Turowski et al., 2008; Wessel et al., 2014).  The proteolytic 
cleavage of key junctional proteins has been shown to also facilitate leukocyte 
extravasation (Schulz et al., 2008; Koenen et al., 2009; Colom et al., 2015).  The present 
study builds on the findings in Chapter 3 by identifying VE-cadherin as the key endothelial 
ADAM10 substrate involved in primary human PBL transmigration.   
Previous studies have shown that cleavage of CX3CL1 and CXCL16 promote leukocyte 
transmigration, but this was based on transfection of these transmembrane chemokines 
into cell lines, rather than the endogenous proteins on primary endothelial cells 
(Hundhausen et al., 2007; Schwarz et al., 2010).  By using flow cytometry screening 
approaches, HUVECs were found to express endogenous levels of CX3CL1, but not 
CXCL16.  These findings are supported by previously published data showing 
endogenous expression of CX3CL1 on HUVECs (Garton et al., 2001) and a weak 
expression of CXCL16 in primary smooth muscle cells and associated HUVECs at the 
mRNA level (Hofnagel et al., 2002) .   To determine whether CX3CL1 could be important 
in facilitating PBL transmigration, levels of its receptor on PBLs, CX3CR1, were measured 
by flow cytometry.  Major peripheral blood lymphocyte subsets were shown not to express 
CX3CR1.  Previous published data highlighted that a select population (~20%) of human 
peripheral blood memory CD8+ T cells stain positive for CX3CR1 (Foussat et al., 2000).  
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However, this specific subpopulation of T cells has been shown not to be the major 
lymphocyte subset (memory CD4+ T cells) that migrates across TNFα/IFNγ stimulated 
HUVECs (Ahmed et al., 2011; Chimen et al., 2015).  As a positive control, CD14+ 
monocytes stained positive for this chemokine receptor.  Human monocyte subsets have 
been shown to differentially express CX3CR1 and the expression of this chemokine 
receptor has been linked to distinct migratory phenotypes of both murine and human 
monocytes (Geissmann et al., 2003).  For example, CD14+CD16++CX3CR1++ monocytes 
have previously been shown to undergo rapid adhesion to activated endothelium by 
binding to CX3CL1 (Ancuta et al., 2004).  Furthermore, PBMCs or monocyte derived 
THP-1 cells have been shown to adhere to TNFα/IFNγ stimulated HUVECs via CX3CR1 
mediated adhesion on endothelial CX3CL1 under static conditions (Hundhausen et al., 
2007; Schwarz et al., 2010).  Cleavage of CX3CL1 by ADAM10 under ionomycin-induced 
conditions was shown to reduce PBMC or THP-1 cell adhesion (Hundhausen et al., 2007; 
Schwarz et al., 2010).  However, it yet remains to be shown if shedding of CX3CL1 
decreases the adhesion of specific human monocyte subsets under physiological 
conditions, namely the non-classical (CD14+CD16++CX3CR1++ monocytes) or 
intermediate (CD14++CD16+CX3CR1++ monocytes) subsets that have important role in 
patrolling and local surveillance of tissue and pro-inflammatory phenotypes, respectively 
(Wong et al., 2011). 
In addition to screening PBL populations for the chemokine receptor CX3CR1, PBL 
subsets were also screened for their expression of CXCR6.  In line with previously 
published data, flow cytometry revealed PBLs differentially express CXCR6, with higher 
levels of the receptor expressed on B cells, CD56low NK cells and NK T cells, and lower 
expression on CD4+ and CD8+ T cells and CD56hi NK cells (Latta et al., 2007).  However, 
a functional role for CXCR6-mediated adhesion can be ruled out due to the lack of it’s 
ligand CXCL16 on HUVECs. 
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Targeting of endothelial ADAM10 using gene knockdown or through the use of the 
ADAM10 inhibitor upregulated the surface expression of another ADAM10 substrate, VE-
cadherin.  This was supported by a subsequent increase in the resistance of endothelial 
monolayers.  In addition, a decrease in VE-cadherin shedding was observed following 
ADAM10 knockdown or inhibition.  Indeed, a reduction in VE-cadherin shedding by 
inhibition of ADAM10 has been previously reported (Schulz et al., 2008).  The same study 
also showed that inhibition of endothelial ADAM10 reduced vascular permeability as 
measured by increased resistance to the passage of 40 kDa FITC-dextran (Schulz et al., 
2008).  In addition, a separate study showed similar findings in which inhibition of 
ADAM10 on human dermal microvascular endothelial cells reduced the release of soluble 
VE-cadherin under TNFα cytokine stimulated conditions, with a subsequent increase in 
trans-endothelial electrical resistance (Flemming et al., 2015).  Collectively, these data 
suggest that endothelial ADAM10 is able to regulate endothelial junctions by enhancing 
endothelial electrical resistance, increasing the surface expression of VE-cadherin and 
subsequently reducing VE-cadherin shedding. 
Though previous studies have highlighted that ADAM10 inhibition or knockdown 
decreases the shedding of VE-cadherin and decreases endothelial monolayer 
permeability (Schulz et al., 2008; Donners et al., 2010; Flemming et al., 2015), it is still not 
clear whether this is the cause of the reduced PBL transmigration.  In order to determine 
whether increased VE-cadherin expression levels were causing the transmigration defect, 
ADAM10 knockdown or inhibition was combined with partial VE-cadherin knockdown 
designed to return VE-cadherin levels to normal.  Strikingly, this approach restored PBL 
transmigration under conditions of ADAM10 knockdown or inhibition.  Flow cytometry 
confirmed that VE-cadherin expression levels had returned to normal following the partial 
knockdown, and quantitation revealed this was significant.  Taken together, these data 
suggest that regulation of VE-cadherin surface levels by ADAM10, most likely due to the 
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5.1 INTRODUCTION 
Tetraspanins are a superfamily of 33 transmembrane proteins in mammals that regulate 
the intracellular trafficking and membrane localisation of the so-called ‘partner’ proteins 
with which they associate (Charrin et al., 2014; Hemler, 2014).  Tetraspanin association 
with specific partner proteins has been shown to be important in the leukocyte adhesion 
cascade.  Following rolling, leukocytes undergo firm adhesion by forming integrin-
mediated interactions with endothelial cell CAMs, ICAM-1 and VCAM-1.  Leukocyte-
expressed CD81 clusters the integrin α4β1, which has been shown to lead to increased 
adhesion strengthening of leukocytes to VCAM-1 (Feigelson et al., 2003).  In addition, 
endothelial tetraspanins CD9 and CD151 cluster the IgSF members ICAM-1 and VCAM-1 
into adhesive platforms that facilitate leukocyte adhesion and transmigration (Barreiro et 
al., 2008).  Indeed, loss of CD9 or CD151 on endothelial cells impaired leukocyte 
adhesion and transmigration, highlighting a fundamental role of tetraspanins in these 
processes (Barreiro et al., 2005).  Moreover, the use of in vitro and in vivo models has 
highlighted a role of the tetraspanin CD63 in regulating the trafficking and subsequent 
clustering of P-selectin, that is required for optimal leukocyte capture such that loss of 
CD63 in endothelial cells resulted in impaired leukocyte recruitment (Doyle et al., 2011).  
These data provide evidence for a role of tetraspanins in leukocyte recruitment and 
adhesion.   
As demonstrated in chapters three and four, endothelial ADAM10 is able to regulate the 
transmigration of PBLs by selectively modulating the surface levels of the adherens 
junctional protein VE-cadherin.  The Tomlinson group and another independent research 
group have recently published that ADAM10 associates with a subgroup of tetraspanins 
termed the TspanC8s that consist of six largely understudied tetraspanins, namely 
Tspan5, 10, 14, 15, 17 and 33, which are related by sequence (Dornier et al., 2012; 
Haining et al., 2012).  Interaction with a TspanC8 was shown to be required for the exit of 
ADAM10 from the endoplasmic reticulum, enzymatic maturation and trafficking to the cell 
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surface (Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012b).  Indeed, different 
TspanC8s have been shown to promote the differential cleavage of various ADAM10 
substrates.  For example, overexpression of Tspan5 and Tspan14, but not Tspan15, has 
been shown to promote ADAM10 dependent shedding of Notch (Dornier et al., 2012).  In 
addition, overexpression of Tspan15 promoted ADAM10-dependent shedding of N-
cadherin in a cell line model (Prox et al., 2012b; Noy et al., 2016; Jouannet et al., 2016).  
Tspan15 has also been shown to both promote and inhibit ADAM10-dependent shedding 
of APP in a cell line model (Prox et al., 2012b; Jouannet et al., 2016).  The difference in 
shedding highlighted by these two studies is most likely due to the different cells that were 
used (HEK293T cells by Prox et al. or U2OS cells by Jouannet et al.) to assess a role of 
Tspan15 mediated ADAM10 shedding.  However, a role for a specific endothelial 
TspanC8 in ADAM10-mediated VE-cadherin shedding and PBL transmigration, has not 
been reported.  The aim of this chapter was to investigate this possibility. 
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5.2.1 HUVECs express the TspanC8 tetraspanins Tspan5, 14, 15 and 17 
Previous studies in the Tomlinson group have shown that HUVECs express four of the 
TspanC8s, namely Tspan5, 14, 15 and 17, by serial analysis of gene expression (SAGE) 
(Bailey et al., 2011) and five TspanC8s by RT-PCR, namely Tspan5, 10, 14, 15 and 17 
(Haining et al., 2012). However, the effects of cytokine-stimulation on the expression of 
these TspanC8s has not previously been investigated and so formed the basis of initial 
investigations in this chapter.  Since antibodies were not available to the TspanC8 
tetraspanins, RT-PCR was used to determine the relative mRNA expression of the 
TspanC8s in HUVECs.  HUVECs expressed four of the six TspanC8s with greatest 
expression for Tspan14 (Figure 5.1 A).  Tspan5 was also expressed at ~50% of the level 
of Tspan14, along with Tspan15 and Tspan17 which were expressed at ~25% and ~10% 
of the level of Tspan14, respectively (Figure 5.1 A).  Tspan10 and Tspan33 were 
undetectable in HUVECs (Figure 5.1 A).  To determine whether HUVEC TspanC8 
expression is altered upon cytokine stimulation, HUVECs were stimulated with 100 U/ml 
TNFα and 10 ng/ml IFNγ.  RT-PCR confirmed that the TspanC8 expression profile was 
not significantly affected by the cytokine stimulation (Figure 5.1 B).  To summarise, at 
least at the mRNA level, HUVECs express Tspan5, 15 and 17, with Tspan14 being the 
most prominently expressed, but lack the expression of Tspan10 or 33. 
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Figure 5.1  HUVECs express endogenous Tspan5, 14, 15 and 17 at the mRNA level.  
HUVECs were harvested and RNA was isolated as previously described in Section 2.4.3.  
Isolated RNA was converted into cDNA before carrying out RT-PCR to assess the endogenous 
expression of the six TspanC8s.  Relative Ct values, as calculated as the point at which the 
threshold meets the amplification curve in the exponential phase of the PCR reaction, were 
converted into 2ΔΔCt corresponding to the relative fold change in expression and plotted as the 
relative mRNA expression taking into account GAPDH expression as a housekeeping gene.  
Endogenous expression levels corresponding to unstimulated HUVECs (A) or HUVECs stimulated 
with 100 U/ml TNFα and 10 ng/ml IFNγ for 24 hours (B) are shown.  Error bars represent the 
standard error of the mean from four individual experiments. 
CHAPTER 5:  ADAM10-INTERACTING ENDOTHELIAL TETRASPANINS TSPAN5 AND 
TSPAN17 PROMOTE LYMPHOCYTE TRANSMIGRATION 
165 
5.2.2 Overexpression of TspanC8s in HUVECs does not affect PBL 
transmigration, but alters ADAM10 surface expression and VE-cadherin 
proteolysis 
To investigate whether overexpression of each of the TspanC8s in HUVECs effects PBL 
transmigration, HUVECs were transduced with lentivirus that expressed the various 
TspanC8s and a puromycin resistance marker.  Puromycin-resistant cells were 
incorporated into static adhesion assays to assess PBL transmigration, as performed 
previously.  Lentiviral overexpression of each of the TspanC8s in HUVECs did not 
significantly alter the percentage of PBLs that were firmly adhered or had transmigrated 
(Figure 5.2 A).  In addition, there were no changes in the total number of PBLs that 
adhered (Figure 5.2 B). 
Lentivirally transduced HUVECs were also monitored for their expression of ADAM10 and 
VE-cadherin by flow cytometry.  Overexpression of Tspan15 and Tspan33 doubled 
ADAM10 surface expression compared to control conditions (Figure 5.3 A & B).  
Overexpression of the other TspanC8s had no effect on surface ADAM10 levels (Figure 
5.3 A & B).  In addition, no changes in VE-cadherin surface expression were observed in 
HUVECs overexpressing any of the TspanC8s (Figure 5.4 A & B). 
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Figure 5.2  Lentiviral overexpression of TspanC8s does not affect lymphocyte 
transmigration under in vitro static conditions.  HUVECs were lentivirally transduced with 
virus-containing media from HEK293T cells transfected individually with the various TspanC8s 
(Tspan5 – orange bars, Tspan10 – yellow bars, Tspan14 – green bars, Tspan15 – blue bars, 
Tspan17 – purple bars, Tspan33 – pink bars) or with a mock control vector (black bar).  48 hours 
after transduction, HUVECs were selected for positive infection by treatment with 2 µg/ml 
puromycin for an additional 48 hours.  Positively selected HUVECs were incorporated into a static 
adhesion assay to assess PBL adhesion and transmigration as previously explained.  PBLs were 
classified as firmly adherent or transmigrated (A).  The total number of cell classified for each of 
the behaviours was combined to give a total adhesion count (B).  Error bars represent the 
standard error of the mean from four independent experiments.  Data were normalised by arcsine 
transformation and statistically analysed by one-way ANOVA and Dunnett’s post-hoc comparisons 
test for total adhesion data (***p < 0.001 compared to ‘control’ overexpressing cell data) or by a 
two-way ANOVA and Bonferroni post-hoc comparisons test for PBL cell behaviour. 
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Figure 5.3  Lentiviral overexpression of Tspan15 and Tspan33 increases surface ADAM10 
expression on HUVECs.  HUVECs were lentivirally transduced and selected as explained in the 
legend to Figure 5.2 before undergoing flow cytometry to measure surface ADAM10 expression.  
The orange, yellow, green, blue, purple, and pink solid lines represent ADAM10 expression in the 
TspanC8 transduced HUVECs.  The broken red line represents basal ADAM10 expression in the 
mock control vector transduced HUVECs.  The black line represents isotype control staining (A).  
Surface ADAM10 levels from panel A were quantitated and geometric mean values are shown in 
(B).  Error bars represent the standard error or the mean from four independent experiments.  
Data were statistically analysed by One-way ANOVA followed by a Dunnett’s multiple-
comparisons post-hoc test (***p < 0.001 compared to ‘mock control vector’ transduced HUVECs).   
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Figure 5.4  Lentiviral overexpression of TspanC8s does not alter VE-cadherin expression 
on HUVECs.  Lentivirally transduced HUVECs were stained for the expression of VE-cadherin 
and data is presented as explained in the legend to Figure 5.3.  Error bars represent the standard 
error or the mean from four independent experiments.  Data were statistically analysed by One-
way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc test.   
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Although the surface levels of VE-cadherin were not effected by overexpression of the 
TspanC8s, cleavage of VE-cadherin may have been altered.  To evaluate this possibility, 
lentivirally transduced HUVECs were assessed for their ability to cleave VE-cadherin 
using Western blotting.  The cells were treated with 10 µM DAPT (a γ-secretase inhibitor) 
to prevent cleavage of the C-terminal fragment and the cells were cultured for an 
additional 24 hours.  Western blotting of cell lysates, using an antibody which binds to the 
cytoplasmic tail of VE-cadherin, showed that overexpression of Tspan15 or 33 reduced 
VE-cadherin shedding from ~60% of VE-cadherin shed in the control lane to ~30% shed 
for either Tspan15 or 33 overexpressing cells (Figure 5.5 A & B).  Overexpression of 
Tspan5, 10, 14 or 17 did not alter cleavage of VE-cadherin (Figure 5.5 A & B).  FLAG 
blotting showed that each of the TspanC8s were overexpressed to varying levels.  It was 
noted that Tspan10, 15 and 33 had considerably stronger expression levels than the other 
TspanC8s (Figure 5.5 C). 
Taken together, the data indicated that overexpression of any individual TspanC8 does 
not regulate PBL transmigration, yet overexpression of Tspan15 or Tspan33 resulted in 
increased ADAM10 surface expression and reduced VE-cadherin shedding.  The latter is 
the opposite of what might have been expected if VE-cadherin shedding was simply 
determined by levels of ADAM10.  Since Tspan15 and Tspan33 were particularly strongly 
expressed, compared with most of the other TspanC8s, it is possible that these were 
sequestering ADAM10 away from VE-cadherin.  To speculate further, it is possible that 
one of the other TspanC8s might promote VE-cadherin shedding, but that its lentiviral 
expression level was too low in the experiments for any significant shedding increase to 
be observed.  To test these ideas, TspanC8 knockdown approached were employed in 
the experiments that follow. 
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Figure 5.5  Lentiviral overexpression of Tspan15 and Tspan33 reduce VE-cadherin 
cleavage.  HUVECs were lentivirally transduced and selected as explained in the legend to 
Figure 5.2.  HUVECs were treated with 10 µM DAPT for 24 hours to prevent further proteolytic 
processing of VE-cadherin after ADAM10 cleavage.  HUVECs were then harvested and subjected 
to Western blotting for VE-cadherin.  The membrane was imaged and bands quantified on the 
Odyssey Infrared Imaging System (A).  The percentage cleaved was calculated by dividing the 
cleaved VE-cadherin fragment (~35 kDa) by the total VE-cadherin (relative band intensities 
corresponding to full length (~100) and cleaved VE-cadherin added together) (B).  The membrane 
was stripped and re-probed with mouse anti-FLAG to assess TspanC8 tetraspanin expression 
(C).  Error bars represent the standard error of the mean from four independent experiments.  
Data were analysed by One-way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc 
test (*p < 0.05 compared to mock ‘control’ vector transduced cells). 
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5.2.3 Knockdown of individual TspanC8s in HUVECs does not affect PBL 
transmigration or ADAM10-dependent changes in VE-cadherin shedding 
A siRNA-mediated gene knockdown approach of endogenous TspanC8s was utilised to 
elucidate a possible role of different TspanC8s in regulating the role of ADAM10 during 
PBL transmigration.  HUVECs were transfected with one of two siRNA duplexes that 
target each of the six TspanC8s or with a non-specific control siRNA duplex.  All duplexes 
were used at a final concentration of 10 nM.  24 hours after transfection, HUVECs were 
stimulated with 100 U/ml TNFα and 10 ng/ml IFNγ for an additional 24 hours, and the 
static adhesion assay was carried out as previously explained.  Knockdown of any one 
TspanC8 did not alter the ability of PBLs to transmigrate or firmly adhere (Figure 5.6 A & 
C).  In addition, no differences in total adhesion of PBLs were observed following 
individual TspanC8 tetraspanin knockdown (Figure 5.6 B & D).  To confirm that each of 
the individual TspanC8 tetraspanin knockdowns had worked, cDNA was produced from 
extracted RNA and quantitative PCR was performed, as previously explained.  
Knockdown of TspanC8s expressed in HUVECs resulted in ~75%, ~52%, ~80% and 
~80% reduction in mRNA expression for Tspan5, 14, 15 and 17, respectively (Figure 5.6 
E).  Since Tspan10 and Tspan33 were not detected at endogenous levels in resting 
HUVECs, the knockdown efficiency could not be calculated and these ‘knockdowns’ 
served as additional negative controls. 
To determine whether knockdown of each of the individual TspanC8s affects ADAM10 or 
VE-cadherin surface levels, HUVECs were transfected with one of two siRNA duplexes 
that target each of the six TspanC8s or with a non-specific control siRNA duplex, as 
explained above.  Flow cytometry analysis revealed that the knockdown of Tspan14 or 
Tspan15 resulted in a ~12% reduction in ADAM10 surface levels (Figure 5.7).  
Knockdown of the other TspanC8s (Tspan5, 10, 17 or 33) did not affect basal ADAM10 
surface levels (Figure 5.7).  Similarly, knockdown of individual TspanC8s in HUVECs did 
not affect basal VE-cadherin surface levels (Figure 5.8).  
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Figure 5.6  Knockdown of individual tetraspanins does not alter the ability of PBLs to 
transmigrate under in vitro static conditions.  HUVECs were transfected with two different 
siRNA duplexes to the various TspanC8s at a final concentration of 10 nM.  24 hours after 
transfection, the HUVECs were stimulated and PBL adhesion and transmigration was assessed 
as previously explained for static adhesion assays.  PBLs were classified as firmly adherent or 
transmigrated (A & C).  The total number of cell classified for each of the behaviours was 
combined to give a total adhesion count (B & D).  HUVECs transfected with siRNA were analysed 
by RT-PCR to measure the relative knockdown efficiency of the various TspanC8s at the mRNA 
level, as explained in the legend to Figure 5.1 (E).  Error bars represent the standard error of the 
mean from four independent experiments.  Data were normalised by arcsine transformation and 
statistically analysed by one-way ANOVA and Dunnett’s post-hoc comparisons test for total 
adhesion data and knockdown confirmation (***p < 0.001 compared to negative control siRNA 
transfected data) or by a two-way ANOVA and Bonferroni post-hoc comparisons test for PBL cell 
behaviour.   
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Figure 5.7  Knockdown of Tspan14 or Tspan15 reduces ADAM10 surface expression.  
HUVECs were transfected with one of two siRNA duplexes to the various TspanC8s or with a 
negative control siRNA as explained in the legend to Figure 5.6.  Following 48 hours, HUVECs 
were harvested processed by flow cytometry to measure surface ADAM10 expression as 
explained in the legend to Figure 5.3 (A & C).  Surface ADAM10 levels from panel A & C were 
quantitated and normalised to the average ADAM10 surface expression in the ‘no siRNA’ 
condition (B & D).  Confirmation of individual TspanC8 knockdowns were assessed by RT-PCR 
as explained in the legend to Figure 5.1 and shown to be 50-90% reduced upon quantitation 
and in line with mRNA levels shown in Figure 5.6 (data not shown).  Error bars represent the 
standard error or the mean from four independent experiments.  Data were statistically analysed 
by One-way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc test (***p < 0.01 
compared to ‘negative control siRNA’ transfected HUVECs).   
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Figure 5.8  Knockdown of TspanC8s do not affect VE-cadherin surface expression.  
Individual TspanC8 knocked down HUVECs were stained for the expression of VE-cadherin and 
data is presented as explained in the legend to Figure 5.7.  Error bars represent the standard 
error or the mean from four independent experiments.  Data were statistically analysed by One-
way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc test.   
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To determine the effects of individual TspanC8 knockdowns on ADAM10 activity towards 
VE-cadherin, HUVECs were transfected with one of two siRNA duplexes to the six 
TspanC8s, as explained above.  24 hours after transfection, 10 µM DAPT was added and 
the cells were cultured for an additional 24 hours.  The cells were harvested, lysed, and 
subjected to SDS-PAGE Western blotting for VE-cadherin, as previously described.  
Knockdown of individual TspanC8s did not alter the shedding of VE-cadherin (Figure 5.9). 
Collectively, these data suggest that knockdown of each individual TspanC8 in HUVECs 
does not affect PBL transmigration, VE-cadherin shedding or VE-cadherin surface levels.  
Furthermore, only a partial reduction in ADAM10 surface levels is observed following 
Tspan14 or Tspan15 knockdown, but ADAM10 surface levels remain unaltered in cells 
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Figure 5.9  Knockdown of TspanC8s does not affect VE-cadherin cleavage.  HUVECs were 
transfected with siRNA duplexes to the various TspanC8s as explained in the legend to Figure 
5.6.  Following 24 hours, HUVECs were treated with 10 µM DAPT for an additional 24 hours to 
prevent further proteolytic processing of VE-cadherin after ADAM10 cleavage.  HUVECs were 
then harvested, lysed and Western blotting was carried out for VE-cadherin as explained in the 
legend to Figure 5.5.  α-Tubulin was used as a loading control.  The membrane was imaged and 
bands quantified on the Odyssey Infrared Imaging System (A).  The percentage cleaved was 
calculated as previously explained in the legend to Figure 5.5 (B).  Confirmation of individual 
TspanC8 knockdowns were assessed by RT-PCR as explained in the legend to Figure 5.1 and 
shown to be 50-90% reduced upon quantitation and in line with mRNA levels shown in Figure 5.6 
(data not shown).  Error bars represent the standard error of the mean from four independent 
experiments.  Data were analysed by One-way ANOVA followed by a Dunnett’s multiple-
comparisons post-hoc test.   
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5.2.4 The presence of Tspan5 or Tspan17 is sufficient to maintain PBL 
transmigration under cytokine stimulatory conditions 
Since individual TspanC8 knockdowns did not affect the ability of PBLs to transmigrate, it 
was speculated that the TspanC8s could be compensating for each other since all the 
TspanC8s expressed in HUVECs can promote ADAM10 maturation (Haining et al., 2012).  
Therefore, a combination knockdown approach was undertaken to investigate the role of 
individual TspanC8s in regulating PBL transmigration.  In these set of experiments, 
HUVECs were transfected with siRNA duplexes corresponding to all six of the TspanC8s 
(30 nM siRNA in total) or five of the six TspanC8s (25 nM siRNA in total) or with a non-
specific siRNA duplex (30 nM).  This approach allowed the function of each individual 
TspanC8 tetraspanin to be investigated without compensation from another family 
member.  24 hours after transfection, HUVECs were stimulated with 100 U/ml TNFα and 
10 ng/ml IFNγ for an additional 24 hours and a static adhesion assay was carried out as 
previously explained.  Interestingly, knockdown of all TspanC8s in HUVECs suppressed 
the transmigration of PBLs to ~45% of the control transfected HUVECs (Figure 5.10 A & 
C).  Knockdown of five of the six TspanC8s also suppressed PBL transmigration, with the 
exceptions of HUVECs that retained the expression of Tspan5 or Tspan17, which 
maintained PBL transmigration equivalent to control transfected HUVECs (Figure 5.10 A 
& C).  No significant differences in PBL total adhesion were observed following 
combination TspanC8 knockdown (Figure 5.10 B & D).  Interestingly, CLUSTAL Omega 
protein sequence analysis showed that Tspan5 and 17 are the two most highly related 
TspanC8s, sharing 78% identity in human (Figure 5.11), which is consistent with their 
common role in regulating PBL transmigration.  Confirmation of TspanC8s knockdown 
efficiency under the various combination knockdown conditions was assessed by RT-
PCR as previously described.  Knockdown of Tspan5, Tspan14, Tspan15 or Tspan17 
resulted in 60%, 50% 70% or 60% reduction in expression, respectively (Figure 5.12).  
Combination knockdown of HUVECs transfected with siRNA duplexes corresponding to 
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five of the six TspanC8s did not alter mRNA expression of the individual TspanC8 not 
targeted by siRNA (Figure 5.12 B – G). 
To determine whether knockdown of multiple TspanC8s affects ADAM10 and VE-
cadherin surface levels on HUVECs, cells with the above siRNA knockdown combinations 
were stained with ADAM10 and VE-cadherin as explained previously.  Flow cytometry for 
ADAM10 revealed a partial reduction in ADAM10 surface levels in knockdown 
combinations that either targeted all of the TspanC8s or retained the expression of 
Tspan5, 10, 15, 17 or 33 (Figure 5.13).  Knockdown combinations that retained the 
expression of Tspan14 maintained normal surface expression of ADAM10 (Figure 5.13).  
Flow cytometry analysis of VE-cadherin surface levels in TspanC8 knockdown 
combinations revealed that the knockdown combinations that retained the expression of 
Tspan5 or Tspan17 reduced VE-cadherin surface levels when compared to control 
transfected conditions (Figure 5.14).  Furthermore, the other knockdown combinations, in 
addition to the knockdown of all TspanC8s in HUVECs, maintained basal VE-cadherin 
levels (Figure 5.14).  Therefore, Tspan5 and Tspan17 are important for PBL 
transmigration and the maintenance of normal VE-cadherin expression levels at the cell 
surface.  This is not because these TspanC8s are critical for ADAM10 surface expression, 
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Figure 5.10  The presence of Tspan5 or Tspan17 is sufficient to maintain basal PBL 
transmigration under in vitro static conditions.  HUVECs were transfected with one of two 
siRNA duplexes corresponding to the various TspanC8 tetraspanins at 5 nM (red bars) or 
transfected with 5 nM negative control siRNA duplex (black bars) for 48 hours.  To evaluate the 
single role of a tetraspanin, all TspanC8s were knocked down using siRNA apart from a single 
tetraspanin hereby revealing the presence of the single tetraspanin.  24 hours after transfection, 
the HUVECs were stimulated and PBL adhesion and transmigration was assessed as previously 
explained for static adhesion assays.  PBLs were classified as firmly adherent or transmigrated (A 
& C).  The total number of cell classified for each of the behaviours was combined to give a total 
adhesion count (B & D).  Error bars represent the standard error of the mean from at least five 
independent experiments.  Data were normalised by arcsine transformation and statistically 
analysed by one-way ANOVA and Dunnett’s post-hoc comparisons test for total adhesion data 
(***p < 0.01 compared to Negative control siRNA transfected HUVECs) or by a two-way ANOVA 
and Bonferroni post-hoc comparisons test for PBL cell behaviour (*p < 0.05, **p < 0.01, ***p < 
0.001 compared to negative control siRNA transfected HUVECs).   
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Figure 5.11  Phylogenetic tree of TspanC8 tetraspanins.  TspanC8s expressed in humans 
were analysed for sequence similarity using Clustal OMEGA protein sequence alignment 
software.  The high level of sequence similarity between Tspan5 and Tspan17 is highlighted. 
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Figure 5.12  Confirmation of TspanC8 knockdown.  HUVECs transfected with combined 
TspanC8 siRNAs were analysed by RT-PCR to measure the relative knockdown efficiency of the 
various TspanC8s at the mRNA level as explained in the legend to Figure 5.1.  ΔCt values were 
analysed as explained in the legend to Figure 5.1 and the relative fold change in expression is 
plotted as the relative mRNA expression (A - G).  The various TspanC8 siRNA knockdown 
combinations are shown (B – G) along with TspanC8 siRNA where all TspanC8s have been 
targeted using siRNA (A).  Error bars represent the standard error of the mean from five  
independent experiments.  Data were analysed by one-way ANOVA followed by Dunnett’s 
multiple comparisons test (*p < 0.05, p** < 0.01, ***p < 0.001 compared to endogenous TspanC8 
tetraspanin expression). 
CHAPTER 5:  ADAM10-INTERACTING ENDOTHELIAL TETRASPANINS TSPAN5 AND 







CHAPTER 5:  ADAM10-INTERACTING ENDOTHELIAL TETRASPANINS TSPAN5 AND 















Figure 5.13  The presence of Tspan14 is sufficient to maintain basal ADAM10 surface 
expression.  HUVECs were transfected with one of two siRNA duplexes corresponding to the 
various TspanC8 tetraspanins at 5 nM (red bars) or transfected with 5 nM negative control siRNA 
duplex (black bars) for 48 hours.  To evaluate the single role of a tetraspanin, all TspanC8s were 
knocked down using siRNA apart from a single tetraspanin hereby revealing the presence of the 
single tetraspanin not targeted using siRNA as explained in the legend to Figure 5.10.  HUVECs 
were processed by flow cytometry to measure surface ADAM10 expression as explained in the 
legend to Figure 5.3 (A & C).  Surface ADAM10 levels from panel A were quantitated and 
normalised to the average ADAM10 surface expression in the ‘no siRNA’ condition (B & D).  
Confirmation of individual TspanC8 knockdowns in the various conditions were assessed by RT-
PCR as explained in the legend to Figure 5.1 and shown to be 50% or more reduced upon 
quantitation and in line with mRNA levels shown in Figure 5.12 (data not shown).  Error bars 
represent the standard error or the mean from five independent experiments.  Data were 
statistically analysed by One-way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc 
test (**p < 0.01, ***p < 0.001 compared to ‘negative control siRNA’ transfected HUVECs).   
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Figure 5.14  Surface VE-cadherin levels are reduced upon combination knockdowns that 
leave either Tspan5 or Tspan17 as the only HUVEC TspanC8.  HUVECs were transfected with 
one of two siRNA duplexes corresponding to the various TspanC8 tetraspanins at 5 nM (red bars) 
or transfected with 5 nM negative control siRNA duplex (black bars) for 48 hours.  To evaluate the 
single role of a tetraspanin, all TspanC8s were knocked down using siRNA apart from a single 
tetraspanin hereby revealing the presence of the single tetraspanin not targeted using siRNA as 
explained in the legend to Figure 5.10.  HUVECs were processed by flow cytometry to measure 
surface VE-cadherin expression (A & C).  Surface VE-cadherin levels from panel A were 
quantitated and normalised to the average VE-cadherin surface expression in the ‘no siRNA’ 
condition (B & D).  Confirmation of individual TspanC8 knockdowns in the various conditions were 
assessed by RT-PCR as explained in the legend to Figure 5.1 and shown to be 50% or more 
reduced upon quantitation and in line with mRNA levels shown in Figure 5.12 (data not shown).  
Error bars represent the standard error or the mean from five independent experiments.  Data 
were statistically analysed by One-way ANOVA followed by a Dunnett’s multiple-comparisons 
post-hoc test (**p < 0.01, ***p < 0.001 compared to ‘negative control siRNA’ transfected 
HUVECs).   
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In addition to the static adhesion assay data and flow cytometry findings, the effects of 
combined siRNA knockdown of TspanC8s on VE-cadherin shedding was assessed.  In 
these assays, HUVECs were transfected with siRNA duplex combinations (25 or 30 nM 
siRNA in total) as described previously or a non-specific siRNA duplex at a final 
concentration of 30 nM.  24 hours after transfection, 10 µM DAPT was added and the 
cells were cultured for an additional 24 hours.  The cells were harvested and subjected to 
Western blotting for VE-cadherin as described previously.  Knockdown of all TspanC8s or 
the various combinational knockdowns revealed no differences in VE-cadherin shedding 
(Figure 5.15).  This result was somewhat surprising, given the previously observed effects 
on VE-cadherin surface expression.  Nevertheless, these data suggest that endothelial 
Tspan5 and Tspan17 are novel facilitators of PBL transmigration through their regulation 
of ADAM10 and VE-cadherin surface levels.  In addition, the effect of Tspan5 or Tspan17 
was not due to differential changes in ADAM10 surface levels. 
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Figure 5.15  Neither knockdown of all TspanC8s nor the presence of an individual TspanC8 
does not affect VE-cadherin cleavage.  HUVECs were transfected with siRNA duplexes 
corresponding to the various TspanC8s as explained in the legend to Figure 5.10.  Following 24 
hours, HUVECs were treated with 10 µM DAPT for an additional 24 hours to prevent further 
proteolytic processing of VE-cadherin after ADAM10 cleavage.  HUVECs were then harvested, 
lysed and converted into cell lysates prior to carrying out Western blotting for VE-cadherin as 
explained in the legend to Figure 5.5.  α-Tubulin was used as a loading control.  The membrane 
was imaged and bands quantified on the Odyssey Infrared Imaging System (A & C).  The 
percentage cleaved was calculated as previously explained in the legend to Figure 5.5 (B & D).  
Confirmation of individual TspanC8 knockdowns in the various conditions were assessed by RT-
PCR as explained in the legend to Figure 5.1 and shown to be 50% or more reduced upon 
quantitation and in line with mRNA levels shown in Figure 5.12 (data not shown).  Error bars 
represent the standard error of the mean from four independent experiments.  Data were 
analysed by One-way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc test.   
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5.2.5 Knockdown of Tspan5 and Tspan17 does not alter PBL transmigration 
or changes in VE-cadherin shedding and surface expression levels 
Having shown that the presence of Tspan5 or Tspan17 are sufficient in maintaining basal 
PBL transmigration, the opposite approach of knocking down Tspan5 and Tspan17 
simultaneously was investigated.  HUVECs were transfected with two siRNA duplexes, 
one targeting Tspan5 and the other targeting Tspan17 (5 nM of each siRNA duplex), or a 
non-specific siRNA duplex as a control.  24 hours after transfection, HUVECs were 
stimulated with 100 U/ml TNFα and 10 ng/ml IFNγ for an additional 24 hours and a static 
adhesion assay was carried out as previously explained.  Knockdown of Tspan5 and 
Tspan17 did not alter the ability of PBLs to transmigrate when compared to control 
transfected cells (Figure 5.16 A).  In addition, no differences in PBL total adhesion were 
observed following the combined knockdown of Tspan5 and Tspan17 (Figure 5.16 B).  To 
confirm the siRNA knockdown of Tspan5 and Tspan17, RNA was extracted from cell 
pellets and cDNA was produced as previously explained.  Tspan5 and Tspan17 mRNA 
levels were assessed by real-time PCR as previously described.  A ~70% reduction in 
Tspan5 expression and a ~75% reduction in Tspan17 expression was observed following 
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Figure 5.16  Knockdown of Tspan5 and Tspan17 does not affect PBL transmigration under 
in vitro static conditions.  HUVECs were transfected with two different siRNA duplexes to 
Tspan5 in combination with two different siRNA duplexes to Tpan17 (orange bars with purple 
dashes) alongside a non-specific siRNA (black bar) at a final concentration of 10 nM.  The 
HUVECs were then incorporated into a static adhesion assay.  PBLs were classified as firmly 
adherent or transmigrated (A).  The total number of cell classified for each of the behaviours was 
combined to give a total adhesion count (A)  HUVECs transfected with siRNA were analysed by 
RT-PCR to measure the relative knockdown efficiency of the various TspanC8s at the mRNA level 
as previously explained in the legend to Figure 5.1 (C).  Error bars represent the standard error of 
the mean from three independent experiments.  Data were normalised by arcsine transformation 
and statistically analysed by one-way ANOVA and Dunnett’s post-hoc comparisons test for total 
adhesion data and knockdown confirmation data (***p < 0.001 compared to negative control 
siRNA transfected cells) or by a two-way ANOVA and Bonferroni post-hoc comparisons test for 
PBL cell behaviour.   
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In addition to the static adhesion assay data, the effects of combined Tspan5 and 
Tspan17 knockdown on VE-cadherin shedding were assessed.  In these assays, 
HUVECs were transfected with siRNA duplexes targeting Tspan5 and Tspan17.  24 hours 
after transfection, 10 µM DAPT was added and the cells cultured for an additional 24 
hours.  The cells were harvested and cell lysates were Western blotted for VE-cadherin 
as described previously.  Knockdown of Tspan5 and Tspan15 did not alter VE-cadherin 
shedding when compared to control transfected cells (Figure 5.17 A & B). 
Tspan5 and Tspan17 combined knockdown HUVECs were analysed for their expression 
of ADAM10 and VE-cadherin as explained previously.  Flow cytometry analysis of surface 
ADAM10 levels revealed no changes in ADAM10 expression levels following combined 
knockdown of Tspan5 and Tspan17 when compared to control transfected cells (Figure 
5.17 C & D).  In addition, no differences in VE-cadherin surface expression levels were 
revealed following the combined knockdown of Tspan5 and Tspan17 when compared to 
control transfected cells (Figure 5.17 E & F). 
Taken together, these data show that combined knockdown of Tspan5 and Tspan17 does 
not suppress PBL transmigration, suggesting the possible compensatory involvement of 
other TspanC8s, namely Tspan14 or Tspan15, and residual Tspan5 and Tspan17 
expression due to the incomplete knockdown, in regulating PBL transmigration.  
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Figure 5.17  Knockdown of Tspan5 and Tspan17 does not alter ADAM10 and VE-cadherin 
expression levels nor VE-cadherin shedding.  HUVECs were transfected with two different 
siRNA duplexes to Tspan5 in combination with two different siRNA duplexes to Tspan17 (orange 
with purple dashes) alongside a non-specific siRNA (black bar) at a final concentration of 10 nM.  
24 hours after transfection, 10 µM of the γ-secretase inhibitor, DAPT was added to the culture 
media to prevent further proteolytic processing VE-cadherin after ADAM10 cleavage.  HUVECs 
were then harvested, lysed and converted into cell lysates prior to carrying out Western blotting 
for VE-cadherin as explained in the legend to Figure 5.5.  α-Tubulin was used as a loading 
control.  The membrane was imaged and bands quantified on the Odyssey Infrared Imaging 
System (A).  The percentage cleaved was calculated as previously described in the legend to 
Figure 5.5 (B).  Transfected HUVECs stained for the surface expression of ADAM10 (C & D) and 
VE-cadherin (E & F) as explained in the legend to Figure 5.3 (C & E).  Surface ADAM10 levels or 
VE-cadherin levels from panels C and E were quantitated and normalised to the “No siRNA” 
treated condition (D & F).  Confirmation of Tspan5 and Tspan17 knockdown was assessed by RT-
PCR as explained in the legend to Figure 5.1 and shown to be 65-80% reduced upon quantitation 
and in line with mRNA levels shown in Figure 5.16 (data not shown).  Error bars represent the 
standard error of the mean from three independent experiments.  Data were analysed by One-
way ANOVA followed by a Dunnett’s multiple-comparisons post-hoc test.   
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5.3 DISCUSSION 
Inflammation induced by injury or infection is characterised by changes in vascular 
morphology, plasma protein and fluid leakage and leukocyte transmigration.  The 
localised proteolytic cleavage of various cell surface adhesion molecules has been 
implicated in the efficient transmigration of leukocytes as well as limiting leukocyte 
transmigration through a process known as de-adhesion (Dreymueller et al., 2012b, 
2015).  The metalloprotease ADAM10 has been suggested to regulate vascular 
permeability and PHA-blast T cell transmigration under static conditions (Schulz et al., 
2008; Donners et al., 2010).  Although ADAM10’s function as an ectodomain sheddase 
has been well documented, little is known about the role of binding partner proteins in 
regulating the function of ADAM10.  All the members of the subgroup of TspanC8 
tetraspanins have been shown to all associate with ADAM10 and facilitate its enzymatic 
maturation (Dornier et al., 2012; Haining et al., 2012).  Emerging evidence now suggests 
that specific TspanC8s regulate substrate cleavage of the ADAM10 substrates Notch, N-
cadherin, APP, CD44 and GPVI (Jouannet et al., 2016; Noy et al., 2016).  However, the 
role of TspanC8s in leukocyte transmigration, and their effects on VE-cadherin shedding 
by ADAM10, have not previously been investigated.  Here the role of endothelial 
TspanC8s in regulating this function of ADAM10 was investigated using in vitro static 
adhesion assays.  In addition, changes in VE-cadherin surface expression and shedding 
were monitored by flow cytometry and Western blotting techniques. 
To analyse the role of TspanC8s in regulating PBL transmigration, initial experiments 
were performed in which HUVECs were lentivirally transduced to overexpress the 
individual TspanC8s before monitoring the effect of TspanC8 overexpression on PBL 
transmigration under in vitro static adhesion assay conditions.  Overexpression of 
TspanC8s in HUVECs did not alter the ability of PBLs to transmigrate under conditions of 
TNFα/IFNγ induced inflammation.  Furthermore, of the TspanC8s endogenously 
expressed in HUVECs, overexpression of Tspan5, 14 or 17 did not alter VE-cadherin 
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shedding nor VE-cadherin cell surface expression.  Surprisingly, overexpression of 
Tspan15 and Tspan33 significantly reduced VE-cadherin shedding.  This phenomenon 
was accompanied by a paradoxical increase in ADAM10 surface levels when Tspan15 or 
33 were overexpressed.  However, overexpression of Tspan15 or 33 did not alter VE-
cadherin surface expression.  It is worth noting that the three most highly expressed 
TspanC8s following lentiviral transduction in HUVECs were Tspan10, 15, and 33.  
Previously published data using overexpression models has shown Tspan10 has a largely 
intracellular localisation in HeLa cells (Dornier et al., 2012) and in HEk293T cells 
(Tomlinson, unpublished data), whilst Tspan15 and Tspan33 promoted ADAM10 
membrane localisation.  Although overexpression of Tspan15 and Tspan33 increased 
ADAM10 surface expression, a paradoxical reduction in VE-cadherin shedding was 
observed.  It is possible to speculate that Tspan15 and Tspan33 could be sequestering 
ADAM10 away from an endogenous TspanC8 (such as Tspan5, 14 or 17), the function of 
which is to promote VE-cadherin shedding.  Furthermore, the decrease in VE-cadherin 
shedding observed following overexpression of Tspan15 or Tspan33 did not affect 
surface levels of VE-cadherin.  This was a surprising result, suggesting that VE-cadherin 
shedding does not necessarily correlate with surface expression.  Certainly, there are 
differences in the basis of the models used to look at VE-cadherin expression.  FACS only 
measures surface levels of VE-cadherin and so does not take into consideration internal 
pools of VE-cadherin that are measured by Western blot, which may encompass newly 
synthesised protein or protein that is passing through the endocytic pathway.  In addition, 
it could be speculated that during the Western blotting lysis procedure a particular pool of 
VE-cadherin may remain attached to the cytoskeleton and therefore be resistant to 
solubilisation (Guo et al., 2004).   Taken together, it may be possible that a significant 
decrease in shedding could be happening to a substantial pool of VE-cadherin that is not 
at the cell surface.  In addition, it is worth noting that overexpression is prone to artefacts 
of abnormally high expression levels, and could in part be responsible for the apparently 
paradoxical data in this section. 
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Since overexpression of TspanC8s yielded data that was difficult to interpret, the focus 
changed to look at endogenous TspanC8s and their role in regulating PBL transmigration 
using a siRNA knockdown approach.  Individual knockdown of TspanC8s in HUVECs did 
not alter the ability of PBLs to transmigrate under in vitro static adhesion assay conditions.  
Moreover, TspanC8 knockdown resulted in no changes in VE-cadherin shedding or VE-
cadherin surface levels.  However, knockdown of Tspan14 and 15 resulted in a small, but 
nevertheless significant reduction in ADAM10 surface levels.  Previously, Haining et al. 
showed that knockdown of Tspan14 in HUVECs resulted in a ~50% reduction in ADAM10 
surface levels which correlated with a reduction in VE-cadherin shedding (Haining et al., 
2012).  The variability in Tspan14 knockdown efficiency, namely ~75% reduced observed 
by Haining et al. and ~50% reduced in the present study, might explain the differences 
observed between the data presented in this chapter and that published by Haining et al.  
Indeed, the effects of prolonged knockdown (for example 48-hour knockdown used in the 
present study vs 72-hour knockdown used by Haining et al.) could differentially alter 
ADAM10 surface expression.  
Since redundancy amongst the TspanC8s could have explained the lack of phenotype 
observed following individual knockdown of the TspanC8s during PBL transmigration, the 
focus changed to utilise a method to investigate the individual function of the TspanC8s 
by ruling out the function of the other TspanC8s.  For these experiments, a combination 
knockdown approach of the TspanC8s proved pivotal in deducing a function of single 
TspanC8s in PBL transmigration.  Knockdown of all TspanC8s in HUVECs resulted in a 
decrease in the ability of PBLs to transmigrate.  This correlated with a reduction in 
ADAM10 surface levels.  However, no changes in VE-cadherin shedding nor VE-cadherin 
surface levels were observed, suggesting that ~50% reduction in ADAM10 surface pools 
is sufficient to maintain basal VE-cadherin shedding, but nevertheless suppresses PBL 
transmigration.  It could be speculated that surface levels of VE-cadherin only form part of 
the total VE-cadherin pool in endothelial cells and subtle changes in VE-cadherin 
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localisation, such as its recycling at the plasma membrane, could ultimately be facilitating 
the functional response in regulating lymphocyte transmigration.  In addition, complete 
loss of TspanC8s expression was not observed, and the remaining expression of the 
various TspanC8s (~50% or less) could still be facilitating leukocyte transmigration. 
Following on from the findings that a ~50% or greater reduction in endogenous TspanC8s 
is sufficient to reduce PBL transmigration, the focus changed to evaluate the individual 
role of specific TspanC8s in maintaining basal PBL transmigration.  For this set of 
experiments, a combinational siRNA knockdown approach was undertaken in which 
HUVECs were transfected with siRNA duplexes corresponding to five of the six 
TspanC8s, to decipher the individual role of the TspanC8 not targeted by siRNA.  
Interestingly, knockdown combinations that retained the expression of Tspan5 (100% 
Tspan5, 50% Tspan14, 25% Tspan15 and 25% Tspan17 expression) or Tspan17 (50% 
Tspan5, 50% Tspan14, 25% Tspan15 and 100% Tspan17 expression) maintained basal 
PBL transmigration.  This was supported by a reduction in VE-cadherin surface levels.  
This capacity of Tspan5 or Tspan17 was not due to increased ADAM10 surface levels, 
because a partial reduction in ADAM10 surface levels was observed and only the 
presence of Tspan14 was sufficient to maintain basal ADAM10 levels.  This is most likely 
due to its relatively high expression levels on HUVECs in comparison to the other 
TspanC8s (Haining et al., 2012).  Interestingly, Tspan5 and Tspan17 share 78% 
sequence homology at the protein level in humans and this might explain the common 
role of these TspanC8s in PBL transmigration.  It is possible to speculate that Tspan5 and 
Tspan17 could be promoting ADAM10s trafficking to sites of VE-cadherin localisation.  
However, it has to be noted that VE-cadherin has been reported to be absent from 
endothelial adhesive platforms that are enriched with tetraspanins CD151 and CD9 that 
promote leukocyte adhesion and subsequent transmigration (Barreiro et al., 2008) and 
was shown to be absent from HUVEC tetraspanin proteomics (Tomlinson, unpublished 
data).  Therefore, it is unlikely that VE-cadherin is tetraspanin associated.  With the 
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emergence of TspanC8s having different interaction profiles with ADAM10, recent data 
from the Tomlinson group showed evidence for TspanC8s having distinct mechanisms of 
ADAM10 binding (Noy et al., 2016).  In particular Tspan5 was shown to bind to the 
cysteine and stalk regions of ADAM10 whilst Tspan17 interaction with the stalk and 
cysteine regions was inhibited by the presence of the disintegrin domain of ADAM10 (Noy 
et al., 2016).  Therefore, Tspan5 and Tspan17 could promote a particular ADAM10 
conformation that is favourable to VE-cadherin cleavage.  A reduction in VE-cadherin 
surface expression in the presence of Tspan5 or Tspan17 did not correlate with a 
reduction in VE-cadherin cleavage.  As mentioned before, this rather paradoxical result 
might be explained by the disparity between surface expression, only accounting for a 
small proportion of the total VE-cadherin in the cells, and Western blotting which takes 
into account internal pools of VE-cadherin including newly synthesised protein and protein 
in that has entered the endocytic pathway. 
Surprisingly, knockdown of Tspan5 and Tspan17 in combination resulted in no changes in 
the ability of PBLs to transmigrate.  This was associated with no changes in ADAM10 and 
VE-cadherin surface levels nor VE-cadherin shedding.  The RT-PCR confirmed that there 
was 100% expression of Tspan14 and 15, 30% expression of Tspan5 and 25% 
expression of Tspan17 following the double knockdown.  Since a reasonable amount of 
Tspan5 and Tspan17 is still expressed following the double knockdown, it is possible to 
speculate that a greater knockdown of the two TspanC8s is required to see a phenotype. 
Overall, the findings in this chapter highlight endothelial Tspan5 and Tspan17 as novel 
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6.1  PROJECT OVERVIEW 
The primary barrier which leukocytes or macromolecules have to overcome during an 
inflammatory response is the venular wall, which acts as a semi-permeable barrier at the 
interface between circulating blood and the interstitial tissue.  The process by which 
leukocytes exit the bloodstream involves a sequence of well-orchestrated signalling and 
adhesive events that occur between leukocytes and the inflamed vessel wall (Nourshargh 
et al., 2010; Nourshargh and Alon, 2014).  Most of the initial interactions that facilitate this 
process occur at the leukocyte-endothelial interface.  Lack of regulation of leukocyte 
recruitment or the inappropriate trigger of this reaction, however, can lead to severe 
pathological inflammatory conditions such as asthma, stroke, atherosclerosis, and cancer 
(Krishnamoorthy and Honn, 2006). 
Proteolytic shedding of key CAMs and membrane-inserted chemokines that regulate the 
distinct stages of leukocyte rolling, activation-induced arrest and transmigration have 
offered hope in further understanding the molecular dynamics of the complex regulation of 
leukocyte transmigration in health and disease (Garton et al., 2006; Dreymueller et al., 
2012b).  Previously published data has largely focused on the use of transfected cells and 
cell lines to reveal an effect of proteolytic shedding during inflammation.  However, 
mechanisms of proteolytic shedding in primary endothelial cells and in physiological flow 
in vitro models of inflammation remain largely unknown.  This PhD thesis aimed to 
investigate the role of the metalloprotease ADAM10 in regulating leukocyte transmigration 
by targeting specific known ADAM10 substrates such as the adhesion molecule VE-
cadherin and the transmembrane chemokines CX3CL1/CXCL16 using primary 
endothelial cells under physiological in vitro flow conditions in a model of chronic 
inflammation.  In addition, the role of six tetraspanin transmembrane proteins, termed 
TspanC8s, as key regulators of ADAM10 function was investigated with the possibility 
that each of the TspanC8s could traffic ADAM10 to distinct substrates, thereby regulating 
leukocyte transmigration. 
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The present data demonstrates the capacity of endothelial ADAM10 to promote the 
transmigration of PBLs, but not other inflammatory leukocyte subsets such as neutrophils 
or monocytes.  These findings were dependent on the regulation of VE-cadherin shedding 
and surface levels through ADAM10 activity.  In addition, the TspanC8 tetraspanins 
Tspan5 and Tspan17 were shown to be novel regulators of ADAM10 during PBL 
transmigration.  Thus, the findings of the present study contribute to our understanding of 
ADAM10 regulation by the TspanC8s in inflammation and have opened novel avenues for 
future research.  The following discussion gives an overview of the possible functional 
consequences of ADAM10 regulation in inflammation and discusses the potential role of 
the TspanC8s in directing ADAM10 responses during PBL transmigration. 
 
6.1.1   Endothelial ADAM10 is a regulator of lymphocyte transmigration 
during inflammation 
The recruitment and activation of leukocytes into inflamed tissue involves a tightly 
regulated and complex process of interactions of leukocytes with different components of 
the venular wall (Nourshargh et al., 2010; Nourshargh and Alon, 2014).  Proteolytic 
cleavage or ‘ectodomain shedding’ by metalloproteases belonging to the ADAM family 
have recently emerged as a possible molecular mechanism that could govern leukocyte-
endothelial cell interactions by proteolytically shedding key CAMs and transmembrane 
chemokines (Garton et al., 2006; Dreymueller et al., 2012b). However, many studies have 
utilised cell line models and transfected cells to overexpress specific transmembrane 
proteins under non-physiological models to decipher the role of proteolytic shedding in 
leukocyte adhesion and transmigration (Hundhausen et al., 2007; Schwarz et al., 2010; 
Schulz et al., 2008). As such, the role of proteolytic shedding in primary cells and under 
physiological flow conditions is still largely unknown.  
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In this study, endothelial ADAM10, targeted on primary HUVECs using siRNA or a 
preferential pharmacological inhibitor, was shown to promote the efficient transmigration 
of human PBLs, but not neutrophils or monocytes in physiological flow and static 
adhesion assays.  These findings are in line with previously published data that showed a 
role of endothelial ADAM10 in regulating the transmigration of PHA-blast T cells in a static 
transwell assay model (Schulz et al., 2008).  A separate study by Schwarz et al. showed 
the migration of the pre B cell line L1.2 was significantly reduced on TNFα/IFNγ 
stimulated HUVECs in a static transwell adhesion assay (Schwarz et al., 2010).  Two 
additional studies have highlighted a role of ADAM10 expressed on human microvascular 
endothelial cells (HMVEC) in regulating the transmigration of the monocytic cell line, THP-
1 cells under static transwell conditions in response to TNFα/IFNγ or CCL2 (Hundhausen 
et al., 2007; Pruessmeyer et al., 2014).  A common feature of many of these studies has 
been the use of leukocytic and endothelial cell lines in basic models of adhesion.  In the 
studies that have used primary endothelium (HUVEC or HMVEC), the isolation methods 
have not been documented, and the cells have been outsourced from external 
companies, which do not disclose the previous culture methods or passage of these cells 
prior to their dispatch.  Furthermore, unpublished data from our group has shown that 
subculture of HUVECs in the presence of growth factors, such as hydrocortisone, 
significantly reduces the response of TNFα-mediated neutrophil recruitment and adhesion 
(Nash/Rainger, unpublished data).  In addition to the use of primary endothelium, many of 
the studies also used ECV-304 cells derived from epithelial bladder carcinoma cells.  
However, these cells do not behave like primary endothelial cells and lack the expression 
of key endothelial markers, such as VE-cadherin (Kiessling et al., 1999).  Another 
difference between the data presented in the present study, compared to previously 
published data is the use of primary leukocytes over leukocytic cell lines.  For example, 
Schulz et al. showed that inhibition of endothelial ADAM10 reduced the transmigration of 
PHA-blast T cells in a static transwell assay (Schulz et al., 2008).  However, the culture of 
PHA-blast T cells requires stimulation of these cells with interleukin-2, which changes the 
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repertoire of proteins at the cell surface, compared to primary PBLs.  For example, PHA-
blast T cells upregulate the expression of αLβ2 that supports adhesion to ICAM-1 
(McGettrick et al., 2009) whilst PBLs use α4β1 for their optimal adhesion (Ahmed et al., 
2011). 
In addition to the use of cell type, there are also differences in the type of experimental in 
vitro model that has been used to decipher a function of endothelial ADAM10 in leukocyte 
transmigration.  Previous studies have relied on the use of chemotaxis assays and 
transwell assays, which heavily rely on sedimentation and do not take into account the 
initial capture events that occur during leukocyte adhesion.  Boyden chamber and 
transwell assays rely on similar principles, namely leukocytes are made to migrate across 
a transwell filter towards a stimulus (e.g. cytokine or chemokine) either in the presence of 
absence of a barrier (e.g. endothelial cells).  These assays typically require a longer 
period of incubation to visualise leukocyte transmigration, compared to physiological flow 
assays or static adhesion assays with primary endothelial cells and human leukocytes 
(McGettrick et al., 2009).  Furthermore, the basis of the static adhesion assays and flow 
adhesion assays used in the present study have been extensively studied and 
characterised in terms of the regulation of CAM expression in response to various 
cytokines.  For example, the combined treatment of HUVECs with TNFα/IFNγ has been 
shown to upregulate the interferon-inducible chemokines that selectively regulate the 
recruitment and transmigration of memory CD4+ T cells (Ahmed et al., 2011).  Another 
difference between data presented in the present study and previously published data is 
the use of an in vitro flow adhesion assay.  It is well documented that many of the CAMs 
that regulate leukocyte recruitment and transmigration are modulated by shear stress.  In 
the present study, a physiological shear stress of 0.05 Pa was used, which is within the 
range found in post-capillary venules, the major site of leukocyte recruitment during 
inflammation (Sheikh et al., 2003).  The use of primary endothelial cells and primary 
leukocytes in physiological flow adhesion and static adhesion assays may account for the 
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differences observed in endothelial ADAM10s role in regulating the transmigration of 
lymphocytes, but not neutrophils or monocytes, when compared to previously published 
data that has relied on the use of cell line models and transwell assays. 
 
6.1.2   Regulation of VE-cadherin surface levels is important in mediating 
paracellular transmigration of lymphocytes 
Following adhesion of leukocytes to the apical surface of the venular wall, leukocytes then 
have to breach the endothelial barrier before migrating into the tissue parenchyma 
towards the site of inflammation (Nourshargh et al., 2010).  Since paracellular 
transmigration (migration of leukocytes at endothelial junctions) is the preferred route of 
transmigration, the role of junctional proteins and their surface regulation has been 
studied in quite some depth (Vestweber, 2015).  One of the junctional molecules that has 
been shown to mediate efficient leukocyte transmigration is VE-cadherin.  Targeting of 
VE-cadherin through the generation of genetically modified mice that contained VE-
cadherin fused to α-catenin was shown to stabilise the VE-cadherin/VE-PTP complex 
hereby maintaining barrier integrity.  Trafficking of leukocytes in a model of cremasteric 
inflammation in these mice revealed leukocyte transmigration into the surrounding tissue 
was significantly compromised (Schulte et al., 2011).  In addition, co-incubation of human 
lymphocytes with endothelial cells resulted in a rapid dissociation of VE-cadherin from the 
endothelial junctions as visualised by the introduction of a VE-cadherin-GFP fusion 
protein (Shaw et al., 2001). 
Data in this thesis highlighted that VE-cadherin regulated lymphocyte transmigration 
through its surface regulation.  Inhibition or knockdown of endothelial ADAM10 enhanced 
VE-cadherin surface expression (~1.5 fold increase in surface expression), reduced VE-
cadhrerin shedding and increased transendothelial electrical resistance.  These findings 
were in line with previous studies that have shown inhibition or knockdown of ADAM10 
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decreases the shedding of VE-cadherin and decreases endothelial permeability (Schulz 
et al., 2008; Flemming et al., 2015).  Following on from these publications, data presented 
in this thesis showed that PBL transmigration could be restored by reducing VE-cadherin 
surface levels back to normal in the presence of ADAM10 inhibition or knockdown 
combined with a partial VE-cadherin knockdown.  This data suggests that the regulation 
of VE-cadherin surface levels by ADAM10 can control the transmigration efficiency of 
PBLs.  In line with these obervations, recent data has highlighted that VE-cadherin 
surface levels can dictate the passage of lmphocytes across brain microvascular 
endothelial cells.  Martinelli et al. recently reported that increased VE-cadherin expression 
in brain microvascular endothelial cells correlated with a decrease in the ability of 
lymphocytes to undergo transmigration at endothelial junctions (Martinelli et al., 2014).  
As such, vascular beds which generally have high endothelial resistance, such as the 
brain microvasculature, correlated with lymphocytes preferring transcellular modes of 
transmigration as opposed to migrating at cell-cell junctions. This was accomplished by 
lymphocytes producing invadosome-like protrusions that extend into the endothelium and 
migrate through the body of the endothelial cell (Martinelli et al., 2014).  It remains to be 
shown if under conditions of increased barrier resistance lymphocytes seek other 
methods of transmigration in other endothelial cell vascular beds.  It has been previoulsy 
documented that heterogeneity between endothelial cells in various vascular beds exists 
and as such preferable regions or ‘hot spots’ of lymphocyte transmigration may dictate the 
mode of lymphocyte transmigration (paracellular over transcellular and vice versa).   
 
6.1.3   Potential roles for the TspanC8 tetraspanins in regulating ADAM10 
activity during lymphocyte transmigration 
The recent identification of six tetraspanin transmembrane proteins, termed TspanC8s, 
that could all interact with ADAM10 and support its enzymatic maturation highlighted a 
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mechanism by which ADAM10 activity could possibly be regulated (Dornier et al., 2012; 
Haining et al., 2012).  Recent evidence now suggests that specific TspanC8s regulate 
substrate cleavage of the ADAM10 substrates Notch, N-cadherin, APP, CD44, and GPVI 
(Jouannet et al., 2016; Noy et al., 2016).  However, the role of TspanC8s in facilitating 
lymphocyte transmigration, and their effects on VE-cadherin shedding by ADAM10 had 
not previously been demonstrated, and so formed the basis of investigations undertaken 
in the final results chapter of this thesis.  A systematic knockdown approach was used to 
target endogenous TspanC8 expression using siRNA by investigating the individual 
function of the TspanC8s by ruling out the function of the other TspanC8s.  Knockdown of 
all TspanC8s reduced the ability of PBLs to transmigrate, to a similar extent (~50% 
reduced) as when ADAM10 was knocked down or inhibited.  However, no changes in VE-
cadherin shedding nor VE-cadherin surface levels were observed, suggesting that a 
~50% reduction in ADAM10 surface pools is sufficient to maintain basal VE-cadherin 
shedding, but nevertheless suppress PBL transmigration.  As mentioned previously in the 
discussion to Chapter 5, surface levels only account for part of the total VE-cadherin pool 
in endothelial cells without taking into consideration internal pools of the protein which 
includes newly synthesised protein being trafficked to the cell surface and protein entering 
the endocytosis pathway.  It also has to be noted that in these experiments, complete 
knockdown of all the TspanC8s was not achieved, and the possible involvement of the 
remaining TspanC8s (~50% or less) in regulating lymphocyte transmigration cannot be 
ruled out. 
Further experiments into the role of individual TspanC8s in lymphocyte transmigration 
revealed that knockdown combinations that retained the expression of Tspan5 (100% 
Tspan5, 50% Tspan14, 25% Tspan15 and 25% Tspan17 expression) or Tspan17 (50% 
Tspan5, 50% Tspan14, 25% Tspan15 and 100% Tspan17 expression) maintained basal 
PBL transmigration.  These knockdown combinations were also shown to reduce VE-
cadherin surface expression.  This capacity of Tspan5 or Tspan17 was not due to 
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increased ADAM10 surface levels.  In fact, a partial reduction in ADAM10 surface levels 
was observed, and only knockdown combinations that retained the expression of 
Tspan14 were shown to maintain basal ADAM10 surface levels.  This is most likely due to 
the relatively high expression levels of Tspan14 on HUVECs (Haining et al., 2012).  
Interestingly, Clustal OMEGA protein sequence analysis revealed that Tspan5 and 
Tspan17 are the most highly related TspanC8s sharing 78% sequence homology, and 
this might explain the common role of these TspanC8s highlighted in Chapter 5.  One 
possible mode of action for Tspan5 and Tspan17 could be by promoting ADAM10 
trafficking to endothelial junctions at sites of VE-cadherin localisation.  Previously 
unpublished data from the Tomlinson group has shown, in a cell line model, that 
TspanC8/ADAM10 complexes have distinct subcellular localisation patterns.  The 
technique used to show these subcellular localisations was bimolecular fluorescence 
complementation (BiFC), which has emerged in the last decade as a technique that 
allows a dimer of two different proteins to be visualised within a living cells (Kodama and 
Hu, 2012).  The most striking differences were between Tspan15-ADAM10 dimers, which 
appeared predominantly localised to the plasma membrane, and Tspan10-ADAM10 
dimers, which were largely intracellular.  Of interest, Tspan5-ADAM10 dimers and 
Tspan17-ADAM10 dimers had varied localisations (some plasma membrane and some 
intracellular) (Tomlinson, unpublished data).  The Rubinstein group recently published 
evidence for junctional localisation of Tspan5 as well as predominant membrane 
localisation in U20S cells through the use of confocal microscopy and single particle 
tracking (Jouannet et al., 2016).  Tspan5 and Tspan17 have also been shown to co-
localise with the late endosomal marker CD63 (Dornier et al., 2012), although ADAM10 
localisation in such compartments was found to be largely absent (Jouannet et al., 2016). 
It may be speculated that Tspan5 or Tspan17 might couple to different Rab GTPases or 
Rab effectors, which orchestrate the trafficking of membrane proteins.  Indeed, Rab14 
knockdown has been shown to prevent ADAM10 trafficking from the endoplasmic 
reticulum to the cell surface in an epithelial cell line (Linford et al., 2012), similar to 
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TspanC8 knockdown (Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012a).  The 
mechanism by which Tspan5 and Tspan17 regulate ADAM10 trafficking and localisation 
in HUVECs remains to be elucidated.  Additionally, it has to be noted that VE-cadherin 
appears not to be tetraspanin associated due to its absence in endothelial adhesive 
platforms (Barreiro et al., 2008) and its absence in HUVEC tetraspanin proteomics 
(Tomlinson, unpublished data).  Recent data from the Tomlinson group has shown that 
the TspanC8s have distinct mechanisms of ADAM10 binding (Noy et al., 2016).  In 
particular, Tspan5 was shown to bind to the cysteine and stalk regions of ADAM10 whilst 
the Tspan17 interaction with the stalk and cysteine regions was inhibited by the presence 
of the disintegrin domain of ADAM10 in HEK293T cells (Noy et al., 2016).  It is possible to 
suggest that Tspan5 and Tspan17 could hold ADAM10 in a particular conformation that is 
favourable for VE-cadherin cleavage.  Further investigations using targeted interaction-
disrupting antibodies to Tspan5 or Tspan17 could be potentially beneficial in 
understanding the importance of the Tspan5/17-ADAM10 interaction in inflammation.  The 
reduction in VE-cadherin surface levels observed in the presence of Tspan5 or Tspan17 
was found not to correlate with an increase in VE-cadherin shedding.  As explained 
previously, this rather paradoxical result might be explained by the fact that the pool of 
VE-cadherin recognised by flow cytometry surface staining only forms a small proportion 
of the total VE-cadherin pools in these cells.  In addition, it could be speculated that 
during the Western blot lysis procedure a particular pool of VE-cadherin may remain 
attached to the cytoskeleton and therefore be resistant to solubilisation.  Further 
investigations into the dynamics of Tspan5 and Tspan17 trafficking of ADAM10 are 
required to confirm if these two TspanC8s favourably take ADAM10 to endothelial cell 
junctions. 
Surprisingly, knockdown of Tspan5 or 17 individually or in combination did not alter the 
ability of PBLs to transmigrate.  This was associated with no changes in ADAM10 and 
VE-cadherin surface levels nor VE-cadherin shedding.  It was noted in these experiments 
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that a complete loss of Tspan5 or Tspan17 individually or in combination was not 
observed and it is possible to speculate that a phenotype with Tspan5 or Tspan17 would 
only be visualised with a greater knockdown.  By using this individual knockdown 
approach, there is also the possibility of redundancy between the TspanC8s, since all the 
TspanC8s have been shown to promote ADAM10 trafficking (Dornier et al., 2012; Haining 
et al., 2012).  
Lentiviral overexpression of the individual TspanC8s in HUVECs yielded data that was 
difficult to interpret.  Overexpression of TspanC8s in HUVECs did not alter the abilities of 
PBLs to transmigrate.  Furthermore, of the TspanC8s endogenously expressed in 
HUVECs, overexpression of Tspan5, 14, 15 and 17, did not alter VE-cadherin surface 
levels.  Surprisingly, overexpression of Tspan15 and Tspan33 significantly reduced VE-
cadherin shedding which was associated with a paradoxical increase in ADAM10 surface 
levels.  It is worth noting that the dominant effect of Tspan15 and Tspan33 was probably 
more likely due to relatively higher expression levels of these TspanC8s compared to 
Tspan5, 14 and 17 following lentiviral transduction.  In addition, Tspan10 has shown to 
have a largely intracellular localisation in HeLa cells (Dornier et al., 2012) and in 
HEK293T cells (Tomlinson, unpublished data) and this may account for the reason why 
Tspan10 does not promote ADAM10 surface expression in the lentivirally transduced 
HUVECs.  It is worth noting that overexpression is prone to artefacts of abnormally high 
expression levels, and could in part be responsible for the apparently paradoxical data 
observed in the lentiviral overexpression studies. 
Nevertheless, the data findings highlight a novel role of the relatively uncharacterised 
tetraspanins, Tspan5 and Tspan17, in regulating ADAM10s activity during lymphocyte 
transmigration (Figure 6.1).  These findings offer a starting point for future studies to 
explore the specific role of these TspanC8s on endothelial cells.   
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Thus, further experimental models are required to decipher the exact mechanisms of 
Tspan5 and Tspan17’s action.  The recent advances in gene editing techniques, such as 
CRISPR/Cas9, would allow the production of Tspan5/17 double knockout HUVECs that 
could be tested for their ability to cleave VE-cadherin and regulate PBL transmigration.  
An alternative mechanism could be to use human induced pluripotent stem cells and 
knock out Tspan5 and Tspan17 in these cells prior to their differentiation into endothelial 
cells.  Protocols for differentiating human induced pluripotent stem cells into endothelial 
cells are already well characterised with the differentiated cells expressing key endothelial 
markers such as, VE-cadherin, PECAM-1 and VEGF (Adams et al., 2013; Rufaihah et al., 
2013).  To date, the functional consequence of deleting Tspan5 or Tspan17 in knockout 
mice has not previously been reported.  Therefore, it would be interesting to genetically 
engineer mice with Tspan5 and Tspan17 deletions, particularly in the endothelial lineage.  
These mice could then be used to investigate lymphocyte recruitment and transmigration 
into the cremasteric tissue following induction of an inflammatory response using intravital 
microscopy.  The use of these definitive methods will allow a more in depth analysis of the 












6.2  OPEN QUESTIONS AND FUTURE PERSPECTIVES 
 
6.2.1  What is the role of ADAM10 in regulating leukocyte transmigration in 
vivo? 
Previous in vitro studies along with the data presented in this thesis showed a strong 
association between ADAM10 and lymphocyte transmigration (Schulz et al., 2008; 
Schwarz et al., 2010).  The mechanisms by which endothelial ADAM10 regulates the 
transmigration of lymphocytes in vivo have not yet been shown.  Since ADAM10 deletion 
6.1 Proposed model of ADAM10 action and regulation during lymphocyte transmigration.  
Tspan5 and Tspan17 associate with ADAM10 and may direct ADAM10 cleavage of VE-cadherin 
via a mechanism that is not understood.  Upon localisation of ADAM10 to endothelial cell 
junctions, ADAM10 is able to cleave the adhesion molecule VE-cadherin, thereby regulating 
normal lymphocyte transmigration. 
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in mice results in embryonic lethality, the generation of the endothelial specific ADAM10 
knockout mice (A10ΔEC) offers a possibility to investigate the role of lymphocyte 
transmigration in vivo (Glomski et al., 2011).  These mice have some vasculature 
abnormalities, but a number of tissues, including muscle, have normal vasculature 
(Glomski et al., 2011).  The role of endothelial ADAM10 in vivo could be assessed by 
using a well characterised in vivo assay of leukocyte transmigration such as visualising 
leukocyte arrest, rolling and transmigration across post-capillary venules in the cremaster 
muscle using video-intravital microscopy following intrascrotal injection of inflammatory 
stimuli such as TNFα.  These studies would further validate the role of endothelial 
ADAM10 in supporting normal lymphocyte transmigration in vivo. 
The role of ADAM10 on macrophages has been shown to be important in regulating the 
progression of atherosclerosis.  Transplantation of bone marrow from conditional 
knockout mice lacking ADAM10 in the myeloid lineage (ADAM10-LysMcre) into lethally 
irradiated atherogenic mice (LDLR-/- knockout mice) resulted in an increase in 
atherosclerotic plaque stability (van der Vorst et al., 2015).  This was associated with 
increased fibrosis and a reduction in the relative macrophage content in the plaque,  
although no difference in total plaque size was observed (van der Vorst et al., 2015).  In 
vitro assays using cultured bone-marrow derived macrophages revealed ADAM10 
deficiency promotes an anti-inflammatory phenotype by dampening the response of 
macrophages to pro-inflammatory stimuli and decreased matrix degrading properties and 
migration of the macrophages (van der Vorst et al., 2015).  These data strongly suggest 
that myeloid ADAM10 may diminish atherosclerotic plaque stability by directing the 
balance from fibrosis to inflammation (van der Vorst et al., 2015).  In chronic inflammation, 
such as atherosclerosis, the regulation of ADAM10 activity by TspanC8s in the various 
different immune cells involved remains unknown.  It is possible to speculate that deletion 
of ADAM10 in immune cells would result in reduced lymphocyte infiltration into 
atherosclerotic plaques, which could reduce the pro-inflammatory composition of plaques 
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thereby hindering atherosclerosis progression, although this remains to be investigated.  
The cross talk between sentinel cells, such as mast cells, macrophages and DCs, and the 
endothelium is critical in supporting the efficient regulation of leukocyte recruitment.  Due 
to the ubiquitous nature of ADAM10, isolated functions of ADAM10 in specific cells may 
only form part of the mechanism by which ADAM10 regulates the complex cascade of 
events of leukocyte transmigration during inflammation. 
 
6.2.2 What is the role of ADAM10 in intracellular signalling pathways that 
are involved in leukocyte transmigration?  
The data in this thesis highlighted an important role of ADAM10 in regulating VE-cadherin 
surface levels during lymphocyte transmigration.  Recent advances in the understanding 
of VE-cadherin’s role during leukocyte extravasation have shown an important role in the 
signalling mechanisms that act upon VE-cadherin during the process of lymphocyte 
transmigration.  VE-cadherin has been shown to have a critical role in paracellular 
transmigration of leukocytes in which the dynamic opening and closing of endothelial 
junctions has to be tightly regulated so that it is sufficient to allow leukocytes to 
transmigrate but avoid vessel leakage (Nourshargh et al., 2010; Vestweber, 2015).  In 
particular, disruption of endothelial junctions using a VE-cadherin antibody has been 
shown to promote leukocyte extravasation into inflamed tissue (Corada et al., 1999; 
Gotsch et al., 1997) suggesting that the adhesive strength of VE-cadherin is important in 
the passage of circulating leukocytes (Schulte et al., 2011). 
Tyrosine phosphorylation of the VE-cadherin-catenin complex has shown promise in 
understanding how VE-cadherin’s adhesive properties can become compromised during 
lymphocyte transmigration (Figure 6.2).  A critical component of VE-cadherin is its 
intracellular association with α-, β-, and γ-catenins that aid its stability within the plasma 
membrane by binding to the cytoskeleton  and mediate its association with VE-PTP 
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(Nottebaum et al., 2008).  Adhesion of leukocytes to vascular endothelium has been 
shown to induce tyrosine phosphorylation of the VE-cadherin-catenin complex at specific 
tyrosine residues, namely Tyr645, Tyr658, Tyr731 and Tyr733 located on the cytoplasmic 
tail of VE-cadherin (Allingham et al., 2007; Nottebaum et al., 2008; Turowski et al., 2008).  
Furthermore, the introduction of tyrosine mutants in the VE-cadherin cytoplasmic tail has 
been shown to decrease the passage of both neutrophils and lymphocytes in vitro 
(Allingham et al., 2007; Turowski et al., 2008).  Wessel et al. reported a critical role of VE-
cadherin phosphorylation status through the use of knock-in mice that express a Y731F 
VE-cadherin mutant (Figure 6.2).  These mice exhibited reduced lymphocyte 
transmigration (Wessel et al., 2014).  Wessel et al. proposed that lymphocytes bind to the 
endothelium through an unknown receptor that then triggers the activity of the SRC 
homology 2-contaning protein-tyrosine phosphatase 2 (SHP2) leading to the 
dephosphorylation of VE-cadherin at Y731.  This then leads to the transient endocytosis 
of VE-cadherin thereby weakening the cell-cell junctions and promoting lymphocyte 
transmigration (Wessel et al., 2014) (Figure 6.2).  Tyrosine phosphorylation of the γ-
catenin complex that forms intracellularly between VE-cadherin and its associated 
tyrosine phosphatase, VE-PTP, has been shown to be crucial in mediating the weakening 
of cell-cell adhesion.  Binding of lymphocytes to inflamed endothelium induces an 
intracellular signalling cascade within endothelial cells that lead to the production of 
reactive oxygen species and enhanced Pyk2 kinase activity.  Through an unknown 
mechanism, this leads to weakening of VE-cadherin-dependent adhesion via the 
dissociation of VE-PTP that is dependent on tyrosine phosphorylation of γ-catenin 
(Broermann et al., 2011) (Figure 6.2).  Although the role of VE-cadherin phosphorylation 
has been extensively studied, the role of VE-cadherin shedding in such models of 
lymphocyte extravasation has been overlooked in these studies (Figure 6.2).  It would, 
therefore, be interesting to investigate the link between VE-cadherin dephosphorylation at 
Tyr731 and ADAM10-mediated VE-cadherin shedding, which increasingly seems to be 
relevant to various inflammatory diseases (Sidibé et al., 2012). 
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It is as yet unknown what happens to the shed ectodomain fragment of VE-cadherin.  
Flemming et al. recently showed that reconstitution of endothelial cells with soluble VE-
cadherin containing media caused disruption of endothelial cell-cell junctions as 
measured by a decrease in transendothelial electrical resistance (Flemming et al., 2015).  
It is also unknown if shedding of VE-cadherin on one endothelial cell promotes the 
shedding of VE-cadherin on the adjacent cell, thereby completely disrupting VE-cadherin 
homotypic interactions between adjacent cells.  
Since the proteolytic shedding of VE-cadherin is irreversible, and the complete loss of VE-
cadherin could be detrimental in causing vessel leakage, it could be speculated that 
efficient lymphocyte transmigration requires both proteolytic shedding and transient 
endocytosis mechanisms (Figure 6.2).  Certainly, it could be considered that upon 
engagement of lymphocytes to endothelial cells, a small pool of apically located VE-
cadherin could undergo shedding which then allows the transient dissociation of a larger 
pool of VE-cadherin that maintains vessel integrity once the lymphocyte has breached the 
endothelial barrier (Figure 6.2).  Since evidence for such a paradigm is lacking, future 
experiments utilising shedding-resistant mutant VE-cadherin constructs, whereby the 
known ADAM10 shedding site has been mutated, could be used to assess this possibility.  
Mass spectrometry on soluble VE-cadherin ectodomain fragments have highlighted 3 
regions within the juxtamembrane region of VE-cadherin that are prone to ADAM10 
mediated shedding (Flemming et al., 2015) and, therefore, such ‘shedding resistant’ 












Figure 6.2.  VE-cadherin acts as a master regulator of lymphocyte transmigration through its shedding and intracellular phosphorylation events.  
The VE-cadherin-dependent opening of cell-cell junctions can be controlled by different signalling or proteolytic shedding events thereby regulating the 
transmigration of lymphocytes.  (A)  ADAM10 has been documented as the primary sheddase that cleaves VE-cadherin releasing a soluble ectodomain 
fragment thereby weakening cell junctions allowing lymphocytes to transmigrate.  Following removal of the soluble ectodomain, the cell-associated 
fragment of VE-cadherin is further processed by intramembrane proteases (namely the γ-secretase complex) releasing the intracellular domain that can 
exert possible intracellular signalling properties or undergo degradation.  (B) Binding of lymphocytes to activated endothelial cells via α4β1/VCAM-1 induces 
an intracellular signalling cascade that leads to the production of reactive oxygen species (ROS) downstream of NADPH-oxidase activity.  Subsequent 
changes in PYK activity enhances phosphorylation of the catenin complex, by an unknown mechanism that leads to weakening of VE-cadherin-mediated 
adhesion.  (C) Separately, through a largely unknown mechanism, activation of SRC homology 2-containing protein-tyrosine phosphatase-2 (SHP2) leads 
to a tyrosine dephosphorylation event on Y731, leading to rapid endocytosis of VE-cadherin, thereby weakening cell junctions and facilitating lymphocyte 





























CHAPTER 6:  GENERAL DISCUSSION 
218 
6.2.3 Could additional known or unknown ADAM10 targets be involved?  
VE-cadherin forms part of an array of junctional proteins that are expressed at endothelial 
junctions.  VE-cadherin has been shown to play an important role in lymphocyte 
transmigration but the involvement of other transmembrane proteins that undergo 
proteolytic cleavage may also be important.  ADAM10 has been shown to be involved in 
the shedding of JAM-A in primary HUVECs (Koenen et al., 2009), although a more 
predominant role of ADAM17 is concluded by the authors of this study.  Other junctional 
proteins such as CD99 and other members of the JAM family are interesting candidate 
molecules for ADAM10-mediated cleavage and further experimental evidence is required 
to conclude such possibility. 
 
6.3  CONCLUDING REMARKS 
The expression of the metalloprotease ADAM10 on endothelial cells is essential in normal 
transmigration of lymphocytes in vitro.  This process is reliant on the shedding of the 
adhesion molecule, VE-cadherin.  Endothelial tetraspanins Tspan5 and Tspan17 can 
facilitate the role of ADAM10 in lymphocyte transmigration in vitro.  These findings open 
up the possibility of ADAM10 therapeutic targeting at the level of Tspan5 and Tspan17-
ADAM10 complexes in the context of lymphocyte transmigration.  This could allow 
ADAM10 targeting in a substrate-specific manner, so reducing the toxic side effects of 
globally inhibiting ADAM10.  With a strong literature of ADAM10’s role in chronic 
inflammatory diseases such as atherosclerosis emerging, targeting of ADAM10 by 
utilising this strategy could prove promising, given the potential role of endothelial 
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